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Abstract 
Poultry are vital to food security, with 60 billion chickens reared worldwide per annum and 
demand fast accelerating.  For many years antibiotic growth promoters have been used to 
promote energy retention from the diet and control intestinal bacterial growth.  Antibiotic 
use for prophylaxis or growth-promotion in farmed animals is prohibited under EU 
Directives due to human health concerns, but a pressing need exists to maintain the 
efficiency of animal production by finding alternatives. 
Antimicrobial peptides (AMPs), part of the innate immune system exist naturally in most 
species and could provide a vast array of potential therapeutics.  Microbial resistance to 
AMPs is unlikely due to their relatively unspecific mode of action, their ability to target 
multiple sites within a cell and diverse immune-modulatory activities.  The avian egg 
provides antimicrobial protection through many mechanisms including AMPs which are 
incorporated into the egg white by the hen.  The ovodefensin family and ‘transiently 
expressed in neural precursors’ (TENP) have been identified as potential novel 
antimicrobials in egg white and therefore formed the basis of the peptide portfolio of this 
study. 
TENP was first identified as having a role in neurological development but has since been 
shown to be an important egg component constituting ~0.1-0.5% of the total protein.  TENP 
is conserved across avian species being found in chicken, turkey, duck and zebra finch.  Its 
homology with the bacterial permeability-increasing family of innate immune genes suggests 
it may contribute to antimicrobial function in the egg.  This study confirmed that expression 
of TENP is confined to the albumen forming region of the oviduct in adult hens and is under 
gonadal steroid control, typical of an oviduct and egg specific gene.   
The ovodefensin family are β defensin related antimicrobial peptides thought to be restricted 
to the albumen producing region of the avian oviduct.  This study identified twenty five 
novel ovodefensin members through genome analysis, expanding the ovodefensin family to 
include reptiles for the first time.  Phylogenetic analysis showed a unique example of the 
evolution of a cysteine spacing motif alongside traditional sequence evolution.  The 
expression of eight ovodefensins was shown to be oviduct specific supporting the hypothesis 
that ovodefensins evolved to protect the egg.  Antimicrobial activity for three ovodefensins 
from chicken and duck was investigated against gram negative organisms E. coli and 
Salmonella including pathogenic strains as well as a gram positive organism, S. aureus, for 
the first time.  The spectrum of activity varied greatly between peptides suggesting a link 
between structure and function. 
Inclusion of recombinant ovodefensin peptides in the feed of chickens showed beneficial 
effects on the gut microbiome, metabolite profile and most crucially an increase in mean 
body weight.  This demonstrates the potential of antimicrobial peptides as alternatives to 
antibiotic growth promoters in poultry. 
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Latin species and common names 
 
Gallus gallus Chicken 
Meleagris gallopavo Turkey 
Anas platyrhynchos Duck 
Taeniopygia guttata Zebra finch 
Cygnus atratus Black swan 
Columba livia Rock Pigeon 
Melopsittacus undulatus Budgerigar 
Ficedula albicol Collared flycatcher 
Geospiza fortis Medium ground finch 
Chrysemys picta bellii Painted turtle 
Caretta caretta Loggerhead turtle 
Pelodiscus sinensis Chinese soft-shell turtle 
Anolis carolinensis Anole lizard 







µ Mu (micro) 
χ Chi 
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1. Introduction 
1.1  Poultry production and food security 
The world food economy is being increasingly driven by food consumption trends 
and a dietary shift towards livestock products (Bruinsma, 2003).  Within this food 
economy poultry represent a major protein source constituting around one third of 
the world’s meat production. It is currently estimated that 55 billion birds are reared 
worldwide each year and demand is fast accelerating owing to population growth and 
rising affluence.  It is predicted that production will need to increase by up to 60% to 
meet global demand by 2050 (FAO, 2013).  Modern poultry have been bred to 
achieve high growth rates in a relatively short time period through improved feed 
conversion efficiency.  In order to fulfil their maximum efficiency poultry need high 
quality feed ingredients, in particular cereals such as wheat (Willems et al., 2013).  
The inherent linkage of livestock production to the crop sector which supplies the 
feed stuffs for both poultry and man means that production of poultry affects the 
food economy as a whole and its efficiency is therefore intrinsically linked to food 
security (Commission of the European Communities et al., 1997).  In addition to 
food security the way in which livestock is reared and the measures put in place to 
control disease affect the food safety of the final products.  With around a million 
incidences of food poisoning annually in the UK at a cost of nearly £1.5 billion it is 
of great importance that food is raised not only efficiently but with safety of the final 
product in mind (FSA, 2011).  Until recently this had been at least in part achieved 
by the use of antibiotics for growth promotion and disease prevention (Barton, 2000). 
1.2  Antibiotics 
Antibiotics were traditionally referred to as “chemical substances produced by 
various microorganisms, especially bacteria, fungi and actinomycetes, and having the 
capacity, in dilute solutions, to inhibit the growth of or to destroy bacteria and other 
microorganisms” (Lietman, 1986). This definition however does not allow the 
inclusion of substances that achieve the same antimicrobial activity but that are not 
produced by microorganisms.  This includes compounds such as sulphonamides,  
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Figure 1.1:  Antibiotic timeline.  Diagrammatic representation of antibiotic 
introduction (depicted above the timeline) and the first observation of 
antibiotic resistance (depicted below the timeline) for the most commonly 
known antibiotics (Clatworthy et al., 2007). 
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man-made semisynthetic modifications of microbial products and chemically 
modified microbial products.  It is therefore now more generally accepted that 
antibiotics are “a substance produced by or a semisynthetic substance derived from a 
microorganism, or a wholly synthetic substance able in dilute solution to inhibit or 
kill a microorganism” (Lietman, 1986).  The key to antibiotics is selective toxicity; 
they must exhibit their antimicrobial effect without harming the host.  It is therefore 
key that the processes which they affect are either non-existent in humans or differ 
significantly from the analogous function (Gale, 1960).  There are many types of 
antibiotics based on molecular structure but the majority of these can be grouped into 
four categories; cell wall active agents, cell membrane active agents, protein 
synthesis inhibitors or enzyme interactors.  With this in mind many of today’s 
antibiotics act on one of five essential bacterial processes: cell wall, DNA, RNA, 
protein or folate synthesis (Baron, 1996). 
The first of the synthetic antibiotics were the sulphonamides, which interfere with 
bacterial folate (vitamin B9) synthesis through competitive inhibition of 
dihydropteroate synthetase (DHPS) (Henry, 1943, Aminov, 2010).  Then, a 
discovery by Alexander Fleming in 1928 led to what most people would associate 
with the start of the antibiotic era; the use of the first microbially derived antibiotic in 
humans, penicillin in 1943. This was followed by a boom in the discovery of 
antibiotic compounds throughout the mid 1900’s (Figure 1.1) (Aminov, 2010).   
However the rate of discovery of novel antimicrobials has drastically dwindled and 
antibiotic resistance is quickly observed when new compounds are introduced 
(Clatworthy et al., 2007).  This void in the development of new antibiotic compounds 
and the increasing levels of  antibiotic resistance saw the issue recommended for 
inclusion in the national risk register at the same level as terrorism, with the premise 
that man is fast approaching an ‘antibiotic resistance era’ (DoH, 2013).    An excerpt 
from Fleming’s Nobel Prize lecture in 1945 demonstrates that this is not a wholly 
surprising phenomenon.  
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“But I would like to sound one note of warning. Penicillin is to all intents and 
purposes non-poisonous so there is no need to worry about giving an overdose and 
poisoning the patient. There may be a danger, though, in underdosage. It is not 
difficult to make microbes resistant to penicillin in the laboratory by exposing them 
to concentrations not sufficient to kill them, and the same thing has occasionally 
happened in the body”. 
There are three classic mechanisms by which bacteria develop resistance to an 
antibiotic.  The first is by developing an enzyme which is able to directly inactivate 
the antibiotic and stop it functioning.  The second is to modify the target site of the 
antibiotic so that it can no longer bind and therefore loses function.  Within this 
category we can also include the ability to produce decoy target sites which the 
antibiotic harmlessly binds to.  Lastly the bacteria are able to reduce the permeability 
of their membranes so that the antibiotics cannot enter and in some cases they have 
developed efflux pumps to remove antibiotics that make it into the cell.  The first two 
mechanisms of resistance can often be transferred from bacteria to bacteria whereas 
the third tends to be clone specific (Silva, 1996). 
1.2.1 Antibiotics for growth promotion 
One traditional use for antibiotics, other than for human or veterinary medicine, is 
the use for growth promotion in animal livestock.  The relationship between a 
healthy gut microbial population and resistance against enteric pathogens is 
extremely important and maintaining homeostasis is vital in ensuring optimal animal 
health (Lee et al., 2010).  For many years antibiotic growth promoters (AGPs) have 
been used as a method of controlling intestinal bacterial growth and ensuring optimal 
animal health in poultry (Bedford, 2000).  When used as growth promoters 
antibiotics are usually administered in low dosages in the feed or water, in this way 
they have been shown to improve not only efficiency and performance but also 
uniformity of a flock (Singer and Hofacre, 2006). 
Studies have shown that the use of AGPs with germ-free birds has no performance 
benefits; this suggests that they work through modification of intestinal microbiota 
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and have no physiological interaction with the bird itself (Bedford, 2000).  The 
mechanisms by which AGPs confer this performance enhancement are not clearly 
understood however the main theories are as follows.  Firstly it is generally accepted 
that the intestinal microbial load competes with the host for nutrients thus utilising a 
significant proportion of dietary energy, therefore a reduction in microbial numbers 
increases the amount of nutrient available to the bird (Apajalahti, 2005).  
Additionally a reduction in microbial numbers can result in the suppression of 
specific microbial by-products such as ammonia which is known to increase the rate 
of enterocyte replacement (Rinttila and Apajalahti, 2013).  Energy which is then used 
to maintain gut integrity must be diverted from elsewhere, often at the expense of 
growth.  In some cases bacteria produce an immune response, this requires energy 
that may otherwise have contributed to growth, and further more immune responses 
can lead to appetite depression, again ultimately affecting growth (Bedford, 2000).   
It should also be noted that as well as generally reducing bacterial load AGPs have 
been shown to reduce the level of harmful pathogens, in particular the gram positive 
organism Costridium perfringens (Stutz et al., 1983) which is responsible for the 
enteric disease necrotic enteritis as discussed in the next section.   
1.2.2 Antibiotic withdrawal 
There has been much debate about the crisis of antibiotic resistance in human 
pathogens and the source of the problem.  Conflicting reports have been issued 
regarding the link between antibiotic usage in animals and resistance in human 
pathogens; although all generally emphasise a need for greater control in antibiotic 
usage across all sectors (Barton, 2000).  Nonetheless, there is mounting evidence that 
antibiotic resistant bacteria can transfer to man from animals resulting in the 
establishment of a community reservoir of resistance genes (van den Bogaard and 
Stobberingh, 1999).  Therefore the decision was made to remove antibiotic growth 
promoters from monogastric diets in the EU.   
When the homeostasis of the gastrointestinal tract is disturbed through factors such 
as dietary changes, antibiotic usage or the introduction of novel microorganism it can 
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result in digestive disorder or disease (Lee et al., 2010).  Digestive disorders such as 
dysbacteriosis occur when normally beneficial bacteria begin to grow unchecked and 
this overgrowth results in lost productivity through reduced nutrient availability for 
the host and gut inflammation (Teirlynck et al., 2011).  The withdrawal of antibiotic 
growth promoters from poultry diets in 1999 has resulted in an increase in the 
incidence of enteric diseases (Bedford, 2000).  It has been suggested that enteric 
disease can predispose an animal to colonisation and eventual infection of pathogenic 
organisms such as Campylobacter and Salmonella which are known to be significant 
causative agents of food poisoning (Choct, 2009).   
A major outcome of antibiotic withdrawal in poultry has been an increase in the 
incidence of necrotic enteritis (Bedford, 2000). This poses a significant economic 
strain on the poultry industry due to the symptomatic problems of reduced growth, 
poor food conversion efficiency and in severe cases mortality (Choct, 2009).  
Necrotic enteritis is estimated to cost the poultry industry globally almost US$ 2 
billion each year (Dahiya et al., 2006).  Necrotic enteritis (NE) was first described in 
broiler chickens by Parish in 1961 and is now the most common and financially 
devastating disease that modern poultry farmers have to contend with (Dahiya et al., 
2006). The gram positive bacteria Clostridium perfringens is the main organism 
responsible, the enterotoxin it produces can be particularly problematic when the gut 
flora are still being established in young poultry and pigs (McDevitt et al., 2006). 
Symptoms of this potentially fatal disease include the sudden onset of diarrhoea and 
mucosal necrosis and are normally observed in chicks 2-6 weeks after hatching 
(Fukata et al., 1991).  However an increase in mortality is not always immediately 
apparent and a reduction in growth rate is often the only observable consequence 
sometime after the event.  The fact that this sub-clinical condition can go undetected, 
particularly in intensive production systems poses a real threat to the sustainability of 
the poultry industry as therapeutic administration of antibiotics tend to be applied too 
late (Porter, 1998, Cooper and Songer, 2009).  Therefore there is a great need for 
alternative antimicrobial agents to control gut microflora and reduce the incidence of 
enteric disease without the need for reliance on therapeutic intervention. 
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1.3  Poultry digestive tract 
The development of the gastrointestinal tract (GIT) begins in ovo and increases 
rapidly over the last four days of incubation with the villi developing in the last three 
(Shane, 2006).  This rapid growth of the GIT continues post hatch with a peak at 6-
10 days in broiler chicks.  However the development of the gizzard and pancreas is 
much slower which limits nutrient digestibility and therefore the yolk sac provides 
the essential nutrients in this period for GIT growth and maintenance (Shane, 2006).  
It has been clearly demonstrated that immediate access to food post hatch 
beneficially improves nutrient digestibility by promoting earlier secretion of enzymes 
from the pancreas and brush border of the intestinal mucosa (Uni and Ferket, 2004).  
The development of villi also increase nutrient absorption through increasing the 
surface area of the GIT and immune protection is improved by mucin production 
which contains innate immune molecules such as defensins from hatch (Shane, 
2006). 
The basic digestive organs of poultry consist of the beak, oral cavity, oesophagus, 
crop, stomach (proventriculus and gizzard), small intestine, paired caeca, large 
intestine (colon) and terminate at the cloaca (Figure 1.2) (Shane, 2006). 
1.3.1 Oesophagus and crop 
The oesophagus is a highly dilatable musculo-membranous tube extending from the 
beak region to the stomach.  Little digestion takes place here but the secretion of 
mucous from oesophageal glands aids the movement of food to the stomach.  The 
crop is a specialised region of the oesophagus and as such very little digestion takes 
place here also. The crop acts as a food reservoir and regulates digesta transit time 
via emptying mechanisms which are dependent on capacity, digestion in the stomach 
and food particle size.  When the stomach is empty peristaltic waves in the  
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Figure 1.2:  Diagrammatic representative of the chicken digestive tract.  
(http://www.poultryhub.org/physiology/body-systems/digestive-system/) 
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oesophagus help the transport of food to the stomach (King and McLelland, 1975, 
Shane, 2006). 
1.3.2 Stomach 
The avian stomach, which includes the chicken, generally consists of two parts, the 
glandular part known as the proventriculus and the muscular region known as the 
gizzard (see Figure 1.2).   The proventriculus is essentially an enlargement at the end 
of the oesophagus which produces pepsin and hydrochloric acid (HCl).  However 
very little chemical digestion takes place in the proventriculus due to the rapid 
digesta transit time and gastric proteolysis takes place in the muscular gizzard.  The 
muscular stomach (gizzard) consists of two muscle parts covered by a thick 
epithelium which physically grind the digesta; this is sometimes aided by the 
swallowing of grit or pebbles.  True protein digestion starts in this region with 
activated pepsin from the proventriculus.  Gastric contractions enable the digesta to 
be moved in both directions to allow further pepsin/HCl treatment in the 
proventriculus if required (King and McLelland, 1975, Shane, 2006), indeed 
retrograde peristalsis is an important mechanism in chickens, much more so than in 
mammals (Jimenez et al., 1994). 
1.3.3 Small intestine 
The small intestine connects the stomach to the caeca/large intestine and is the main 
site of digestion and nutrient absorption; it can be divided into three regions.  In 
chickens the duodenum is approximately 20 cm long and forms a distinct loop.   The 
distinction between the jejunum and ileum is less obvious and the Meckel’s 
diverticulum (yolk stalk) is normally used as a landmark to separate them, the 
combined length of this region is approximately 120 cm (King and McLelland, 1975, 
Shane, 2006). 
Within the small intestine digestion is enzymatic.  Enzymes for the digestion of 
carbohydrates, lipids and proteins e.g. amylase, lipase and trypsin are produced in the 
pancreas and transported to the lumen of the small intestine.  Bile is secreted into the 
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duodenum from the gall bladder which helps to neutralise acid from the 
proventriculus enabling other digestive breakdown.  Bile also plays a key role in 
lipid digestion by emulsifying lipids to allow lipase binding and activity.  
Additionally the intestinal wall of chickens contains mucosal projections called villi 
which are covered in enterocytes as well as some mucous producing goblet cells.  
Enterocytes are covered with microvilli which form the ‘brush border’ lining the 
small intestine, this is where absorption of digested nutrients takes place and is the 
site of terminal carbohydrate digestion through brush border enzymes such as 
maltose and sucrose.  Smaller peptides are also broken down to amino acids here 
through the enzymatic activites of amino peptidase and dipeptidases from the 
pancreas (Shane, 2006). 
1.3.4 Caeca 
Caeca arise at the junction of the ileum and large intestine; in chickens they are 
paired and are particularly large (up to 20 cm long).  Although they have little 
digestive function caeca contain symbiotic micro-organisms which are able to digest 
cellulose and fibre to volatile fatty acids (VFAs) such as acetate, propionate and 
butyrate.  The concentration of VFAs, particularly acetate, in the caeca is high and 
VFAs are therefore passively absorbed by cells.  The caeca also plays an important 
role in amino acid absorption (King and McLelland, 1975, Shane, 2006). 
1.3.5 Large intestine and cloaca 
The large intestine (colon) is a short (~7 cm), straight region terminating in the 
cloaca.  The large intestine allows the absorption of some water and electrolytes 
however undigested feed is quickly excreted and the absence of villi mean that little 
digestive function takes place here (King and McLelland, 1975, Shane, 2006). 
1.4  Poultry intestinal microflora 
The intestinal microbiota of an animal species has undergone co-evolution with its 
host and has enormous metabolic potential, affecting both the nutrition and health of 
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the host (Rinttila and Apajalahti, 2013).  Each individual gut compartment of the GIT 
has its own unique physiochemical attributes and microbial community (Dethlefsen 





/g in the distal intestine (Savage, 1977, Whitman et al., 1998).  
With this in mind it is unsurprising that intestinal microflora affects intestinal health 
and ultimately, even in the absence of disease, animal production. 
The intestinal microflora of a broiler chicken starts developing from hatch and 
initially consists of microbes from the egg shell which originate from the mother and 
also that of the surrounding environment.  Exposure to this post-hatch inoculum is 
critical in the establishment of the intestinal gut community and plays a key role in 
shaping the immune system of the bird thus effecting intestinal microbiota over its 
lifetime (Apajalahti et al., 2004). 
The bacterial density of the chicken GIT develops rapidly from hatch with the 




 cells/g digesta 
respectively just one day post hatch in a broiler chick.  Maximal density is reached 
within one week of hatch and remains relatively stable in healthy birds (Apajalahti et 
al., 2004).  Facultative aerobes such as Enterobacteriaceae and Streptococcus are the 
initial colonisers of the GIT and become established in the small intestine and caeca 
within two-four days post hatch.  After seven days Lactobacillus is the predominate 
organism of the small intestine (Barnes et al., 1972, Lu et al., 2003).  The oxygen 
consumption of these facultative aerobic species results in a more reducing condition 
in the lower intestine allowing subsequent colonisation by obligate anaerobes and the 
caeca becomes predominately colonised by E .coli and Bacteroides (Barnes et al., 
1972, Gong et al., 2002, Wise and Siragusa, 2007).  
During the development of a mature GIT the bacterial flora undergo a transition 
towards the profile we associate with an adult bird.  The upper GIT or small intestine 
consisting of the duodenum, jejunum and ileum is where the majority of digestion 
takes place and therefore the majority of nutrient absorption also (Renner, 1965).  
Due to rapid passage of digesta and low pH the bacterial counts in the duodenum and 
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jejunum are low, however these increase dramatically towards the distal end of the 
ileum where enzymatic activity is reduced (Apajalahti et al., 2004, Rinttila and 
Apajalahti, 2013).  The most dominant species in this region are Lactobacilli which 
make up approximately 80-90% of the commensal bacteria; the remaining organisms 
are mainly Enterobacteria and Enterococci.  As these commensals are able to utilise 
the same readily fermentable nutrients as the host this is where the main dietary 
competition between microflora and host takes place (Apajalahti, 2005).  Normally 
the host can recover part of the energy lost to the commensal microflora through 
utilising bacterial fermentation end products (Rinttila and Apajalahti, 2013).   
Intestinal microbial fermentation principally produces short-chain fatty acids (SCFA) 
including acetate, butyrate, lactate and propionate as end products (Topping and 
Clifton, 2001, Hooper et al., 2002, Bjerrum et al., 2006).  SCFA production in the 
caeca of the chicken produces readily used energy sources for the host and lowers the 
pH of the intestinal environment which is thought to inhibit acid-sensitive pathogenic 
bacteria such as Enterbacteriaceae (Apajalahti, 2005).  Of all the SCFAs produced 
by microbial fermentation, butyrate is thought to be one of the most beneficial as it is 
the preferred energy source of enterocytes and can regulate cell proliferation and 
differentiation within the intestinal mucosa resulting in an improved intestinal barrier 
(Le Blay et al., 2000, Fukunaga et al., 2003).  Butyrate is produced by many 
microbial species found in the caeca; these include many Clostridial clusters from 
the Firmicutes phylum as well as Lachnospiraceae family members such as 
Roseburia spp and Eubacterium rectale (Rinttila and Apajalahti, 2013).  However 
these species are particular sensitive to changes in carbohydrate intake which in turn 
can affect butyrate levels in the lower GIT (Duncan et al., 2007). Butyrate has also 
been shown to increase endogenous defensin expression in the intestine thus 
contributing to the immune protection of the GIT (Sunkara et al., 2011).   
The vast amount of research into the function of the gut microbiota has led to the 
insight that most interactions between the microbiota and the host are either 
commensal with the microbes benefiting without harm to the host or, mutualistic in 
which both the host and microbes benefit (Dethlefsen et al., 2007).  The beneficial 
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relationship with commensal intestinal microbiota is well known: they aid digestion 
and synthesis of beneficial dietary compounds; they play a role in gastrointestinal 
development and epithelial proliferation, inflammatory immune responses and the 
energy metabolism of the host (Noverr and Huffnagel, 2004, Guarner, 2006, Forder 
et al., 2007, Klasing, 2007).  Commensal bacteria can also synthesise vitamins and 
they fill an environmental niche that may otherwise be colonised by harmful enteric 
pathogens; in return they are provided with a constant supply of nutrients and secure 
growth conditions (Savage, 1977). 
1.5 Current research into antibiotic alternatives 
There are many ways in which we are able to influence the intestinal microbiota that 
do not involve the use of traditional antibiotics.  It is likely that the immediate 
response to the withdrawal of prophylactic antibiotic usage will be an increase in the 
therapeutic usage, and indeed this has been seen in countries such as Denmark 
(DANMAP, 2010).  Ironically this will likely increase the incidence of the 
emergence of resistant microorganisms and therefore many suggestions have been 
put forward for an antibiotic-free alternative to gut modulation (Bedford, 2000).  
Many of these strategies can only partially compensate for, rather than replace AGPs 
completely and it may ultimately be necessary to employ more than one strategy.  
Although any strategy should of course be combined with good hygiene management 
and consideration of diet composition.  Broadly speaking most alternative strategies 
aim to either limit the nutrient availability to intestinal bacteria, promote the 
dominance of beneficial commensals or improve the immunity of the animal to 
disease (Bedford, 2000). 
1.5.1 Probiotics 
Direct-fed microbials or probiotics have been previously defined as “live microbial 
feed supplement which beneficially affects the host animal by improving its 
intestinal balance” (Fuller, 1999).  It is suggested that probiotics when fed early in 
life can influence the intestinal environment and favour the establishment of 
beneficial bacteria thus reducing the likelihood of pathogenic colonisation (Bedford, 
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2000).  The proposed mechanisms of probiotics include: (a) competitive exclusion 
and antagonism of pathogens through the maintenance of beneficial commensals, (b) 
altering metabolism decreasing bacterial ammonia production and enzyme activity 
whilst increasing digestive enzyme activity, (c) improving feed intake and digestion, 
(d) neutralising enterotoxins and (e) stimulating the immune system (Dahiya et al., 
2006).  There are a number of possible mechanisms which may be responsible for the 
competitive exclusion of pathogens.  These include competition for mucosal binding 
sites and nutrients or production of inhibitory substances such as volatile fatty acids 
or bacteroicins which are antibacterial for pathogenic bacteria (Tannock, 1997). 
Probiotics are broadly categorised as ‘undefined’ or ‘defined’ preparations.  
Undefined probiotics contain preparations of ‘normal’ avian gut microbiota 
originating from healthy adult individuals which are free from specific pathogenic 
microorganisms.  Defined preparations on the other hand comprise of a single or 
very small number of characterised bacterial strains (Dahiya et al., 2006).  
Preparations are normally fed orally to newly hatched chicks in order to prevent 
colonisation by pathogens in the rearing environment (Nurmi et al., 1992, Nisbet, 
1998). 
Interestingly a number of studies have reported that undefined preparations have a 
beneficial effect on the incidence of necrotic enteritis including reduced mortality 
and caecal colonisation.  For example, Craven et al. (1999) demonstrated a reduction 
in C. perfringens colonisation and subsequent reduction in the incidence of necrotic 
enteritis.  Another field study found that the use of undefined microflora preparations 
delayed the intestinal proliferation of C. perfringens and the appearance of necrotic 
lesions (Kaldhusdal et al., 2001). 
1.5.2 Prebiotics 
Another potential approach to modulate the chicken gut microbiome is the dietary 
supplementation of prebiotics.  Prebiotics are indigestible feed ingredients that 
selectively stimulate the growth or activity of resident beneficial bacteria thus 
proving advantageous for the host (Gibson and Roberfroid, 1995).  To be classed as a 
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prebiotic the ingredient must not be hydrolysed or absorbed in the small intestine and 
must be a selective substrate for beneficial bacteria in the large intestine thus 
promoting their growth and activity (Collins and Gibson, 1999).  Most prebiotics are 
polysaccharides including fructooligosaccharides (FOS) and lactulose although it has 
been suggested that some oligosaccharides such as mannan oligosaccharides (MOS) 
may exhibit some prebiotic activity (Dahiya et al., 2006). 
1.5.3 Organic acids 
Organic acids are already widely used in Europe in the poultry industry for 
antimicrobial protection of raw ingredients and finished feed against pathogenic 
organisms such as Salmonella (Dahiya et al., 2006).  Depending on the concentration 
and type of organic acid used it can either act as a carbon or energy source for 
bacteria or as an inhibitory agent (Cherrington et al., 1991).  Although widely used 
the mode of action of organic acids is not fully understood however the basic 
principle is that they are able to penetrate the cell wall of certain types of bacteria 
and disrupt the normal physiology (Dahiya et al., 2006).  Lambert and Stratford 
propose that on exposure to the internal pH of the bacteria the acid will dissociate 
releasing H+ and anions.  This will decrease the internal pH which is not tolerated by 
many bacteria as they utilise a H+-ATPase pump to bring the pH back to a normal 
level.  This requires a large energy expenditure which can lead to reduced growth or 
even death of the bacteria.  In addition to this it is thought that the anionic part of the 
acid also gets trapped within the bacteria and is eventually toxic (Lambert and 
Stratford, 1999).  
The performance enhancement recorded in broilers is dependant on dose, type of 
acid used and whether the acid is included in the diet or drinking water (Patten and 
Waldroup, 1988).  Propionic acid has been shown to successfully reduce the level of 
E. coli in the intestinal tract of broilers when included in the diet (Izat et al., 1990) 
and was effective at alleviating enteritis in turkey poults (Roy et al., 2002).  It has 
also been suggested that organic acid inclusion in drinking water can eliminate 
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Campylobacter potentially reducing Campylobacter infection in chicks (Chaveerach 
et al., 2004). 
1.5.4 Herbs, spices and essential oils 
Herbs, spices and their essential oils have been used as pharmaceuticals in alternative 
medicine and natural remedies for many years.  Herbs have been shown to have 
antiviral and antioxidative properties and have been found to enhance antimicrobial 
activity as well as stimulate the endocrine and immune system (Dahiya et al., 2006).   
They are said to promote a higher metabolic status and several botanical ingredients 
are reported to have beneficial effects on the gut microbiome (Rao and Nigam, 1970, 
Besra et al., 2002).  Essential oils are reported to stimulate digestive enzymes and 
many have shown antibacterial activity in vitro including essential oil of clove which 
killed greater than 99% of several bacterial strains including S. aureus and E. coli 
(Briozzo et al., 1989).  However, although there are many studies reporting the 
effectiveness of essential oils in vitro there have been few in vivo trials to test this in 
an animal model and it may be that the essential oils would need to be greatly 
concentrated to work in such a system (Dahiya et al., 2006).  However some 
promising research by Mitsch et al. (2004) found that specific blends of essential oils 
were able to reduce the proliferation of C. perfringens in the broiler intestine which 
may in turn reduce the incidence of necrotic enteritis. 
1.5.5 Feed enzymes 
Feed enzymes have been considered as a means for improving animal performance 
and health in antibiotic growth promoter-free broiler diets.  Enzymes benefit the host 
through increasing the rate of diet digestibility and improving nutrient availability; 
additionally this improvement also affects the substrate quality and quantity available 
to the intestinal microflora (Bedford, 2000).  For example if the in-feed inclusion of 
an enzyme results in less undigested starch and protein in the anterior small intestine 
then the result is less nutrient availability for the microflora.  As a consequence, 
microbial populations are reduced and with this potentially the risk of disease 
(Bedford, 2000).  The effect of feed enzymes is also more apparent in diets high in 
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indigestible components, for example the use of xylanases and β-gluconases 
significantly increase utilisation of diets high in xylans and β-glucans (Wu and 
Ravindran, 2004).  It is difficult to determine if an improvement in animal 
performance is due to the improved digestibility of the diet or a reduction in 
microbial populations.  However it is clear that the effect of feed enzymes is much 
more pronounced when there is a significant residential microbial population and as 
such are likely to be more effective in the absence of AGPs (Bedford, 2000).     
1.5.6 Bacteriophages 
Bacteriophages are viruses that are capable of entering bacterial cells and using the 
bacteria’s own metabolic machinery to replicate before utilising cell lysis to kill the 
host and release new phages into the environment (Joerger, 2003).  These viruses 
have received much attention as potential alternatives to antibiotics due to their 
highly specific activity towards bacterial replication (Joerger, 2003).  In mice 
bacteriophages were successfully used to treat vancomycin-resistant Enterococcus 
faecium infection and it has also been suggested that bacteriophages could be used to 
control necrotic enteritis in broilers as they are also effective against C. perfringens 
(Biswas et al., 2002).  Additionally Sklar and Joerger observed that phage-treated 
chickens had lower counts of Salmonella enteritidis in the caeca than untreated birds 
(Sklar and Joerger, 2001).  The use of bacteriophages has not only been suggested as 
a replacement for AGPs but they may also be useful in microbial control of feed and 
food meaning they could be effective along the whole production pathway (Dahiya et 
al., 2006).  However phage therapy against intestinal bacteria may prove more 
difficult than uses outside of the bird as there is likely to be little support from the 
immune system.  Therefore any bacteria with resistance mechanisms to phage attack 
may be able to multiply favourably and affect the delicate balance of the intestinal 
microflora (Joerger, 2003). 
1.5.7 Nutrition: diet formulation and ingredient selection 
The importance of nutrition in the poultry industry is well documented and it has 
been demonstrated that both the physical and chemical attributes of the diet can not 
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only modify the intestinal microbiome but also affect the integrity of the intestinal 
epithelium (Langhout et al., 1999, Apajalahti et al., 2001).  The quality of the raw 
ingredients used in the feed has a direct effect on bird performance; higher quality 
materials have a greater host digestibility which results in reduced substrate 
availability for bacterial growth.  Higher quality ingredients also tend to contain less 
antinutritional factors such as lectins that can damage gut epithelial tissue (Bedford, 
2000).  Diet composition also affects the intestinal microbiome; a study documenting 
broiler microbiomes by Apajalahti in 2004 reported that increased numbers of 
Enterococcus were recorded when a feeding corn and sorghum based diets whereas 
barley increased the number of Lactobacillus.  Apajalahti also documented that the 
growth of Lactococcus and Escherichia were promoted when an oat based diet was 
fed and rye increased the Streptococcus populations (Apajalahti, 2004).  An increase 
in Lactobaccili was also observed when poultry were fed a diet containing linseed 
(Alzueta et al., 2003) and numerous studies have reported the reduced incidence of 
necrotic enteritis in poultry fed corn based diets due to reduced viscosity when 
compared to those fed diets based of wheat, oats or rye (Dahiya et al., 2006).  
Additionally the use of whole cereal grain in the diet has also been shown to result in 
more efficient digestion as whole grains stimulate gizzard development resulting in a 
digesta with a smaller average particle size (Svihus et al., 1997).  Furthermore some 
nutrients are known to be potentiators or down regulators of the immune system 
(Korver and Klasing, 1997, Klasing, 1998) and suppression of inflammatory 
responses may prove beneficial to growth rate providing the bird is still able to illicit 
an effective immune response against disease (Bedford, 2000).  One such dietary 
compound of interest in immune modulation is linoleic acid (Cook, 1998).  Another 
consideration when formulating the diet is the level of protein and amino acid 
supply.  Undigested protein acts as a food source for putrefactive organisms in the 
lower gut which can be detrimental to health; it is therefore beneficial to limit excess 
protein in the feed (Bedford, 2000, Drew et al., 2004). 
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1.5.8 Host defence peptides 
Host defence peptides (HDPs) are naturally occurring components of the innate 
immune system and play a role in the antimicrobial protection of the host (see 1.3.1) 
(Zasloff, 2002, Espinoza et al., 2003, Ganz, 2003).  They have recently received a lot 
of attention as potential alternatives to antibiotics due to their direct ability to kill 
bacteria, particularly as topical agents for microbial infection (Hancock and Lehrer, 
1998, Hancock and Sahl, 2006).  For example a hybrid of cecropin (moth) and 
melittin (bee venom) was effective at treating Pseudomonas aeruginosa in rabbit eye 
infections (NosBarbera et al., 1997).  Additionally nisin, a broad spectrum 
bacteriocidin was able to reduce S. aureus, Klebsiella pneumoniae and E. coli 
numbers when applied topically to cow teat skin (Sears et al., 1992).  In addition to 
their direct killing activities some HDPs are also potent immunomodulators and have 
the ability to dampen down potentially harmful pro-inflammatory responses which 
make them interesting candidates for an entirely new class of therapeutic agents 
(Hancock and Sahl, 2006, Bowdish et al., 2006).  Indeed some trials have shown 
promising results for treating systemic infections with host defence peptides.  For 
example two -helical peptides derived from silk moth cecropin (MBI-27 and MBI-
28) were effective at treating a P. aeruginosa peritoneal infections (Gough et al., 
1996) and a pig derived β-sheet-protegrin showed promise in treating methicillin-
resistant S. aureus and P. aeruginosa infections (Steinberg et al., 1997).  Although 
much of the therapeutic interest in HDPs has focussed on infection and disease they 
may have potential uses in the poultry industry linked to the withdrawal of antibiotic 
growth promoters (Bedford, 2000).  There has been little research done to this end 
and the work that has been carried out has focussed on protection to disease 
challenge rather than modulation of the intestinal microbiota.  One particular study of 
interest fed the cationic peptide BT-TAMUS 2032 (BT) from the soil bacterium 
Brevibacillus texasporus to broiler chickens for four days post hatch.  In this study 
BT peptide resulted in protection from extra-intestinal challenge by Salmonella 
enterica Enteritidis and up-regulated functional efficiency of heterophils (Kogut et 
al., 2010).  A repeat of this study confirmed the previous finding and demonstrated 
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that there was also increased functional efficiency of monocytes when compared to 
broilers fed a control diet (Kogut et al., 2012).  This work gives an exciting insight 
into the possibilities of the in-feed application of HDPs although whether peptides 
such as these, or indeed those from the host itself are able to replicate the growth-
enhancing effects of AGPs has yet to be elucidated.  
1.6  The innate immune system 
The innate immune system is responsible for providing the host with the mechanisms 
and machinery it requires for protection against invading organisms.  The first line of 
defence is a physical one, epithelial cells provide an anatomical barrier that prevents 
most invading organisms from gaining access to the host.  Any organisms that have 
adhered to this surface are removed when the surface is shed during desquamation.  
Also in the gastrointestinal and respiratory tract cilial movement helps to move 
adhering pathogens and mucous traps the infectious agents (Ryu et al., 2010).  In the 
gut the natural microflora of the host helps to prevent the colonisation of pathogenic 
microbes by secreting toxic substances to kill invading organisms.  They also 
compete with pathogenic microbes for nutrients and space which helps prevent 
colonisation of unfavourable organisms and in turn prevent the associated diseases 
(Sadowska and Rozalska, 2008). 
The innate immune system also produces chemical factors such as cytokines which 
recruit immune cells to the site of infection.  Cytokines mediate an inflammatory 
response which provides a physical barrier to prevent the spread of infection whilst 
injured cells are repaired and infectious agents are cleared from the system.  The 
innate immune system also activates the adaptive immune system through antigen 
presentation by macrophages and dendritic cells to T-cells so a ‘specific’ immune 
response to that pathogen can take place.  The ‘non-specific’ innate immune system 
is evolutionarily older than the adaptive immune system and is also responsible for 
producing antimicrobial agents which can directly kill invading organisms (Janeway, 
1993). 
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Two particular families of innate immune peptides/proteins were identified as 
candidates for this study; host defence peptides (see 1.6.1), more specifically 
defensins (1.6.1.1) and the lipid transfer/lipopolysaccharide binding family of 
proteins (see 1.6.2). 
1.6.1 Host defence peptides 
As part of the innate immune system epithelia cells secrete peptides which kill or 
slow the growth of invading microbes (Zasloff, 2002, Espinoza et al., 2003, Ganz, 
2003). Host defence peptides (HDPs) are a diverse group of small, cationic peptides 
found in a wide variety of organisms (Cuperus et al., 2013).  Originally known as 
antimicrobial peptides (AMPs) their principal mode of action is dependent on their 
interaction with the bacterial cell membrane, although it is suggested that their lethal 
mode of action involves disruption to the cytoplasmic membrane (Figure 1.3) 
(Hancock and Rozek, 2002). This interaction is thought to be driven by an 
electrostatic attraction between the positively charged peptide and negatively charged 
components on the outer bacterial envelope.  In gram positive bacteria these negative 
components are thought to be lipoteichoic acids and in gram negative the phosphate 
groups within the lipopolysaccharides (LPS).  The result of these interactions is 
either the disruption of the cell membrane or the translocation of the peptide across 
the membrane into the cytoplasm to interact with internal targets without causing 
major disruption to the membrane.  There have been many proposed models for the 
exact events that happen at the cell membrane but they all lead to one of three 
outcomes:  formation of a transient channel, micellarisation of the membrane or 
translocation across the membrane (Jenssen et al., 2006). 
In addition to their direct antimicrobial activity it is becoming increasingly accepted 
that HDPs exhibit an immunomodulatory effect (Figure 1.4).  It is suggested that this 
effect has the dual function of being able to stimulate immune function in response to 
potentially harmful pathogens to prevent infection, as well as suppressing the pro-
inflammatory response to avoid excessive inflammation.  Some antimicrobial 
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Figure 1.3:  Proposed model of defensin pore formation.  The 
amphipathic nature of most defensins (shown as ovals) allows them to 
interact with microbial membranes.  The positively charged region of the 
peptide (pink) interacts electrostatically with the negatively charged 
phospholipid headgroups of the bacterial membrane and the defensin is 
pulled into the membrane, this is in part due to the hydrophobic nature of the 
other amino acid side region (green).  As the defensins accumulate in the 
membrane they move into another arrangement (shown in the lower panel) 
and pores are created (Ganz, 2003). 
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Figure 1.4:  Multiple immunomodulatory functions of antimicrobial 
peptides in host defence.  Host defence peptides (HDPs), otherwise known 
as antimicrobial peptides (AMPs) have multiple functions in in host defence.  
AMP activity includes the induction of responses in immune cells such as 
monocytes and macrophages, alteration of gene expression in host cells and 
induction of chemokine and cytokine production (Lai and Gallo, 2009).   
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peptides also have the ability to synergise with cytokines in order to modify their 
immunomodulatory activity (Auvynet and Rosenstein, 2009). 
The chemotactic activity of HDPs are particularly effective for leukocytes and 
despite an overlap in activity of different HDPs they are able to complement each 
other in order to direct effector cells to the site of inflammation and modulate local 
immune response by organising the appearance of different immune cells in different 
situations (Lai and Gallo, 2009).  For example human cathelicidin LL-37 is effective 
in attracting neutrophils, monocytes and T-cells (Lai and Gallo, 2009) whereas 
human β-defensin 2 (hBD2) is able to recruit mast cells (Niyonsaba et al., 2002a).  
Certain α-defensins such as human neutrophil peptides (HNP) 1 and 2 can increase 
local densities of monocytes (Territo et al., 1989) whilst hBD3 and hBD4 are both 
chemotactic for monocytes and macrophages (Yang et al., 2002).  The result of all 
these effects is the promotion of antigen presentation to stimulate the clonal 
expansion of B and T-lymphocytes and to mount an adaptive response which then 
contributes to the clearance of microbes through phagocytosis (Auvynet and 
Rosenstein, 2009).  As well as these chemo-attractant activities some HDPs 
indirectly promote chemotaxis through the induction of chemokine secretion, for 
example interleukin-8 (IL-8) release in lung epithelial cell lines can be induced by 
LL-37 (Scott et al., 2002, Tjabringa et al., 2003). 
HDPs are also able to function as anti-inflammatory molecules with many processes 
for this activity having been observed.  Some HDPs such as LL-37 have been 
observed to neutralise the endotoxin effects of LPS and in doing so limit the extent of 
inflammation (Scott et al., 2002).  HDPs also have the ability to abolish the 
expression of pro-inflammatory molecules such as IL-6 and TNF-α, and LL-37 has 
been shown to modulate the toll-like receptor (TLR) response by interacting with 
TLR ligands through an LPS-binding mechanism (Mookherjee et al., 2006).  In 
addition to this they are able to selectively permeabilise the membranes of apoptotic 
leukocytes through a mechanism similar to their direct antimicrobial mode of action 
discussed previously (Bjorstad et al., 2009).   
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A combination of all the functions of HDPs allows both the triggering of the immune 
response and the termination of the immune response through the elimination of 
immune cells and a shift in balance between pro-inflammatory and anti-
inflammatory effects.   
1.6.1.1 Defensins 
Defensins are a family of evolutionarily related cationic host defence peptides with a 
characteristic framework of 6 cysteines linked by 3 disulphide bonds.  There are two 
main subfamilies of defensins, the beta defensins and alpha defensins.  Beta 
defensins are characterised by a beta pleated sheet structure.  Both subfamilies 
consist of a triple stranded beta sheet and characteristic defensin-fold yet differ in the 
length of peptide residues between cysteines and the arrangement of disulphide 
bonds between each of the cysteine residues.  Another structurally distinct sub-
family of defensins, the theta defensins also exist, these form a cyclic peptide and the 
cysteine pairing differs from both α and β defensins (Figure 1.5) (Ganz, 2003, Xiao 
et al., 2004).  It has recently been sugested that the folded structures produced by the 
disulphide bonds may not be important in the antimicrobial activity of the peptide 
and that their activity is in fact increased when the peptide is linearised.  However, 
linear mutants of human beta defensin 1 with the cysteines replaced with arginine 
show a loss of activity, particularly those without the three cysteine residues at the 
carboxyl terminal (Schroeder et al., 2011).  This could suggest that the availability of 
the cysteines may be an important factor in the peptides activity.  The folded form of 
the peptide may therefore provide the host with the ability to produce and store these 
peptides in an inactive form to be activated through breakage of the disulphide bonds 
when the host is challenged by an infectious agent. 
In birds both α and θ defensins appear to be absent, however several β defensins (or 
gallinacins) have been isolated suggesting they are the oldest of the defensin families 
(van Dijk et al., 2008).  To date 14 avian β defensins have been identified in the 
chicken genome, all being encoded on chromosome 3 (Lynn et al., 2007).  
Phylogenetic analysis of vertebrate defensins shows clustering of chicken and  
Chapter 1  Introduction 






Figure 1.5: Sequences and disulphide pairing of cysteines of , β and θ 
defensins.  Corresponding cysteines between the  and β defensin are 
indicated by a dotted line and disulphide bonds are represented by a solid 
line.  In -defensins the six cysteines are linked in a 1-6, 2-4, 3-5 formation 
whereas in β-defensins the pattern is 1-5, 2-4, 3-6.  Circular θ-defensins do 
not have a free N or C-terminus. 
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mammalian β defensins suggesting that this family arose before birds and mammals 
diverged (Xiao et al., 2004).  Defensin-like sequences can also be found in plants and 
insects where they are also involved in the innate antimicrobial defence of the host 
(Raj and Dentino, 2002).  The variety of multicellular organisms capable of 
producing defensin peptides means that defensins can be considered as an ancient 
first line of defence against pathogenic organisms. 
Defensins are synthesised in granulocytes such as neutrophils in mammals (Duits et 
al., 2002) and heterophils in poultry (Evans et al., 1995), or secreted by epithelial 
cells (Zhao et al., 2001).  Avian β defensins (AvBD) are stored in heterophils as a 
tripartite prepropeptide sequence with a NH2-terminal precursor signal sequence, a 
neutral or basic propiece and a mature cationic peptide.  In  defensins the negative 
charge of the propiece usually neutralises the positive charge of the mature peptide 
thus preventing premature interactions with the epithelial membrane (Ganz, 2003).  
However the propeptide of AvBD1 is not negatively charged and AvBD2 only has 
one negative charge and it is therefore unlikely that they are able to neutralise the 
mature peptide in this way.  As such it is likely that there is another mechanism 
responsible for preventing premature activity of chicken β defensins (Brockus et al., 
1998).  Defensins are widely distributed across a variety of tissues and are either 
constitutively expressed or produced in response to microbial infection.  For example 
in the chicken AvBD1 and AvBD2 are present in heterophil granules (Harmon, 
1998) as well as tissues including the lung and testis (van Dijk et al., 2008) whilst 
AvBD3 is constitutively expressed in tissues such as the tongue, skin and oesophagus 
(Zhao et al., 2001).  AvBD8 has so far only been detected in the liver and gall 
bladder and AvBD7 appears to be found mostly in the bone marrow (van Dijk et al., 
2008).  The diverse expression of defensins suggests a generalised protective role of 
these peptides as part of the innate immune system.   
Antimicrobial activity of defensins has been observed against bacteria, fungi, 
parasites and viruses and under optimal conditions such as low ionic strength is 
observed at concentrations as low as 1-10 µg/ml (Ganz, 2003).  Avian β defensins 1 
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and 2 were both found to be greater than 90% effective against Escherichia coli and 
Listeria monocytogenes at 16 µg/ml (Evans et al., 1995). 
As with all host defence peptides described previously defensin activity is primarily 
associated with their ability to depolarise and permeabilise microbial membranes.   
This is achieved through electrostatic interactions with negatively charged 
components of the outer membrane e.g. LPS in gam negative bacteria and teichoic 
acid in gram positive bacteria (Wimley et al., 1994).  Defensins are also involved in 
immune modulation through processes such as chemotactic activity as discussed 
previously (1.3.1).   
1.6.2 Lipid transfer/lipopolysaccharide binding proteins 
The human lipid transfer/lipopolysaccharide binding proteins (LT/LBP) are a gene 
family; the membership of this family is based on sequence homology.  They are 
structurally related proteins that are capable of binding phospholipids and 
lipopolysaccharides, albeit with differing affinities.  The founding members of this 
gene family are bacterial permeability-increasing protein (BPI), lipopolysaccharide 
binding protein (LBP), phospholipid transfer protein (PLTP) and cholesterol ester 
transfer protein (CETP).  All of these proteins are thought to arise from a common 
ancestor due to their amino acid similarity and intron/exon organisation (Mulero et 
al., 2002).   
BPI is a ~50kDa, boomerang shaped, cationic protein consisting of two domains, 
BPI1 and BPI2 which have a very similar folded structure (Figure 1.6).  These 
domains both contain a non-polar pocket which is capable of binding phospholipids.  
The BPI1 domain is the N-terminal half of the molecule and is responsible for 
mediating LPS and bacterial binding, antibacterial cytotoxicity and the neutralisation 
of endotoxins. The C-terminal (BPI2 domain) on the other hand is responsible for 
opsonisation and mediating an immune response (Schultz et al., 2001).  More recent 
additions to this family are the bacterial permeability-increasing like-proteins BPIL1, 
BPIL2 and BPIL3.  BPIL1 and BPIL3 form a cluster with BPI on chicken  
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Figure 1.6: A ribbon diagram of human bacterial permeability-
increasing protein (BPI). The N-terminal domain (BPI1) is white. and the C-
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chromosome 20 whereas BPIL2 maps to chromosome 22.  All three BPIL molecules 
share a highly conserved intron/exon organisation with BPI (Mulero et al., 2002). 
1.7   The chicken oviduct 
In chickens the reproductive system and in particular the egg is a large and varied 
source of antimicrobials (Kovacs-Nolan et al., 2005).  This therefore seemed a good 
starting point for identifying novel antimicrobial candidates for study in this PhD 
thesis. 
The female chicken reproductive system consists of the ovary and oviduct (Figure 
1.7).  Follicles are produced in the ovary and contain an ovum or yolk, which if 
reaching maturity will go on to be incorporated in an egg.  A mature follicle passes 
into the infundibulum, the start of the oviduct, where fertilisation of the ovum by the 
spermatozoa can occur.  From here it passes through to the magnum (or ampulla) 
where egg albumen (egg white) is secreted before passing through to the isthmus 
where the shell membrane is deposited.  It is in the magnum that gallin, an 
ovodefensin is most highly expressed.  Next the egg passes through to the shell gland 
(or uterus) where the  eggs shell and pigmentation is deposited before finally entering 
the vagina where it is positioned ready for lay (King and McLelland, 1975, Jonchere 
et al., 2010).    In a non-laying bird the oviduct is short and relatively small in 
diameter, however, when the birds’ oviduct becomes active during egg-laying the 
oviduct grows and can become up to 70-80 cm in length (Dougherty and Sanders, 
2005). 
1.7.1 The egg 
The egg must provide an embryo with the nutrients is needs to grow as well as 
protection from pathogens to ensure it survives to hatch.  An egg’s antimicrobial 
defence can be considered as two major mechanisms; physical and chemical 
(Wellman-Labadie et al., 2007). 
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Figure 1.7: Diagrammatic representation of the avian oviduct (adapted 
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1.7.1.1 Physical defence 
The shell and cuticle provide the first line of physical defence and acts as a barrier to 
microbial penetration; however the shell contains thousands of pores for allowing 
gaseous exchange which can be a route of entry to microbes.  The shell membrane is 
composed of a network of fibres which are thought to act as a microbial filter to 
impede bacterial penetration.  Although intact shell and the shell membranes offer 
physical protection it is not completely impenetrable and once bacteria have crossed 
this barrier the viscosity of albumen acts as a final physical hindrance in reaching the 
nutrient rich yolk (Nys et al., 2011). 
1.7.1.2 Chemical defence 
The relative alkalinity of egg albumin (pH 9-10) makes it inhospitable to many 
bacteria helping to prevent contamination; in addition to this albumen proteins 
provide antimicrobial protection through a variety of mechanisms. Some of the best 
known antimicrobial albumen proteins are lysozyme, ovotransferrin and avidin (Nys 
et al., 2011).  It was suggested by Fleming in 1922 that lysozyme was able to cause 
bacterial cell lysis and it has since been demonstrated that this effect is achieved 
through catalyzing hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid 
and N-acetyl-D-glucosamine residues in peptidoglycan, a major component of gram-
positive bacterial cell walls (McKenzie and White, 1991).  It is also suggested that 
lysozyme aids physical defence through forming a network with ovomucin that aids 
egg viscosity (Cotterill and Winter, 1955).  Ovotransferrin is a heat stable 
glycoprotein that can bind iron and therefore plays an important role in nutrient 
transfer to the embryo.  However its ability to bind iron also makes ovotransferrin an 
important antimicrobial agent in egg white as through binding iron it makes it 
unavailable to bacteria thereby hindering survival.  The binding capacity of 
ovotransferrin is greatly reduced at low pH meaning the alkalinity of the egg 
accentuates its activity (Giansanti et al., 2012).   Similarly, avidin indirectly 
functions as an antimicrobial through forming an indigestible complex with biotin 
and preventing its utilisation by bacteria (Laitinen et al., 2002).   
Chapter 1  Introduction 
~ 34 ~ 
 
1.7.1.2.1 Ovodefensins 
One candidate of interest in the egg was gallin, a 41 amino acid peptide belonging to 
a particular group of avian defensins (see 1.3.1.1); the ovodefensins.  This group of 
defensins are expressed in the oviduct of widely divergent bird species and it is 
thought that they play a role in protecting the growing embryo from pathogenic 
organisms whilst it is developing in the egg.  Gallin has been shown to possess 
antimicrobial activity against E.coli, and three copies of the gene are expressed from 
3 separate loci on chicken chromosome 3.  A number of these ovodefensins have 
been identified in the genomes of the chicken, turkey, duck and zebra finch. 
Meleagrin has been described in the turkey, dBPS1 and 2 in the duck and 
taeniopygin 1 and 2 in the zebra finch (Gong et al., 2010).  This study also observed 
another meleagrin-like gene in the turkey genome and a potential additional copy of 
taeniopygin 1 in the zebra finch genome.  These extra copies may be an adaptation to 
increase levels of expression in the egg white as previously suggested for gallin.  
Interestingly the 3D structure of chicken ovodefensin gallin has recently been solved 
which confirmed the presence of the three-stranded antiparallel β-sheet observed in 
all classical beta defensins confirming its classification as a beta defensin (Herve et 
al., 2014).  However, gallin contains an additional short two-stranded β-sheet (Figure 
1.8) (Herve et al., 2014), this five-stranded arrangement supports the hypothesis that 
gallin, and presumably the other ovodefensins, form a structurally distinct sub-family 
of β-defensins. 
1.7.1.2.2 Transiently expressed in neural precursors (TENP) 
Another egg protein of interest is the protein ‘transiently expressed in neural 
precursors’ (TENP); it has been found to show homology with the BPI antimicrobial 
peptide family, in particular BPIL1 (Mulero et al., 2002).  It was first described as a 
transiently expressed gene during neurogenesis in the chicken (Yan and Wang, 1998) 
and has since been identified during proteomic studies of the chicken egg white.  It 
has been proposed that its function is associated with the innate defence of eggs  
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Figure 1.8:  Comparison of defensin 3D structure and alignment of avian 
ovodefensins with classical avian β-defensins.  The 3D structure of ovodefensin 
gallin (A) (Herve et al., 2014), human β-defensin 1 (B) (Bauer et al., 2001) and avian 
β-defensin 2 (C) (Zhang and Sunkara, 2014) are shown.  Gallin contains an 
additional two β-sheets (labelled β1-5) (A) when compared to both classical 
mammalian (B) and avian β-defensins (C). A CLUSTALW alignment between 
ovodefensins and classical avian β-defensins is shown in D: from (Gong et al., 
2010).  Conserved cysteines are highlighted in black with the black bars 
representing cysteine bonds; a conserved glycine is highlighted in grey.  The 
difference in inter-cysteine spacing between ovodefensins and classical avian β-
defensins is clearly apparent and gaps in the alignment are shown by a ‘-‘. 
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against pathogens (Guerin-Dubiard et al., 2006, Mann, 2007, D'Ambrosio et al., 
2008), however its proposed function is based on its relationship to the LT/LBP 
family and antimicrobial activity has yet to be experimentally proven. 
1.8 Therapeutic potential of ovodefensins 
Antimicrobial peptides could present an interesting alternative to prophylactic 
antibiotics if used as a feed additive due to their potential for rapid, broad spectrum 
bactericidal activity and low predisposition for resistance development (Marr et al., 
2006).  They are naturally occurring in the host cells of almost all species as part of 
the innate defence against invading organisms and could therefore provide a vast 
array of potential therapeutics. Cationic HDPs selectively choose bacterial cells due 
to their affinity for the highly negatively charged cell membranes.  This makes the 
likelihood of interactions with eukaryotic cells, in which the cell surface consists of 
predominately uncharged lipids, low (Jenssen et al., 2006).  Microbial resistance is 
unlikely due to their relatively unspecific electrostatic mode of uptake and their 
ability to target multiple sites within a cell.  Resistance can generally not be directly 
selected for under laboratory conditions and requires multiple passages at sub 
minimum inhibitory concentration (MIC) levels as opposed to antibiotics which 
generally induce resistance after only a few passages at sub-MIC levels (Marr et al., 
2006).  Despite the risk of resistance being comparably less than traditional 
antibiotics some instances of resistance within specific strains of bacteria have been 
reported.  For example some bacteria such as particular Yersinia strains are able to 
utilise efflux transporter systems to pump cationic antimicrobial peptides out of the 
cell (Bengoechea and Skurnik, 2000).  Other bacteria such as certain strains of 
Klebsiella, Streptococcus and Pseudomonas produce anionic capsule polysaccharides 
which block the bactericidal activity of AMPs by binding them, thereby reducing the 
amount of peptides reaching the bacterial surface (Llobet et al., 2008).  Both of these 
resistance mechanisms revolve around the required direct association between 
cationic HDP and the bacterial cell.  However as well as their direct interaction with 
micro-organisms HDPs play a role in mediating the immune response (Hancock and 
Scott, 2000), therefore the eradication of pathogens may still be possible due to this 
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indirect effect on the invading organism (Oyston et al., 2009).  In addition to the 
eradication of pathogens, prophylactic HDP use may make it possible to reduce the 
inflammatory response of the host without reducing immune protection; this would 
allow the redistribution of energy and potentially avoid the reduction in growth often 
observed during infection.   In order to increase the activity of a given dose, 
combinations of HDPs could be formulated for a synergistic effect.  This could either 
be to reduce the required minimum dosage or to broaden the spectrum of activity. 
There are of course some limitations and critical needs that need to be addressed for 
the development of HDPs as alternative AGPs, or indeed as a therapeutic in any 
application.  Firstly in order to create a range of products it is necessary to be able to 
discover a large number of antimicrobial peptides to identify those with different 
spectrums of bactericidal activity and immunomodulatory properties.  Testing a wide 
variety of peptides could also aid in the design of synthetic peptides with improved 
function, stability or lability.  However the single largest issue in peptide therapeutics 
is arguably the high cost of solid-phase peptide production and to date efforts to test 
and develop a large number of variants has largely been limited by this expense.  The 
high cost of peptide production will indeed also limit the potential clinical targets to 
which these molecules can be applied.  Potential toxicity of HDPs would also need to 
be addressed as well as understanding the real efficacy of the peptides in the context 
of animal models as opposed to the efficacy in vitro (Hancock and Lehrer, 1998, 
Hancock and Sahl, 2006).  Recombinant systems such as the fungal system used in 
this PhD may provide the tools for cheaper production this allowing screening of a 
greater number of candidates which will aid the addressing of these limitations. 
1.9   Assay selection 
The limitations of testing naturally occurring antimicrobial peptides in vitro has long 
been under scrutiny and the potency of their activity in often directly affected by the 
conditions they are tested under (Schwab et al., 1999).  Whether the peptide is tested 
under solid or liquid phase conditions or the absence/presence of salt, serum or 
proteins in the test conditions have all been shown to affect activity (Schwab et al., 
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1999).  There is also some debate on how relevant in vitro results are for inferring 
activity in vivo; in any instance the activity observed is specific to the conditions of 
the assay and may not reflect activity in different conditions.  Before moving to  
testing in vivo, the studies in this PhD used an ex vivo gut model to evaluate 
promising candidates against a mixed community of microorganisms that directly 
resemble those conditions in which the peptide would need to work in terms of 
microbial microbiome structure, pH and metabolites.   
1.10  Project aims 
Antibiotic use has driven the evolution of transmissible antibiotic resistance that has 
reduced the effectiveness of human and veterinary medicines (Hancock, 1997).  A 
recent ban under EU Directives of in-feed antibiotics used to promote energy 
retention from the diet and prevent microbial infections has led to production losses, 
increased incidence of disease and welfare concerns in the poultry industry (Bedford, 
2000).  Poultry are crucial to global food security and therefore a pressing need exists 
to maintain the efficiency of animal production by finding alternatives.  One of the 
critical needs in realising the potential of alternative antimicrobial strategies was 
identified as the characterisation of a wide range of molecules and their properties 
(Hancock and Sahl, 2006).  Antimicrobial peptides have been suggested as an 
alternative due to their potential for rapid, broad spectrum bactericidal activity and 
low predisposition for resistance development (Hancock, 1997).  The large 
abundance of natural antimicrobials make the egg an invaluable reservoir of potential 
candidates (Kovacs-Nolan et al., 2005) particularly as the clinical application for this 
study relates to the food industry.  Naturally derived egg products, as already widely 
consumed by humans, would offer a level of acceptability and therefore form the 
basis of the peptide portfolio for this PhD study. 
The overall aim of this study was to identify novel antimicrobial peptides from the 
egg and characterise their biology, evolution and function for consideration as 
peptide feed additives.  
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The first phase of the project focused primarily on identification of novel candidate 
peptides.  Available literature was used to prioritise peptides from the egg that were 
largely uncharacterised but had some supporting evidence of antimicrobial function 
or homology with known antimicrobials.  Phase two involved characterisation of the 
biology of selected candidate genes, in particular evolutionary aspects, transcript 
investigation and expression analysis.  Finally the most promising candidates were 
assessed for antimicrobial function, initially in vitro and in an ex vivo gut model but 
ultimately in an in vivo peptide feed trial.   
The aim of the research described in chapters 3 and 4 was to determine if the 
expression of selected genes was restricted to the oviduct and therefore indicative of 
an egg specific protein.  This was achieved through RT-qPCR analysis across a wide 
range of tissues and where possible was confirmed at protein level with 
immunohistochemistry.  The purpose of these chapters was also to identify homologs 
of each gene to determine if they were avian specific or spanned other species to gain 
an insight on the drivers of evolution.    
In chapter 5 selected candidates were evaluated for antimicrobial activity in an in 
vitro assay and one candidate was assessed under challenge conditions (pH and salt).  
The most promising candidates were selected for trial in an ex vivo gut model to 
determine activity in a more relevant setting and evaluate whether they could 
modulate whole gut microbiomes.   
Finally chapter 6 evaluated the efficacy of two peptides in an in vivo peptide feed 
trial.  Mean body weight was used as an indicator of growth performance and 
parameters such as intestinal microbiota and metabolites were used as correlates of 
good gut health.  This trial resulted in improved growth and a reduction in known 
pathogenic bacteria such as Clostridium perfringens showing promise for the use of 
antimicrobial peptides as alternatives to antibiotic growth promoters. 
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2.1. Reagents and solutions 
All medium and buffer recipes are shown in Appendix 1. 
2.2. Bioinformatic analysis 
2.2.1. TENP 
The TENP protein sequence (NCBI accession no. AF029841) was used to perform a 
TBLASTN search  of the May 2006 release of the chicken EST database using the 
default parameters of the NCBI blast database (http://blast.ncbi.nlm.nih.gov/) to 
identify  ESTs and sequences related to the locus.  The Staden package (Staden, 
1996) was used to build a consensus sequence using the ESTs available. This 
allowed a gap present in the genome build to be bridged and allowed a comparison to 
be made between the genomic, EST and published TENP mRNA sequences in order 
to address differences in sequence identity. Primer3(http://frodo.wi.mit.edu/primer3/) 
was used to design primers (Table 2.1) for re-sequencing across the length of the 
consensus sequence including a putative alternative transcriptional start site 
identified in the consensus sequence.   
Signal P (Bendtsen et al., 2004) was used to assess the likelihood of a signal peptide 
produced by each translational start site.  The protein sequence is submitted to the 
Signal P website in FASTA format using the eukaryotic setting; all other settings 
were used in default mode.   A graphical output is produced showing the position of 
three different scores; C, S and Y on the sequence.  The C score is the raw cleavage 
site score and indicates the most probable location of the first amino acid of the 
mature peptide; the score is highest at this point.  The S score is the signal peptide 
score and is used to distinguish between positions within a signal peptide and other 
parts of the mature protein or proteins that do not have a signal peptide.  The S score 
is therefore highest across the signal peptide and a loss in signal should coincide with 
a peak in the C score if a signal peptide is likely.  Finally the Y score combines the C 
and S scores to give a likelihood of a signal peptide.  This is required as it is possible 
to have multiple high C scores in any given sequence yet to determine a true signal 
peptide it is necessary to have an accompanying peak in the S score.  In addition 
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signal P also provides two additional data points.  The mean S value is the average S 
score across the whole of the predicted signal peptide and the D-score is an average 
of this mean S value and the maximal Y value.  The D-score gives the overall 
prediction for the likelihood of a sequence containing a signal peptide.  For non-
secretory proteins all scores should be close to the negative target value of 0.1 
(Petersen et al., 2011). 
Exon contributions were estimated from genomic DNA using BDGP NNSPLICE 
version 0.9 (Reese et al., 1997) (Chapter 3, Table 3.2).  Genomic sequences were 
submitted in FASTA format and default settings were used.  Where a large number 
of potential splice sites were retrieved the minimal 5’ and 3’ splice site score were 
increased to 0.7.   BDGP NNSPLICE analyses a sequence for donor and acceptor 
sites, the program only considers genes which conform to specific constraints with 
the consensus splice sites.  For example GT for the donor and AG for the acceptor 
site, the outputs contain a score which indicates the likelihood of a particular splice 
site which is based on motifs in the surrounding sequence.  
The duck genome database (Anas platyrhynchos – version 1) (http://pre.ensembl.org) 
and turkey genome database (Meleagris gallopavo – assembly UMD2) 
(http://www.ensembl.org) were searched using TBLASTN for potential homologues 
using the 629 amino acid mature TENP protein. 
2.2.2. Ovodefensin 
Available genome databases Ensembl (http://www.ensembl.org), PreEnsembl 
(http://pre.ensembl.org) and UCSC (http://genome.ucsc.edu/) were searched using 
TBLASTN and BlastP to locate potential homologs using the 41 amino acid mature 
peptide sequence of gallin (GenBank: CBE70283.1) and the previously published 39 
amino acid mature peptide sequence of taeniopygin 2 (Gong et al., 2010).  Further 
iterative searches were made with the homologues discovered.  Protein database Uni-
prot (http://www.uniprot.org/) was also searched using BlastP to identify peptide 
sequences previously unidentified as ovodefensins.  Primers (Table 2.2) were 
designed to ensure complete coverage of each ovodefensin’s coding sequence. 
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Forward primer name Forward primer sequence Reverse primer name Reverse primer sequence 
TENP Exon1F1 AGGATGGGAACAGCAAACAG TENP End1 ATCCTCCTTCTGCACCAAAA 
TENP RTF CACTGCTGGAGGAGCTGTT TENP RTR ACAACGTTGACGTCGGTGTA 
D.TENP F3 AGACCATACGCAGAGGTGGT D.TENP R3 AGGTTGCACAGGAGCAAGAC 
D.TENP F8 AGGGAATCACCATGTCCTTG D.TENP R10 TGATCTTCTGTGCCATGGTG 
T.TENP F1 GTCTCAAAGCCACATGCAGA T.TENP R1 GGTTTTCCACTGCTTTCACC 
  TENP SP1 ATCTGGAGGACTTGCTTTCC 
  TENP SP2 CCCATGTCTACGTGGAGGTC 
 
Table 2.1 – Names and sequences of TENP primers used in the study. 
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Forward primer name Forward primer sequence Reverse primer name Reverse primer sequence 
Chicken OvoDB1 F/RTF GTGCTCTTTGCTGTGCTCCT Chicken OvoDB1 R/RTR AGAGCTGCTCCTGCTCCAC 
Turkey OvoDA1 F TGGGCTAAGTTTCCCAGCTA Turkey OvoDA1 R AGTGACTGTGGCTGTCATCG 
Turkey OvoDA1_2 F AGCTCCTCTCCTCCAGCTCT Turkey OvoDA1_2 R TACTTTGCATGGGGTCAACA 
Turkey OvoDB1 F/RTF TGTGCTCCTGCTCTTTTCCT Turkey OvoDB1 R/RTR AGAGCCTCTCCTGCTCCACT 
Duck OvoDA1 F AGGGGGTGGCAGTTGAGTAG Duck OvoDA1 R GACGAAAGGCTGGAAAACAG 
Duck OvoDB1 F GAGATCCCCACCGTCCTC Duck OvoDB1 R TCAAAGCAACGAAACCGTCT 
Zebra finch OvoDA1 F AAATGGGGAAGAGCAATGG Zebra finch OvoDA1 R AATCGTGGGGACACCAGTAA 
Zebra finch OvoDB1 F GCTGTGGTCCTGGTGGATA Zebra finch OvoDB1 R TTGCTGCAAGCATCACTTTC 
Chicken OvoDA1 RTF CTCCAGCCTCGCTCACAC Chicken OvoDA1 RTR TTGAGAGGAGGGGATGACAC 
Turkey OvoDA1/1_2 RTF GCTGTCCTCCTGCTGGTCT Turkey OvoDA1/1_2 RTR CCTTGCAGTCGGAGGAGTAG 
Duck OvoDA1 RTF GCTACGGGTTTCCCCTTC Duck OvoDA1 RTR AGGTCGGGTACTGCTCCAG 
Duck OvoDB1 RTF GTGCTCCTGCTTTTCTCCAT Duck OvoDB1 RTR GCACGCAATGAACACAGC 
Zebra finch OvoDA1 RTF CCTTCCAGGCTATGGGAAGT Zebra finch OvoDA1 RTR GCAGTCGCCAGAGGTGTATT 
Zebra finch OvoDB1 RTF CGTTGTCTTTGCTGTTTTCCT Zebra finch OvoDB1 RTR GTGCTCCTCCCTCTCTCCTT 
Chicken OvoDA1 SP5 ACACGTGCTCCAAGACACAG Chicken OvoDA1 SP1 GCAGGCAGCAGTACATCTTG 
  Chicken OvoDA1 SP2 GCCCAGATCTGTGTCTTGGA 
 
Table 2.2 – Names and sequences of ovodefensin primers used in the study. 
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As described for TENP (2.2.1) Signal P (Bendtsen et al., 2004) was used to assess 
the likelihood of a signal peptide when a potential translational start site could be 
identified in the genome. 
2.3. Phylogenetic analysis 
2.3.1. TENP 
A phylogram indicating the evolutionary history of TENP was inferred using the 
Neighbor-Joining method (Saitou and Nei, 1987) from an alignment of the mature 
proteins.  Included for comparison were human LPLUNC2 (NCBI reference 
sequence no. NM_025227) and chicken Ovocalyxin 36 (NCBI reference sequence 
no. NM_001030861). The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (1000 replicates) are shown next to the 
branches (Felsenstein, 1985). The branch lengths are proportional to the evolutionary 
distances which were computed using the Poisson correction method (Zuckerkandl 
and Pauling, 1965).  The units are the number of amino acid substitutions per site.  
All positions containing gaps and missing data were eliminated. Evolutionary 
analyses were conducted in MEGA5 (Tamura et al., 2011).  The common name of 
the species is included with the protein names.   
2.3.2. Ovodefensin 
A distance matrix based on the amino acid sequence length between each of the 
cysteines and the conserved glycine residue was built in R for all known and newly 
discovered ovodefensins (Chapter 4, Table 4.1).  Hierarchical clustering for each 
distance matrix was calculated using R (http://www.r-project.org/) which was then 
used to produce a cladogram of the phylogenetic relationships using the R ‘hclust’ 
function.  Similarly cladograms based on spacing were produced separately for avian 
species and reptiles 
In addition to this a cladogram was constructed using the Neighbour-Joining function 
(Saitou and Nei, 1987) in Mega5 with a bootstrap test of 1000 replicates (Felsenstein, 
1985) of the core peptide sequence from the conserved glycine until the fourth 
cysteine residue inclusively for sequences where the number of amino acids within 
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this region was identical.  These functions were again used in Mega5 to construct 
phylograms based on the whole mature peptide sequences for OvoDA family 
members and also OvoDB. 
2.4. Birds and tissue collection 
2.4.1. Broilers 
Oviduct tissue (magnum, shell gland, isthmus, vagina), ovarian stroma and liver were 
collected from sexually mature broiler breeders (n=3).  A diagrammatic 
representation of the region of the oviduct and descriptions of their function can be 
found in Chapter 1, Figure 1.7. 
2.4.2. Layers  
The following tissues were taken from sexually mature White Leghorn LSL hens 
(Gallus gallus) (Lohmann): Oviduct (magnum, shell gland, isthmus, vagina), ovarian 
stroma, crop, duodenal loop, gizzard, caeca, cloaca, lung, adrenals, cerebellum, 
retina, spleen, liver, kidney, and heart (n=4).   
2.4.3. Turkeys  
The following tissues were collected from sexually mature turkeys (Kelly Bronze, 
Scotland): Oviduct (magnum, isthmus, shell gland, vagina), ovarian stroma, 
oesophagus, crop, duodenal loop, gizzard, caeca, cloaca, lung, adrenals, cerebellum, 
tongue, spleen, breast muscle, skin, liver, kidney and heart (n=4).   
2.4.4. Ducks 
Tissue was collected from sexually mature Pekin ducks (Anas platyrhynchos) 
(Cherry Valley): Oviduct (magnum, shell gland, isthmus, vagina), ovarian stroma, 
crop, proventriculus, small intestine, duodenal loop, gizzard, large intestine, caeca, 
cloaca, gall bladder, lung, trachea, pituitary, adrenals, cerebellum, hypothalamus, 
tongue, spleen, breast muscle, liver, kidney and heart (n=3).  
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2.4.5. Zebra fiches 
Adult female zebra finches were supplied courtesy of Dr Karen Spencer, University 
of St Andrews, Scotland.  Tissues collected were oviduct (magnum, isthmus shell 
gland), ovarian stroma, small intestine, duodenal loop, gizzard, lung, spleen, breast 
muscle, skin, liver, kidney and heart (n=5).  Tissues for immunolocalisation studies 
(2.12) (magnum, isthmus, shell gland and breast muscle) were harvested from 5 of 
these laying hens birds post mortem  and fixed in 10% buffered-neutral formalin 
(BNF) prior to being processed to paraffin wax. 
2.4.6. Embryonic tissue 
Brain, retina and heart tissue was taken from embryonic day 10 (E10) (n=6) and day 
16 White Leghorn chickens (E16) (n=6).  E10 and E16 correspond with Hamburger–
Hamilton (HH) embryonic developmental stages HH36 and HH42 respectively. 
2.4.7. Time of oviposition 
Magnum tissue was obtained from sexually mature White Leghorn hens with an 
ovum at various positions in the oviduct; see Gong et al. (2010) for details.  Briefly, 
magnum tissue was processed either when the egg was in the magnum (n=5), in the 
shell gland where the stage of calcification was determined by electron microscopy 
and recorded as early (n=8), mid (n=9) and late (n=10) calcification or during a 
pause day (n=11) when there was no evidence of ovulation. 
The time of ovipoisition q-PCR on Gallus gallus OvoDB1 was carried out by 
Maisarah Maidin as part of a summer placement project which I designed and 
supervised. 
2.4.8. Effect of oviduct development 
In domestic chickens the onset of incubation behaviour is characterised by the 
regression of the oviduct due to the withdrawal of gonadotrophic support (Dunn et 
al., 1996).  This natural phenomenon was exploited to determine if expression 
differed between in lay hens and those where the oviduct had regressed.  Magnum 
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and shell gland tissue from both states was collected from hens of a Silkie x White 
Leghorn cross which readily show incubation behaviour, (n=11). 
All tissues were rapidly dissected using sterile instruments and placed in RNA free 
Eppendorf tubes.  After dissection tissue was either frozen in liquid nitrogen and 
directly stored at -80°C or placed in RNA later (Ambion, Applied Biosystems, 
Warrington, UK) and stored at 4°C overnight before storage at -80°C.  Samples 
weighed no more than 100 mg. 
2.4.9. Administration of steroid hormones 
The administration of steroid hormones was adapted from a method described 
previously (Kunnas et al., 1992).  Three week old ISA brown chicks (n=60) were 
given an intramuscular injection of 0.5mg diethylstilbestrol (DES) in 0.5 ml 
propylene glycol daily for seven days (primary stimulation) and then split into two 
groups.  Following the primary DES treatment there was a period of withdrawal from 
DES for 12 days in group one (non-primed) birds (n=30) followed by a single 
injection of progesterone (20 mg/kg) (n=10), oestradiol (10 mg/kg) (n=10) or vehicle 
(propylene glycol; 1 ml/kg) (n=10).  In the second group (primed) the birds (n=30) 
were re-stimulated daily for two days with DES after a withdrawal period of 10 days 
followed by a single injection of progesterone (n=10), oestradiol (n=10) or vehicle 
(n=10) as already detailed for the non-primed birds.  All chicks were killed 12-16 
hours after the single injection; magnum tissue was removed and immediately frozen 
in liquid nitrogen then stored at -80°C. 
This experiment had been carried out previously by those named in the above paper 
(Kunnas et al., 1992); RNA was kindly provided for reverse transcription and 
subsequent q-PCR analysis. 
2.5. RNA processing 
2.5.1. RNA purification 
Soft tissues (magnum, shell gland, isthmus, lung, cerebellum, spleen, liver,  kidney 
and embryonic) were homogenised in Lysing matrix D tubes (Qbiogene-Alexis Ltd. 
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Nottingham, UK) containing Ultraspec II total RNA isolation reagent (AMS 
Biotechnology, Oxon, UK) using a FastPrep FP120 homogeniser (Qbiogene-Alexis 
Ltd. Nottingham, UK).  All other tissues were homogenised in Ultraspec II total 
RNA isolation reagent (AMS Biotechnology, Oxon, UK) using a Ultraturrax 
homogeniser (IKA
®
-Werke GmbH & Co. KG, Germany).  Samples were 
homogenised in 1ml of UltraSpec II solution and were kept chilled on ice throughout 
the homogenisation period. 
Samples were then processed as per the Ultraspec protocol which utilises a 
phenol/chloroform solution to isolate RNA in the aqueous phase, this is then 
separated by centrifugation.  The quantity and purity of the isolated RNA was 
checked using a nanodrop (Thermo Scientific, Wilmington, USA). 
2.5.2. Reverse transcription 
Total RNA (1 µg) was reverse transcribed using a high capacity cDNA reverse 
transcription kit (Applied Biosystems, UK) according to the manufacturer’s protocol.  
Before reverse transcription took place all samples were treated with RQ1 RNase-
Free DNase (Promega, Madison, USA) as per manufacturer’s instructions to remove 
potential residual genomic DNA contamination left over from the RNA purification. 
2.6. Polymerase chain reaction (PCR) 
2.6.1. Primer design  
Primers were designed with Primer3 (http://frodo.wi.mit.edu/primer3/) using the 
default settings and all primer pairs were tested using the UCSC Genome Browser 
Gateway (http://genome.ucsc.edu/) in silico PCR tool to check specificity and ensure 
they did not amplify other regions of the genome. 
2.6.2. PCR conditions and product purification 
PCR was carried out using Faststart Taq (Roche, UK) according to the 
manufacturer’s protocol.  Amplification was performed using the following 
conditions:  an initial denaturation at 95°C for 4 minutes, followed by 40 cycles of 
30s at 95°C, 30s at 58°C and 30s at 72°C, followed by an extension of 7 minutes at 
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72°C.  All products were separated by 2% agarose-gel electrophoresis and visualised 
using SYBR Safe DNA gel stain (Invitrogen, UK).  Bands were excised from the gel 
and the cDNA purified from the matrix using a Qiaex II Gel Extraction Kit (Qiagen, 
UK).  The Qiagen kit solubilises agarose to release the DNA from the matrix; this is 
then bound to silica gel particles under high salt concentrations.  Dissociation of the 
DNA from the silica gel particles is achieved through subsequent washes in a low 
salt solution. 
The purified PCR fragments were sequenced with their respective forward and 
reverse primers.  Sequences were assembled by Staden (Staden, 1996) to produce 
consensus sequences.   
2.7. Reverse transcription quantitative PCR (RT-QPCR) 
2.7.1. Primer design 
Primers for RT-QPCR were designed for chicken and duck TENP (Table 2.1) and 
chicken, turkey, duck and zebra finch ovodefensin genes (Table 2.2).  Primers were 
designed using the default settings of Primer3 (http://frodo.wi.mit.edu/primer3/) with 
a product length of 100-200 bp.  Where possible primers were designed to span an 
intronic region to prevent amplification of genomic contamination, however in some 
cases the PCR primers used for whole sequence amplification were used for RT-
QPCR for the ovodefensin genes (Table 2.2), however all RNA was treated with 
DNase before reverse transcription (see 2.5.2) and no genomic contamination was 
detected. 
2.7.2. Standard curve production and experimental procedure 
PCR was carried and single bands excised and purified from the agarose gel as 
outline in 2.6.2.  Purified cDNA was diluted 1/500 the top standard which was 
detectable at around 8 cycles during RT-QPCR amplification and six ten-fold serial 
dilutions from this formed the standard curve. 
Reverse transcribed samples (2.5.2) were diluted by a factor of 10 with MilliQ H2O 
prior to use.  RT-QPCR was carried out with 10 µl of the diluted cDNA and a primer 
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concentration of 20 mM according to Agilent Brilliant II SYBR® Green QPCR 
master mix (Stratagene, UK) instructions.  The following conditions were used for 
RT-QPCR; 95°C for 2 min, then 40 cycles of 95°C for 15s, 60°C for 30s using an 
MX3000 (Stratagene, UK).  Reactions containing no template were run as a control.  
Products were run on an agarose gel to confirm only products of the correct length 
with no primer-dimer were amplified as well as ensuring that there was only a single 
peak dissociation curve, correct amplification was also confirmed through 
sequencing of the PCR product.  Lamin B-receptor (LBR) expression was shown 
previously to have only minimal variation between samples and was measured in the 
same way to normalise concentrations (McDerment et al., 2012).   
2.7.3. RT-QPCR statistical analysis 
One way or two way ANOVA and least significant difference to test between the 
means were used as appropriate for statistical analysis of log transformed data. 
(Genstat 13
th
 edition, VSN International Ltd, Oxon, UK). 
2.8. Rapid amplification of cDNA ends (RACE) 
2.8.1. 5’RACE 
5’RACE (Roche Diagnostics 2
nd
 Generation, Mannheim, Germany) was carried out 
to determine the transcriptional start site of chicken TENP.  Briefly, synthesis of first 
strand cDNA was carried out on magnum RNA using primer TENP SP1 (Table 2.1) 
and the mRNA template degraded.  cDNA was purified using a High Pure PCR 
Product Purification kit (Roche Diagnostics, Mannheim, Germany) and polyA tailed 
at the 3’ end.  The tailed cDNA was amplified by PCR using the Oligo (dt)-anchor 
primer provided and a further nested primer TENP SP2 (Table 2.1).  The product 
from this PCR was run using 3% agarose-gel electrophoresis and visualised using 
SYBR Safe DNA gel stain (Invitrogen, UK).  PCR product was excised from the gel 
and cleaned from the agarose using a QIAEX II Gel Extraction Kit (Qiagen, UK) 
(see 2.6.2) and sequenced using primer SP2. 
5’RACE and 3’ RACE (see 2.8.2) were also carried out to determine the number of 
exons encoding Gallus gallus OvoDA1 (gallin).  The reaction was carried out as for 
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TENP using primers OvoDA1SP1 and OvoDA1SP2 (Table 2.2) and sequenced using 
primer OvoDA1SP2.  
2.8.2. 3’RACE 
3’RACE (Roche Diagnostics 2
nd
 Generation, Mannheim, Germany) used the 
oligo(dT)-anchor primer to initiate cDNA synthesis at the poly(A)-tail of magnum 
RNA.  Amplification using a PCR anchor primer and OvoDA1SP5 (Table 2.2) was 
then performed directly.  PCR product was excised from the gel and cleaned from the 
agarose as before (2.6.2) and sequenced using primer OvoDA1SP5.  
2.9. Sequencing and database submission 
All sequencing was carried out by GATC biotech (Konstanz, Germany) and 
consensus sequences were submitted to EMBL.  
Chicken TENP (EMBL accession no. HG007958)  
Turkey TENP (EMBL accession no. HG425203)  
Duck TENP (EMBL accession no. HG425202)  
Gallus gallus OvoDB1 (EMBL accession no. LN717248)  
Meleagris gallopavo OvoD1_2 (EMBL accession no. LN717249)  
Meleagris gallopavo OvoDB1 (EMBL accession no. LN717250) 
Taeniopygia guttata OvoDA1 (EMBL accession no. LN717251)  
Taeniopygia guttata OvoDA1_2 (EMBL accession no. LN717252) 
Taeniopygia guttata OvoDB1 (EMBL accession no. LN717253).  
Putative ovodefensin sequences for budgerigar, medium ground finch, anole lizard, 
american alligator, collared flycatcher, painted turtle and chinese soft-shelled turtle 
were not submitted because they remain predicted but can be found in Chapter 4, 
Table 4.2. 
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2.10. Northern analysis 
RNA was subject to electrophoresis on a 2% agarose gel under denaturing conditions 
(Pelle and Murphy, 1993) and SYBR safe DNA gel stain (Invitrogen, UK) was used 
for visualisation. The RNA was then transferred to an Amersham Hybond N+ nylon 
membrane (GE Healthcare Life Sciences, Buckinghamshire, UK) after washing the 
gel in dH20 for 30s; 50 mM NaOH, 10 mM NaCl for 45 min; 0.1 M Tris HCl pH 7.5 
for 45 mins; 20xSSC for 60 mins and UV-crosslinked (Stratagene Stratalinker) at 
120,000 microjoules/cm
2
.  A Riboprobe In-vitro Transcription Systems kit (Promega, 
Southampton, UK) was used to produce a single stranded RNA probe via the T3 
RNA polymerase system and incorporated 
32
P labelled UTP. Hybridisation of 
32
P 
probe was detected using the Typhoon FLA7000 (GE Healthcare Life Sciences, 
Buckinghamshire, UK). 
2.11. Production and titres of polyclonal antibodies 
Production of antibodies was carried out by Dundee Cell Products Ltd, Dundee.  
Briefly, two rabbits per peptide were immunised four times at three week intervals 
by intramuscular injection of synthesised Gallus gallus OvoDB1 (R108 and R109) 
epitope (CNKKDEWSFHQ), Taeniopygia guttata OvoDB1 (R112 and R113) 
epitope (KGEREEHTED) or TENP (R106 and R107) epitope 
(AWMDDVLREGVHLPHLSH and DAELSLAASNVGLVRAA) emulsified in 
Freund’s adjuvant.  Serum was collected after each immunisation.  Antiserum was 
purified via a two-step affinity purification using cognate peptides coupled to beads.   
To measure the titres of antibody in the antisera, the synthesised epitopes were 
diluted with 50 mM Na2CO3 (pH 9.6) to a final concentration of 1 ng/µl (0.5 ng/µl of 
each epitope) and 50 µl of the solution was added to each well of a 96 well plate.  
The plate was covered and stored overnight at 4°C.  This was aspirated and the wells 
incubated for 2 hours at room temperature with 200 µl tris-buffered saline (pH 7.5), 
0.5% Tween 20 (TBST), 1% bovine serum albumin (BSA) to block unsaturated 
binding sites.  Pre-immune (null) sera and antisera were serially diluted 1/1000 to 
1/32000 with TBST, 1% BSA, pH 7.5.  To each well, 10 µl of diluted null sera or 
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antisera were added and the plate incubated for 2 hours at room temperature.  The 
plate was washed 5 times with TBST.  Horse radish peroxidase (HRP) conjugated 
Anti-rabbit IgG (SAPU, Edinburgh, Scotland) diluted 1/2000 with TBST, 1% BSA, 
pH 7.5 100 µl was applied to each well and the plate incubated at room temperature 
for 2 hours.  After five washings with TBST, peroxidase activity was detected by 
adding 100 µl detection solution (100 mM citric acid, 200 mM Na2HPO4, O-
Phenylenediamine (OPD), H2O2)).  The reaction was stopped with 50 µl 2 M H2SO4 
and absorbance (490 nm) measured spectrophotometrically. 
2.12. Immunohistochemistry 
All immunohistochemistry was carried out in collaboration with Maureen Bain and 
Lynn Stevenson at the College of Medical, Veterinary and Life Sciences (MVLS), 
University of Glasgow, Glasgow, Scotland, G61 1QGH, UK using the antibodies 
from 2.11.  Chicken tissues (magnum, isthmus, shell gland and caecum) were 
harvested from five laying hens post mortem (Gong et al., 2010) or zebra finches 
(magnum, isthmus, shell gland and breast muscle) (see 2.4.5) and fixed in 10% 
buffered-neutral formalin (BNF) for 24 hours prior to being processed to paraffin 
wax using a 16 hour processing cycle in a Thermoshandon Excelsior tissue 
processor. 
2.12.1. TENP 
Wax embedded tissues were sectioned at 3 microns  using a Thermoshandon Finesse 
microtome, lifted onto vecta slides and incubated at 60°C for 1 hour before they were 
de-waxed and taken down to water.  Each section was then treated with Proteinase K 
for 20 minutes at room temperature (antigen retrieval) before loading onto a Dako 
Autostainer (Dako, Cambridgeshire, UK).  A standard IHC protocol was then used; 
optimal staining was achieved at a 1:3000 dilution of the polyclonal anti-TENP 
antiserum (107_AWM_1.1) for 30 minutes.  The sections were viewed using a Leica 
DM 4000 B microscope and images captured using a Leica DC480 camera with 
Qwin program for PC (Leica, London, UK). 
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2.12.2. Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1 
Wax embedded tissues were sectioned at 3 microns  using a Thermoshandon finesse 
microtome, lifted onto Vetabond slides and incubated at 60
0
C for 1 hour before they 
were de-waxed and taken down to water.  Heat induced epitope retrieval (HIER) was 
carried out using a Menarini Access Retrieval Unit, in buffer (Sodium Citrate pH 6) 
for 1 minute 40 seconds at 125
o
C full pressure. Each section was then loaded onto a 
Dako Autostainer (Dako, Cambridgeshire, UK).  A standard IHC protocol was then 
applied; optimal staining was achieved at a 1:500 dilution for the polyclonal zebra 
finch anti-OvoDB1 (113_KGE _2.1) and 1:1000 for the chicken anti-OvoDB1 (108 
CNK-1.3).  The sections were viewed using a Leica DM 4000 B microscope and 
images captured using a Leica DC480 camera with Qwin program for PC (Leica, 
London, UK). 
2.13. Synthetic peptide production 
Gallus gallus OvoDA1 (LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASWKWK), 
OvoDB1 (KRKGTCKGYCAPTCNKKDEWSFHQSCKKMYCCLLPLKKGK) and Anas 
platyrhynchos OvoDA1 (QVRKYCPKVGYCSSKCSKADVWSLSSDCKFYCCLPPGWKGK) 
were commercially obtained from Almac Group (East Lothian, Scotland).  The 
peptides were synthesized on a 0.2 mmol scale using an automated Applied 
Biosystems 433 peptide synthesizer and fluorenylmethoxy (Fmoc) solid phase 
peptide synthesis protocols.  Each amino acid was coupled after activation with 
diisopropylcarbodiimide/Oxyma pure.  Upon completion of the synthesis the peptide 
was cleaved from the resin and the side chain protecting groups removed using a 
cocktail of trifluoroacetic acid, ethanedithiol triisopropylsilane and H2O.  The 
peptide was folded in the presence of oxidised and reduced glutathione at pH 8 and 
the final product isolated using preparative HPLC and a gradient of H2O, acetonitrile 
and 0.1% trifluoroacetic acid.  Freeze dried peptides were reconstituted in 10% 
dimethyl sulfoxide (DMSO).  
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2.14. Recombinant peptide production 
Recombinant Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1 were 
produced by Roal, Finland using a continuous fungal fermentation system.  For 
production information sheets were given to Roal for each gene (Appendix 2) which 
contained cDNA and amino acid sequences for the mature peptide to be produced as 
well as detailed peptide information including molecular weight, charge, isoelectric 
point and inclusion body probability.  Modified Trichoderma sp. with reduced 
endogenous protein production expressing a vector containing each ovodefensin was 
used as the production organism and the resulting supernatant was purified further 
using molecular weight filters of <3 kDa and >50 kDa before being spray dried to 
powder form for the final product.  A Trichoderma system expressing an empty 
vector was treated in the same way to act as a control in the in vitro and ex vivo 
evaluation. 
Due to the confidential nature of the system further details on production cannot be 




Chapter 2  Materials and methods 
 
~ 58 ~ 
 
2.15. Antimicrobial assay 
The antimicrobial assay, adapted from methods described previously (Nagaoka et al., 
2000, Townes et al., 2004, Gong et al., 2010) was used to determine the efficacy of 
synthetic Gallus gallus OvoDA1, OvoDB1 and Anas platyrhynchos OvoDB1.  E. 
coli K-12 strain DH5, avian pathogenic E. coli (APEC) O78:H9 strain χ7122, 
Salmonella enterica serovars Enteritidis (SE125109) and Typhimurium (ST4/74) and 
Staphylococcus aureus (8325-4) were cultured overnight at 37°C in Luria broth (LB) 
or tryptone soya broth (TSB) (S. aureus).  Two hundred and fifty µl of overnight 
culture was sub-cultured into 20 ml of LB or TSB and incubated at 37°C for 3 hours.  
After the second incubation 20 µl of culture was diluted with 2 ml of phosphate 
buffered saline (PBS), pH 7.4.  Ten µl of Gallus gallus OvoDA1, OvoDB1 or Anas 
platyrhynchos OvoDB1 peptide or DMSO (control) or PBS was added to 50 µl of 
diluted culture.  After vortexing this was incubated at 37°C for 3 hours and then the 
suspensions were serially diluted to 1x10
-4
 with PBS, all dilutions were plated on LB 
or tryptone soya agar plates.  Plates were incubated overnight at 37°C and the 
colonies were counted.  Results are expressed as a reduction in colony forming units 
per ml (CFU/ml). 
2.15.1. Campylobacter jejuni 
Synthetic Gallus gallus OvoDA1 was also evaluated against a strain of 
Camplybacter jejuni 11168 known to possess genes (cj0423 and cj0424) which are 
thought to confer resistance to cationic antimicrobial peptides as well as a mutant of 
this strain (11168H) which lacks these genes (Unpublished data, supplied by Cosmin 
Chintoan, Roslin Institute).  The same broth based assay as described previously 
(2.15) was used but MH broth was used in this assay and blood free campylobacter 
selective agar containing CCDA selective supplement was used for enumeration of 
C. jejuni colonies.  Overnight cultures were grown in a microaerophilic cabinet at 
400 rpm in pre-equilibrated media.  Plates for enumeration were counted after a 2 
day incubation period in microaerophilic conditions. 
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2.15.2. pH sensitivity 
The antimicrobial assay as outlined above (2.15) was adapted to test the effect of pH 
on the efficacy of synthetic Gallus gallus OvoDA1 against E. coli DH5.  The assay 
was carried out as before but using PBS at pH 6.4, 7.4 and 8.4 (Appendix 1).   
pH sensitivity was carried out by Tian Chee Lu as part of a summer placement 
project which I designed and supervised. 
2.15.3. Salt sensitivity 
The antimicrobial assay (5.3.2) was adapted to test the effect of salt sensitivity on 
Gallus gallus OvoDA1 efficacy.  PBS with NaCl concentrations of 50, 100 and 
150 mM, pH 6.4 were used (Appendix 1). 
Salt sensitivity was carried out by Tian Chee Lu as part of a summer placement 
project which I designed and supervised. 
2.15.4. Bacterial metabolic state 
Some traditional antimicrobials are only able to kill replicating bacteria.  To 
determine if metabolic state has an effect on synthetic Gallus gallus OvoDA1 
activity it was assessed against Avian Pathogenic E. coli in both a metabolically 
active and static state.  Ampicillin was used as positive control in these experiments 
as it is known to interfere with cell wall synthesis and therefore requires bacterial 
cells to be metabolically active (Kong et al., 2010a).  The standard assay produces 
bacteria in a metabolic state and was carried out as before (2.15) to produce 
metabolically active APEC.  To produce static APEC the culture medium was 
centrifuged at 10,000 rpm for 5 minutes, the LB broth removed and the bacterial 
pellet resuspended in the same volume of PBS.  This step was repeated three times to 
ensure all traces of LB nutrient were removed from the system before the bacteria 
was incubated in PBS with Gallus gallus OvoDA1. 
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2.16. Viral plaque assay 
The antiviral activity of synthetic Gallus gallus OvoDA1, OvoDB1 and recombinant 
Taeniopygia guttata OvoDB1 was evaluated against a H1N1 Influenza A virus 
(A/WSN/33) (obtained by Gareth Hardisty, Roslin Institute) using a eukaryotic 
MDCK (Madin-Darby canine kidney) cell monolayer.  A known antiviral peptide 
FluPep (Nicol et al., 2012) (curtesy of Seema Jasim, Roslin Institute) was used as a 
positive control.  FluPep is a small peptide of 2.785 kDa which blocks the uptake of 
influenza virus into cells by interacting with haemagglutinin and preventing virus to 
cell binding. 
Monolayers  of MDCK cells were grown to confluence in six-well dishes and 
infected with 250 plaque forming units of influenza virus per well.  Virus and cells 
were incubated in the presence or absence of peptide at 37°C with 5 % CO2, in a total 
volume of 400 µl.  Peptide and virus were mixed immediately prior to addition to the 
cell monolayer; 10% DMSO was used as a negative control.    After 1 hour unbound 
virus and/or peptide were removed and a 1% agarose in DMEM/N-acetylated trypsin 
was overlaid onto the cell layer.  The cell monolayers were fixed with 10% neutral 
buffered formalin, stained with 0.1% toulidine blue and the plaques were counted 
after 3 days.  Results were expressed as a reduction in plaque forming units when 
compared to virus alone. 
2.17. Macrophage infection assay 
The ability of Gallus gallus OvoDA1 at 1 and 10 µM to directly activate a chicken 
macrophage-like clonal cell line (HD11) was evaluated using Salmonella-gentamicin 
assay.  One million HD11 cells were added per well in a six-welled dish and 
incubated at 37ºC, 5% CO2 overnight.  Peptide or 10% DMSO was incubated with 
the cells for 2 hours and then removed.  10 µl of Salmonella (10
6
) was added to each 
well, swirled gently, centrifuged at 400 rpm for 6 minutes and incubated at 37ºC, 5% 
CO2 for 45 min to allow interactions to take place.  After incubation 2 µl gentamicin 
(50 mg ml
-1
) was added to give a final concentration of 100 µg ml
-1
 and incubated for 
90 min at 37ºC, 5% CO2.  Cells were washed twice with Hanks solution (2-3 ml) to 
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remove gentamicin and 1 ml Hanks, 0.1% Triton X100 was added to lyse the cells.  
Lysates were serially diluted and plated on LB agar plates to determine number of 
intracellular bacteria; this represents net total number of Salmonella phagocytised by 
the macrophages as well as the intracellular Salmonella replication of those 
phagocytised.  Results are expressed as a % reduction in Salmonella colony forming 
units compared to the negative control (10% DMSO).  
2.18. Ex vivo gut model 
This method was adapted for poultry from work published on pigs (Apajalahti et al., 
2009).  The ex vivo model and analysis of pH, gas and bacterial metabolites, which 
will be referred to as environmental analysis  from this point on was carried out by 
Alimetrics, Finland.  I assisted with the experimental analysis of the microbial 
community and carried out the analysis shown in this thesis.   
Conditions for the ex vivo intestinal simulation study were adjusted to mimic chicken 
ileal and caecal conditions as accurately as possible.  For the simulations, 
recombinant Gallus gallus OvoDA1 was tested at 0.0047, 0.047 and 0.47 g/kg and 
Taeniopygia guttata OvoDB1 was tested at 0.0045, 0.045 and 0.45 g/kg of dry 
peptide product.  These gave approximate final concentrations of 50, 100 and 
200 µM; the control supernatant was tested at 0.047 g/kg, a dose equivalent to 
100 µM of recombinant peptide.  A negative control containing no additional 
supplement was included for comparison. 
For preparation of the growth medium for the ileum simulation, digesta was collected 
from a section of the ileum ranging from the meckel’s diverticulum to the ileal-
caecal junction of thirty 4-week old broiler chickens.  The digesta was mixed 1:1 
with the ileal buffer (see appendix 1) and centrifuged at 18000 x g for 20 minutes to 
pellet the solids.  The supernatant from this step was removed and mixed 11:1 with 
ileal buffer to create the ileal medium for all ileum simulations.  All transfer steps 
were carried out in an anaerobic glove box and reagents were kept under anaerobic 
conditions.  Ileum digesta inoculum (untreated from original collection) which had 
been kept anaerobically and used within 4 hours of collection was mixed with the 
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ileum medium at 0.1%.  Immediately 10 ml aliquots of the ileum medium-inoculum 
were introduced anaerobically to fermentation vessels containing pre-weighed test 
compounds. 
For preparation of the growth medium for the caecal simulation, digesta was 
collected from the caeca of thirty 4-week old broiler chickens.  The digesta was 
mixed 1:1 with the caecal buffer (see appendix 1) and centrifuged at 18000 x g for 20 
minutes to pellet the solids.  After centrifugation the supernatant from this step was 
mixed with ileal medium and caecal buffer in a ratio (vol/vol) of 3.5:1.5:5.0 to create 
the caecal medium for all caecal simulations.  Again all transfer steps were carried 
out in an anaerobic glove box and reagents were kept under anaerobic conditions.  
Caecal digesta inoculum (untreated from original collection) which had been kept 
anaerobically and used within 4 hours of collection was mixed with the ileum 
medium at 10%.  As before 10 ml aliquots of the caecal medium-inoculum were 
immediately introduced anaerobically to fermentation vessels containing pre-
weighed test compounds. 
Fermentation vessels were closed with thick butyl rubber stoppers, transferred to 
37°C and continuously mixed in a gyratory shaker at 100 rpm. The simulations had 
five replicate vessels for each treatment, and the inoculation was done in a random 
order to avoid any potential systematic shifts. Incubation was continued for 10 hours 
prior to sampling of the vessels for various analyses.  
At samplings, the total gas production was measured by puncturing the rubber 
stopper with a needle connected to an accurate 20 ml glass syringe with a sensitive 
ground plunger. The volume of gas released from the vessels was recorded. After 
opening the simulation vessel, the pH of the fermentation medium was measured 
with a calibrated pH meter. This measurement was done immediately after the gas 
measurement to avoid pH shifts caused by the escape of CO2 from the medium. The 
medium was then sampled for the analysis of short chain fatty acids (SCFA) and 
bacterial density. The SCFA were analysed as free acids by gas chromatography, 
using pivalic acid as an internal standard, as described elsewhere in detail (Holben et 
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al., 2002). The acids measured were acetic, propionic, butyric, iso-butyric 2-methyl-
butyric, valeric and lactic acid. 
For bacterial quantification the bacteria in the samples were separated by differential 
centrifugation, bacterial cell walls disrupted, and the chromosomal DNA 
quantitatively purified using the Alimetrics in-house protocol.  Total bacteria and 
specific bacterial species were quantified using q-PCR. 
Treatments were compared using ANOVA to identify significant differences.  To 
determine if the differences were peptide specific or a result of background fungal 
components the Least Significant Difference (LSD) test was used to compare the 
negative control, supernatant control and 100 µM treatments. 
2.19. In vivo feed trial 
To test the hypothesis that the inclusion of ovodefensin peptide in poultry feed can 
improve growth performance of poultry through the modulation of the gut 
microbiome and environmental profile Gallus gallus OvoDA1 and Taeniopygia 
guttata OvoDB1 peptide produced using the recombinant fungal system outlined in 
2.14 was administered to chickens in the feed.  The negative control for this 
experiment was the absence of peptide from the feed. 
Trial design was carried out jointly by Alimetrics, AB Vista and me; I carried out the 
feed formulation under the supervision of AB Vista.  This experimental feed trial 
was carried out at Alimetrics, Finland and the sample collection was carried out 
according to my instruction.  I carried out the analysis shown in this thesis. 
2.19.1. Animals and housing 
Newly-hatched male Ross 508 broiler chicks (HKScan, Finland) were randomly 
allocated to the feeding treatments. Birds were housed in 64 open pens (1.125 m
2
 
each) with wood shavings litter, 17 chicks per pen, 8 replicate pens and 1088 birds in 
total. The mean weight of the hatchlings in the pens was set between 38 g and 45 g. 
Chicks with compromised health were excluded from the trial. 
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 Feed and water were available ad libitum at all times during the trial.  Water was 
provided using nipple watering lines and feed was provided in half bell shaped 
feeders attached to the side of the pen.   
On day 1, the lights were on for 24 hours.  From day 2, the dark period increased an 
hour per day until on day 7 there was 18 hours of light and 6 hours of dark per day. 
This 18:6, light:dark cycle was continued until the end of the trial.  On day 1, the 
temperature was set to 29°C, and heat bulbs were used to give additional warmth. 
The light bulbs were kept on for the first seven days, after the first week the 
temperature was dropped by 0.5°C by day.  
All welfare standards complied with The Finnish Act on Animal Experimentation. 
2.19.2. Feed formulation 
The diet was a wheat-soya based commercial-type mash feed for broiler chicks. A 
starter formula was used during the 3-week trial.  The main feed ingredients were 
analysed for basic nutrients and amino acid profiles for the final formulation which 
can be found in Table 2.3. 
The test substances were carefully mixed by hand into 5 kg premixes with wheat.  
Each premix batch will replace 5 kg of wheat from the final formula. The feeds were 
manufactured at Agri-Food Research, Finland.  Three grab samples of 200 g each per 
diet from start, mid-point and the end of the diet manufacture run were collected, 
mixed and 300 g sent for analysis of moisture, crude protein, crude fibre, oil, ash, 
calcium and phosphorus to an accredited laboratory. 
2.19.3. Sample collection 
The chicks were weighed on days 1, 11 and 21. Correspondingly, feed intake per pen 
and the feed conversion ratio (FCR) was measured for the following periods: days 1-
11, days 11-21 and days 1-21.  The birds were monitored on a daily basis and any 
dead birds or birds euthanized because of health problems were weighed. Daily 
mortality was recorded and FCR was calculated both corrected and uncorrected for 
mortality. 
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On day 11, two birds per pen were weighed and euthanized by cervical dislocation. 
The abdominal cavity was opened, and the entire ileum and the paired caeca 
removed, packed in individual plastic bags, frozen immediately and stored at -20°C 
until analysis.  On the day 21, a similar set of samples were collected, and all the 
remaining birds were weighed and euthanized. 
2.19.4. Metabolite and intestinal environment analysis 
The SCFAs were analysed as free acids by gas chromatography, using pivalic acid as 
an internal standard, as described elsewhere in detail (Holben et al., 2002).  Total 
SCFAs, acetic, propionic, butyric, iso-butyric, 2Me-butyric, valeric, isovaleric and 
lactic acid were measured from the highest dose of each peptide and treatments were 
compared using a Kruskal-Wallis test as the data could not be normalised using 
typical transformations.  Where significance was observed a Mann-Whitney ranked 
test was used to compare peptide treatments to the control. 
2.19.5. Microbiome analysis 
For DNA extraction the bacteria in the samples were separated by differential 
centrifugation, bacterial cell walls disrupted, and the chromosomal DNA 
quantitatively purified using the Alimetrics in-house protocol, which is optimised 
and validated for the bacterial DNA extraction from chicken digesta samples. In the 
initial washing step of the samples the major target is to remove feed particles and 
complex polysaccharides, which disturb the subsequent DNA purification process 
and the downstream PCR applications.  
Bacterial numbers were measured using quantitative real time PCR.  In this study, all 
results are expressed as a number of ribosomal RNA (rRNA) gene copies per 1 g of 
digesta. In order to estimate the number of chromosomes/genomes in the analyses the 
results were divided by the average rRNA copy number of the target organisms. For 
example for E. coli the copy number is 7, while Eimeria genome encodes roughly 
100-200 copies rRNA depending on the species.  Measurements were made for the 
highest dose of each peptide treatment and the negative control and significance was 
tested using Kruskal-Wallis as the data could not be normalised using typical 
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transformations.  Where significance was observed a Mann-Whitney ranked test was 
used to compare peptide treatments to the control. 
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A Ingredient Inclusion (g/kg) C Nutrient Starter (g/kg) 
 
Wheat - Feed 572.7 
 Crude 
protein  223.2  
 Rapeseed Solvent 
Extract 60.0 
 
Calcium  9.0 
 Soybean meal 48 286.6  Phos   7.6  
 Sunflower oil 44.2  Avail Phos   4.5  
 Salt 3.7  Fat   5.9 
 DL Methionine 2.6  Fibre   30.9  
 Lysine HCl 2.4  Met   5.9  
 Threonine 0.5  Cys   4.0  
 Limestone 7.2  Me+Cys   9.9  
 Dicalcium Phos 15.3  Lys   13.4  
 Vitamin premix 4.9  His   5.6  
    Tryp   2.8 
    Thr   8.7  
B Detailed composition of the vitamin premix  Arg   14.3  
 Calcium 331.33 g/kg  Iso  9.1  
 Vitamin A 1800 mg/kg    Leu   16.3  
 Vitamin D3 56.25 mg/kg  Phe   10.3  
 Vitamin E 30,000 mg/kg  Tyr   7.4  
 E-tokoferol 27,270 mg/kg  Val   10.1  
 Vitamin K3 1,505 mg/kg  Gly   9.3 
 Vitamin B1 1257.3 mg/kg  Ser   10.4  
 Vitamin B2 3,000 mg/kg  Gly+ser 19.8 
 Vitamin B6 2009.7 mg/kg  Phe+Tyr   17.7  
 Vitamin B12 12.5 mg/kg  Phytate P  2.1  
 Biotin 75 mg/kg  Na   1.8  
 Folic acid 504 mg/kg  Cl   3.8  
 Niacin 20,072 mg/kg  K  9.1  
 
Pantothenic acid 7506.8 mg/kg 
 Linoleic 
acid  28.1  
  
Table 2.3:  Detailed composition of feed 
ingredients and analysis for in vivo 
feed trial (2.19).  Inclusion of raw 
ingredients are shown in A; a detailed 
composition of the vitamin premix is 
shown in B and a breakdown of the overall 
nutrient composition of the starter diet is 
shown in C. 
DUA 334.1 
 Sulphur 2.8 
 Magnesium 1.8 
 Choline 1.64 
 Poult ME 
MJ/kg 12.55 
 Poult NE 
Kcal/kg 2,023 
 Poult ME 
kcal/kg 3,000  
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3.1. Introduction 
Poultry are crucial to global food security and until a recent ban under EU Directives 
in-feed antibiotics were used to promote energy retention from the diet and prevent 
microbial infections (Bedford, 2000).   Antibiotic use has driven the evolution of 
transmissible antibiotic resistance that has reduced the effectiveness of human and 
veterinary medicines (Hancock, 1997).  Despite restrictions, therapeutic antibiotic 
use remains possible but a pressing need exists to maintain the efficiency of animal 
production by finding alternatives.  One of the critical needs in realising the potential 
of alternative antimicrobial strategies was identified as the characterisation of a wide 
range of molecules and their properties (Hancock and Sahl, 2006).  Antimicrobial 
peptides have been suggested as an alternative due to their potential for rapid, broad 
spectrum bactericidal activity and low predisposition for resistance development 
(Hancock, 1997).  The large abundance of natural antimicrobials make the egg an 
interesting reservoir of potential candidates particularly as the clinical application for 
this study relates to the food industry.  Naturally derived egg products, as already 
widely consumed by humans, would offer a level of acceptability and therefore form 
the basis of the peptide portfolio for this study.  One such potential candidate is the 
egg white protein ‘transiently expressed in neural precursors’ (TENP), however, as 
little is known about TENP or its function in the adult hen this was first characterised 
to determine if it is a suitable candidate. 
The TENP gene was first identified in the brain and retina of developing neural 
tissues of chickens using reverse transcription polymerase chain reaction (RT-PCR), 
and was proposed to function in an early neurological event occurring in post-mitotic 
cells before they enter the stage of overt differentiation (Yan and Wang, 1998).  The 
47kDa protein has since been identified during proteomic studies of chicken egg 
white (Guerin-Dubiard et al., 2006, Mann, 2007, D'Ambrosio et al., 2008), vitelline 
membrane (Mann, 2008), shell (Mann et al., 2006) and yolk (Mann and Mann, 2008, 
Farinazzo et al., 2009).  Although TENP expression in the embryo has been 
documented little is known about where, when and under what conditions it is 
expressed in the adult.  TENP expression in the oviduct and caecum of the adult hen 
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had previously been reported by Chiang et al in 2011, yet both this and the 
embryonic work were qualitative studies which leaves unanswered questions 
regarding the predominant areas of expression in the adult hen and how this 
compares to levels in the embryo.  
Similarity searches have shown homology of TENP with the 
bactericidal/permeability-increasing (BPI)-like family of innate immune genes (Yan 
and Wang, 1998), which are found in adjacent chromosomal regions to TENP on 
chromosome 20 (Chiang et al., 2011). Computer analysis of the primary sequence of 
TENP predicted three putative transmembrane helices suggesting it may be a 
membrane protein (Yan and Wang, 1998).  This was supported by the immune 
detection of TENP in cellular membrane fractions after expression in chicken 
embryonic fibroblast cells (Yan and Wang, 1998).  However, it has been suggested 
that TENP, as previously proposed for BPI, may be membrane associated rather than 
an integral membrane protein (Beamer et al., 1998).   It has been proposed that TENP 
is a divergent ortholog of human LPLUNC2 (Chiang et al., 2011). The PLUNC 
(palate, lung and nasal epithelial clone) protein family are structural homologues of 
BPI proteins (Chiang et al., 2011) and are divided into two groups; short (SPLUNC) 
and long (LPLUNC) proteins.  SPLUNCs contain a region structurally homologous 
to the BPI N-terminal domain whereas LPLUNCs contain domains similar to both 
the BPI domains (Bingle and Craven, 2002).  The N-terminal domain of BPI is 
responsible for lipopolysaccharide (LPS) and bacterial binding as well as endotoxin 
neutralisation and antibacterial cytotoxicity whereas the C-terminal domain is 
associated with opsonic effects thus enhancing phagocytosis (Schultz et al., 2001).  
The TENP molecule detected in the embryo has two distinct regions which 
demonstrated are analogous to the BPI1 (N-terminal) and BPI2 (C-terminal) domains 
of the BPI protein.  However, there was little evidence from EST data 
(http://genome.ucsc.edu/) to support a full length TENP transcript in adult birds 
which would allow both the BPI-like domains present to be expressed in one 
molecule; yet the proteomic evidence supported both domains being present in egg 
white (Karlheinz Mann, Germany, personal communication, November 11 2010).  
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As each domain of the molecule is analogous to a BPI domain and therefore 
potentially associated with differing functions it was of interest to know how the 
TENP transcript is expressed in the adult bird.   
It has been proposed that the function of TENP is associated with the innate defence 
of eggs against pathogens (Guerin-Dubiard et al., 2006, Mann, 2007, D'Ambrosio et 
al., 2008) however its proposed function had yet to be experimentally proven and is 
largely based on its relationship to the BPI-like family.  A chicken member of the 
BPI/PLUNC super-family, is found in the egg shell and has previously been shown 
to possess modest antibacterial activity against a range of gram positive and gram 
negative bacteria (Gautron et al., 2011).  It is also documented that this protein is 
able to bind E.coli LPS in vitro (Gautron et al., 2011) and its expression in the 
infundibulum is up-regulated after systemic administration of LPS (Bedrani et al., 
2013) strongly supporting a role in egg antimicrobial defence.  Although mammalian 
members of the LBP family have been documented to interact with LPS this has 
been demonstrated to be both pro and anti-inflammatory and the family’s role in host 
defence against bacteria is still to be fully elucidated (Bingle and Craven, 2004).  
However, due to the large number of known antimicrobial proteins, including 
Ovocalyxin 36 (Gautron et al., 2011), already identified in the egg, and the known 
role of TENP in the emu egg (Maehashi et al., 2014), an antimicrobial role of TENP 
in the chicken would seem plausible. 
3.2. Objectives 
To test the hypothesis that TENP is predominately expressed in the magnum as one 
transcript encoding for both BPI domains in the adult hen and is under the control of 
gonadal steroids as expected for an egg specific protein.  This study also aimed to 
identify TENP homologs across divergent bird species and to determine the 
suitability of TENP as a antimicrobial feed additive. 
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3.3. Methods 
3.3.1. Bioinformatic analysis 
The TENP protein sequence (NCBI accession no. AF029841) was used to perform a 
BLAT search (Kent, 2002) of the May 2006 release of the chicken EST database 
using the default parameters of the UCSC genome browser (http://genome.ucsc.edu/) 
to identify  ESTs and sequences related to the locus.  The Staden package (Staden, 
1996) was used to build a consensus sequence using the ESTs available. This 
allowed a gap present in the genome build to be bridged and allowed a comparison to 
be made between the genomic, EST and published TENP mRNA sequences in order 
to address differences in sequence identity.  Primer3 
(http://frodo.wi.mit.edu/primer3/) was used to design primers (Chapter 2, Table 2.1) 
for re-sequencing across the length of the consensus sequence including a putative 
alternative transcriptional start site identified in the consensus sequence.  Signal P 
(Bendtsen et al., 2004) was used to assess the likelihood of a signal peptide produced 
by each translational start site.  Exon contributions were estimated from genomic 
DNA using BDGP NNSPLICE version 0.9 (Reese et al., 1997). 
The duck genome database (Anas platyrhynchos – version 1) (http://pre.ensembl.org) 
and turkey genome database (Meleagris gallopavo – assembly UMD2) 
(http://www.ensembl.org) were searched using TBLASTN for potential homologues 
using the 629 amino acid mature TENP protein.  Primers were designed using 
Primer3 (http://frodo.wi.mit.edu/primer3/) to amplify both the potential turkey and 
duck TENP sequences from cDNA (Chapter 2, Table 2.1). 
3.3.2. Animals and tissue collection 
To determine the location of TENP expression in the adult bird, tissues were taken 
from sexually mature White Leghorn LSL hens (Gallus gallus) (Lohmann), sexually 
mature Pekin ducks (Anas platyrhynchos) (Cherry Valley) and sexually mature 
turkeys (Meleagris gallopavo) (Kelly Bronze).  Details of tissues taken can be found 
in section 2.4.   
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For quantitative comparison with embryonic expression brain, retina and heart tissue 
was taken from embryonic day 10 (E10) (n=6) and day 16 White Leghorn chickens 
(E16) (n=6).  E10 and E16 correspond with Hamburger–Hamilton (HH) embryonic 
developmental stages HH36 and HH42 respectively.   
In order to assess the effect of oviposition on TENP expression magnum tissue was 
obtained from sexually mature White Leghorn hens with an ovum at various 
positions in the oviduct, see section 2.4.7 for details.    
TENP expression was measured in hens that were in lay (n=11) and those where the 
oviduct had regressed due to incubation behaviour (n=11) to establish the effect of 
oviduct development, (section 2.4.8). 
The induction of TENP with steroid hormones was adapted from a method described 
previously by Kunnas, et al.  Details can be found in section 2.4.9. 
3.3.3. RNA preparation 
RNA was extracted from tissues and processed as per the Ultraspec protocol (section 
2.5.1).  
3.3.4. Transcript determination 
3.3.4.1. PCR and sequencing 
1 µg samples of chicken, duck and turkey magnum RNA were reverse transcribed 
using a high capacity cDNA reverse transcription kit (Applied Biosystems, UK) 
according to the manufacturer’s protocol (2.5.2).  Primers TENPExon1F1 and 
TENPEnd1 (chicken), D.TENPF3, D.TENP R3, D.TENP F8 and D.TENP R10 
(duck) and T.TENPF1 and T.TENPR1 (turkey) (Chapter 2, Table 2.1) were designed 
to ensure complete coverage of the TENP sequence (see 3.3.1).  PCR amplification 
was performed using standard conditions (section 2.6.2).  Amplified PCR fragments 
were sequenced with the forward and reverse primers.  Sequences were assembled by 
Staden (Staden, 1996) to produce consensus sequences. 
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A phylogram was constructed using Mega5 to infer the evolutionary history of the 
TENP homologues.  Included in this analysis was human LPLUNC2 (NCBI 
reference sequence NM_025227) and chicken Ovocalyxin 36 a BPI like gene (NCBI 
reference sequence NM_001030861) as outliers. 
3.3.4.2. Northern analysis 
Magnum RNA (2 µg) from in-lay, layer (n=3) and broiler (n=3) lines and broiler 
liver RNA (12 µg) were electrophoresised on a 2% agarose gel under denaturing 
conditions (Pelle and Murphy, 1993), SYBR safe DNA gel stain (Invitrogen, UK) 
was used for visualisation. The RNA was then transferred to an Amersham Hybond 
N+ nylon membrane for northern analysis (section 2.10).  Template DNA consisted 
of a HindIII linearised pBluescript plasmid (p347_TENP) containing the cloned 
BPI2 (EMBL HG007958 position 1196-1569) domain present in both potential 
TENP transcripts.  Hybridisation of 
32
P probe was detected using the Typhoon 
FLA7000 (GE Healthcare Life Sciences, Buckinghamshire, UK). 
3.3.4.3. 5’RACE 
5’RACE (Roche Diagnostics 2
nd
 Generation, Mannheim, Germany) was carried out 
using primers SP1 and SP2 to determine the transcriptional start site of TENP 
(section 2.8.1).  PCR product was sequenced using primer SP2 (Chapter 2, Table 
2.1).  
3.3.5. Reverse transcription quantitative polymerase chain reaction   
 (RT-QPCR) 
1 µg of cDNA was prepared (section 2.5.2) and used for RT-QPCR analysis as 
detailed in section 2.7.2. Primer3 (http://frodo.wi.mit.edu/primer3/) was used to 
design primers TENP RTF  and TENP RTR  for amplification of chicken TENP; 
D.TENP F8 and D.TENP R10 for duck TENP (Chapter 2, Table 2.1).  Reactions 
containing no template were used as a control.  Lamin B-receptor (LBR) expression 
was measured in the same way to normalise concentrations as used previously 
(McDerment et al., 2012).  One way or two way ANOVA and least significant 
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difference to test between the means were used as appropriate for statistical analysis 
of log transformed data. (Genstat 13
th
 edition, VSN International Ltd, Oxon, UK). 
3.3.6. Production and titres of polyclonal anti-TENP antibodies 
Production of antibodies was carried out by Dundee Cell Products Ltd, Dundee 
(section 2.11); titres of anti-TENP in the antisera were measured (section 2.11) for 
use in immunohistochemistry. 
3.3.7. Immunohistochemistry (IHC) 
Wax embedded tissues were prepared (section 2.12), a standard IHC protocol was 
then used; optimal staining was achieved at a 1:3000 dilution of the polyclonal anti-
TENP antiserum (107_AWM_1.1) for 30 minutes. 
All immunohistochemistry was carried out in collaboration with Maureen Bain and 
Lynn Stevenson at the College of Medical, Veterinary and Life Sciences (MVLS), 
University of Glasgow, Glasgow, Scotland, G61 1QGH, UK. 
3.3.8. Sequencing and database submission 
All sequencing was carried out by GATC biotech (Konstanz, Germany) and 
consensus sequences were submitted to EMBL, chicken TENP (EMBL accession 
HG007958), turkey TENP (EMBL accession HG425203) and duck TENP (EMBL 
accession HG425202).  
3.4. Results 
3.4.1. Bioinformatic analysis and transcript confirmation 
A BLAT search of the May 2006 chicken genome (http://genome.ucsc.edu/) using 
the published TENP protein sequence (NCBI reference sequence. NM_205026) 
returned a result indicating a 98.2% identity.  However there was a gap in the 
genomic data between 10248912-10249705 bp on chromosome 20.  Searching the 
EST and cDNA database produced the following sequence accession numbers; 
Genbank accession no. DT657251, BM439389, DT655485, DT655483, DT654774, 
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DT657764, BU357647, BX265690, BX265691, BU210629, BU266397 and 
AF029841.  All sequences were derived from hen reproductive tract except 
AF029841 which was from the original TENP publication (Yan and Wang, 1998) 
that used embryos. These were aligned using Staden (Staden, 1996) and the 
consensus sequence produced was used to close the gap in the genomic sequence.  
The EST and genomic data either side of the gap were identical; the published 
sequence for TENP was 99.1% identical to the sequence generated by the Staden 
alignment.  When the TENP PCR products generated in this study were sequenced 
they were identical to the available genomic and EST sequences.  However they 
differed from the current RefSeq (NM_205026) by an insertion of G between 
positions 190-191 (NM_205026.1:c.190_191insG) and a deletion of G at position 
251 (NM_205026.1:c.251delG) resulting in a partial frame shift, altering part of the 
protein sequence (Figure 3.1).  Analysis of the sequence from this study (EMBL 
HG007958) identified a potential alternative translational start site (Figure 3.1).  The 
published translational start site (Yan and Wang, 1998) at genome position 
Chr20:10,647,277 (reverse strand) of the November 2011 build with the signal 
peptide prediction MGALLALLDPVQPTRA gives a signal peptide probability of 
0.661 and a max cleavage site probability of 0.651 whilst the new putative 
translational start site at position Chr20:10,647,544 (reverse strand) in the November 
2011 build identified in this study results in a signal peptide prediction of 
MGTANRKGSAVPLLCTMGALLALLDPVQP that gives a stronger prediction for 
the signal peptide probability (0.996) and a maximum cleavage site probability of 
0.534.  5’RACE using magnum RNA supported the presence of the transcript 
postulated in this thesis, which in turn supported the new translational start site 
(Figure 3.1). No evidence was found for a sequence which would support the 
previously published translational start site, however this may be expressed below 
the detection level of the methods used (Figure 3.1).  The same method was used to 
detect the transcriptional start site used in embryonic brain tissue (not shown) 
however no transcript was detected. 
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It was noted that the EST data, although supporting the presence of each BPI-like 
domain in the reproductive tract, offered little evidence for their expression in one 
full length TENP transcript, rather supporting that the protein may be expressed as 
two separate molecules each encoding one of the BPI domains (Figure 3.2).  PCR 
using magnum cDNA with primers TENP Exon1F1 and TENPEnd1 designed to 
amplify the whole of the TENP protein coding region from chr20:10642981-
10647548 resulted in two strong bands.  Sequencing of these PCR products 
confirmed that one of the transcripts encoded for a full length transcript including the 
new predicted translational start site, the second smaller transcript would if translated 
encode only the BPI2 region of the TENP protein (Figure 3.2).  In order to confirm 
the expression of these TENP transcripts in magnum tissue northern analysis using 
an RNA probe corresponding to the BPI2 domain, present in both forms detected by 
PCR, was carried out.  The results proved the presence of only the full length 
transcript in both layer and broiler type birds (Figure 3.1) but showed no indication 
of a smaller transcript despite the PCR evidence. In general the intensity of the signal 
from the layer line was lower and more variable than that of the broiler (Figure 3.1).  
In agreement with previous work (Chiang et al., 2011) it was predicted that chicken 
TENP has 16 exons (Table 3.1). 
Potential TENP homologues were identified in both duck and turkey genomes and 
their expression was confirmed using PCR and sequencing.  The phylogenetic 
analysis (Figure 3.4) suggests that TENP molecules from avian species are more 
similar to each other than either Ovocalyxin 36 or LPLUNC2. 
3.4.2. Tissue expression 
TENP expression was detected in embryonic brain and retinal tissues (Figure 3.5) 
and decreased as development progressed from E10 to E16. In contrast measurement 
of TENP expression in adults indicated that expression was restricted to the oviduct 
of adult hens and almost exclusively the magnum with no detectable expression in 
either the brain or retina suggesting TENP plays a different role in the adult bird 
(Figure 3.6).  Expression was also restricted to the magnum of the oviduct in the  
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Table 3.1 – Exon Contributions.  Exons are shown as nucleotide contributions in 
relation to the TENP sequence produced in this study (EMBL HG007958). 
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Figure 3.1 – Northern analysis and 5’RACE. A)  Northern analysis of p347_TENP.  
Lanes A-C contain 2 µg broiler magnum RNA, lanes D-F contain 2 µg layer magnum 
RNA, 12 µg  liver RNA (G) is used as a negative control.  B) 5’RACE using primer 
SP2 resulting in one band.  C) cDNA sequencing of  the 5’RACE product from B 
confirmed the presence of an alternative translational start site (underlined), the 
published start site is highlighted (). D) The first 180aa of the new putative protein 
(HG007958) translated from the alternative start site in C is shown in a clustal 
alignment with the published TENP sequence (AF029841); the location of the 
frameshift is highlighted (). The proposed new protein has 455 amino acids. 
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Figure 3.2 – Schematic representation of chicken ESTs using the EST data 
displayed by the UCSC Genome Browser website.  ESTs were all isolated from 
the reproductive tract of adult hens and provided no evidence for a transcript where 
both BPI-like domains are expressed in one molecule. 
 
Figure 3.3 – TENP PCR – Amplification of TENP from magnum cDNA using primers 
TENP Exon1F1 and TENP End 1 in the first and last exon of TENP. Lane 1, 100 bp 
molecular weight marker; lane 2 and 3 magnum cDNA.  Results indicate two TENP 
transcripts with sizes corresponding to a transcript encoding the full TENP protein 
and also that of just one BPI domain. 
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Figure 3.4 - Evolutionary relationships of avian TENP homologues, LPLUNC2 
and Ovocalyxin 36.  A phylogram indicating the evolutionary history of TENP was 
inferred using the Neighbor-Joining method (Saitou and Nei, 1987) from an 
alignment of the mature proteins.  Included for comparison were human LPLUNC2 
and chicken Ovocalyxin 36. The percentage of replicate trees in which the 
associated taxa clustered together in the bootstrap test (1000 replicates) are shown 
next to the branches (Felsenstein, 1985). The branch lengths are proportional to the 
evolutionary distances which were computed using the Poisson correction method 
(Zuckerkandl and Pauling, 1965).  The units of the branch lengths are the number of 
amino acid substitutions per site.  All positions containing gaps and missing data 
were eliminated. Evolutionary analyses were conducted in MEGA5 (Tamura et al., 
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duck tissues sampled (Figure 3.6).  TENP expression was measured in the magnum 
of the oviduct when the egg was either in the magnum, the shell gland or during a 
pause day.  Eggs in the shell gland were classified as either early, mid or late 
depending on the level of calcification as determined by electron microscopy. The 
position of the egg in the oviduct or the occurrence of a pause day, when the hen did 
not ovulate and so no egg was present, did not significantly alter the level of TENP 
expression in the magnum (Figure 3.7) (ANOVA, P=0.083) although showed a clear 
trend. However if the data was categorised into when an egg was in the magnum or 
had just recently left it (early) versus the later stages of calcification (mid/late) then 
the difference is approaching significance (ANOVA, P=0.051). The level of TENP 
expression in both the magnum and the shell gland was higher (P<0.001) in birds in-
lay than in adult hens whose oviduct had regressed due to incubation behaviour 
(Figure 3.8) which suggests that the level of TENP expression is affected by the 
reduction in gonadotrophins which in turn causes reduction in steroid secretion from 
the ovary.  Oestrogen is well characterised as a key regulator in the development and 
function of the oviduct and is therefore unsurprisingly linked to regulation of the 
expression of many egg specific genes.  When oestrogen and progesterone were 
administered to juvenile hens TENP expression (Figure 3.9) was higher in birds 
treated with the two steroids (P<0.001) and where  priming with an oestrogenic 
compound had been performed overall expression increased (P<0.001). 
3.4.3. Immunohistochemistry 
The anti-TENP antiserum (107_AWM_1.1) produced positive staining in the tubular 
gland cells of the magnum (Figure 3.10 A).  The ciliated and non-ciliated cells lining 
the magnum region of the oviduct did not react to the primary antibody. No staining 
was observed in the isthmus, shell gland or caecum (Figure 3.10 C-E). 
3.5. Discussion 
The conservation of TENP among avian species, and the results outlined in this study 
strongly suggest a major egg specific role for TENP protein in the adult hen.  
Although local tissue activity, for example antimicrobial protection of the oviduct    
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Figure 3.5 – Expression of TENP mRNA in embryonic day 10 () and 16 
() chicken brain, retina and heart tissues measured by RT-QPCR (n=6, 
mean ± sem).  TENP expression was corrected for LBR expression to 
normalise for any differences between tissues in processing.  ANOVA 
indicated that embryonic stage was significant at P<0.001 and tissue was 
significant at P<0.001.  TENP expression clearly diminished with 
development.  Heart was included as a negative control, as expected no 
expression was detected. Significance between embryonic stage within 
tissue is indicated P<0.001(***) and P<0.01 (**). 
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Figure 3.6:  Expression of TENP mRNA in a range of adult chicken (n=4, mean 
± sem) and duck (n=3, mean ± sem) tissues measured by RT-QPCR. TENP 
expression was corrected for chicken LBR and duck LBR expression to normalise 
for any differences between tissues.  Expression is restricted to the oviduct in both 
species with the greatest level of expression seen in the magnum. 
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Figure 3.7:  Expression of TENP mRNA in magnum tissue at different stages 
of egg formation measured by RT-QPCR (n= 8, mean ± sem).  TENP expression 
was corrected for LBR expression.  Pause represents a day when the hen did not 
ovulate so no egg is present. Magnum represents tissue when an egg is present in 
the magnum and early, mid and late describes the stage of shell formation in the 
shell gland and indicates the egg has left the magnum. ANOVA, P=0.083. 
 
Figure 3.8:  Expression of TENP mRNA in A) magnum and B) shell gland 
tissue of laying (L) and out of lay (NL) birds measured by RT-QPCR (n=11, 
mean ± sem).  Non-laying hens were those where the oviduct had regressed due to 
the withdrawal of gonatrophic support with the onset of incubation behaviour. TENP 
expression was corrected using LBR expression. Note the large difference in the Y-
axis scale between A and B.  Significance between laying state is indicated at 
P<0.001, ***. 
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Figure 3.9:  Expression of TENP mRNA in the magnum of juvenile chicks 
treated with steroids measured by RT-QPCR (n=10, mean ± sem).  TENP 
expression was corrected using LBR expression. Female chicks at 3 weeks of age 
were either primed with diethylstilbestrol or not primed (vehicle control) then 
subsequently treated with either progesterone, oestradiol (oestrogen) or vehicle 
(control). ANOVA indicated primed or not primed was significant at P<0.001; steroid 
treatment was significant at P<0.001.  Significance between primed state within 
treatment is indicated, P<0.001(***) and significance between treatments regardless 
of primed state between the brackets, P<0.001(***). 
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Figure 3.10: The tubular gland cells of the magnum region (A) of the oviduct stained positive and the surface epithelium (ciliated and 
non-ciliated cells) did not stain with anti-TENP antisera (107_AWM_1.1). The corresponding negative controls for A are shown in image B.  
The Isthmus (C), Shell gland (D) and Caecum (E) were not reactive to the primary antibody. 
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cannot be ruled out and it may serve both these roles.  The fact that this protein also 
plays a transient role in the developmental stages (Yan and Wang, 1998), at least in 
the brain, of the chicken embryo suggests a dual purpose for TENP.  This makes 
understanding how expression of TENP is controlled and its purpose extremely 
valuable in understanding the biology of not only the egg but the chick as well. 
The EST data aligned to the May 2006 chicken genome assembly confirmed the 
expression of both of the TENP BPI domains in the hen reproductive tract but 
offered little evidence for their expression in one full length TENP transcript, as 
originally identified in neural precursors (http://genome.ucsc.edu/), rather supporting 
the conclusion that the protein may be expressed as two separate molecules each 
encoding for one of the BPI domains (Figure 3.3).   Sequencing of PCR products 
using magnum cDNA with primers designed to amplify the whole of the TENP 
protein coding region produced a full length transcript including the new predicted 
translational start site and a second smaller transcript, which if translated would 
encode only for the BPI2 region of the TENP protein (Figure 3.2).  Although in 
theory intensities of DNA bands on a gel amplified from targets with the same 
primers should be indicative of the relative abundance of each transcript in the 
starting sample if amplification efficiency is equal (Cottrez et al., 1994), factors such 
as amplicon size or sequence can lead to a bias in amplification with smaller 
amplicons being amplified more efficiently (Cha and Thilly, 1993) or possibly 
differences in reverse transcription efficiency.  Indeed Northern analysis indicated 
that the full length transcript (Figure 3.1) was the dominant form of TENP and the 
lack of signal for the smaller transcript suggested that it may be below the threshold 
of detection for this method contrary to the PCR results.  Although these results 
indicate that a transcript encoding both BPI-like domains is the dominant form in the 
oviduct the presence of a smaller transcript cannot be ruled out completely.  It may 
be that this gene encodes for alternate forms of TENP where only one of the BPI 
domains is expressed, as seen with SPLUNCs (Bingle and Craven, 2002). 
The PCR products from this study (TENP Exon1F1-Tenp End1) were identical to the 
available genomic and EST sequences yet contained an indel when compared to the 
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previously published TENP sequence (Yan and Wang, 1998) resulting in a frameshift 
(Figure 3.1).  I therefore propose that the previously published protein sequence for 
TENP is either incorrect or specific to the strain used in that study.  Potential TENP 
homologues were identified in both the duck and turkey genomes and sequencing of 
PCR products confirmed the presence of TENP mRNA in the magnum of both 
species.  A potential TENP homolog is predicted in the zebra finch (NCBI Reference 
Sequence: XP_002192628.1) and TENP has also been identified in proteomic 
analysis of emu egg white (Maehashi et al., 2010).  These results coupled with a high 
level of sequence similarity suggest that TENP is highly conserved across avian 
species.  From the phylogenetic analysis (Figure 3.4) the TENP molecules are more 
similar to each other than either Ovocalyxin 36 or LPLUNC2.  The analysis infers 
that TENP is a divergent ortholog of LPLUNC2, and that Ovocalyxin 36 may have 
evolved from an ancestral LPLUNC2-related gene as previously suggested(Chiang et 
al., 2011), perhaps from a duplication event occurring before mammals and birds 
diverged.  
Since this analysis was carried out deposits in the GenBank database made by 
Kinoshita K., et al became visible (accession no. BAM13270.1, BAM13271.1, 
BAM13272.1, BAM13273.1, BAM13274.1 and BAM13275.1).  The text proposed 
that TENP is identical to the chicken egg white protein ovoglobulinG2 and is 
expressed as a full length protein in the adult reproductive tract which would concur 
with the results seen in this study, however no paper has apparently been published 
relating to this observation.  It is probable that these submissions refer to a globulin 
fraction separated by Longsworth et al in 1940.  In the paper Longsworth et al 
identified three globulins G1, G2 and G3 using electrophoresis to separate egg white 
and examined the electrophoretic patterns of ovalbumin and the globulin fractions. 
Analysis of TENP sequence from the genome discovered a potential alternative 
translational start site which was confirmed as the dominant site used for 
transcription in magnum tissue.  Because the expression of TENP is low in the 
embryo it was not possible to confirm the transcriptional start site.  The proof from 
the magnum that the predominant translational start site is at position 32 (Figure 
Chapter 3   Comparative biology and expression of TENP 
 
~ 91 ~ 
 
3.1C) combined with the Signal P predictions probability score of 0.996 for the new 
signal peptide probability  and the signal peptide cleavage point  suggest that at least 
in the adult the sequence proposed in this thesis is correct.  There is no experimental 
evidence to support the translational start site, however, if we were to assume a 
typical Kozac initiation of translation (Kozak, 1999) then the evidence for the 
transcription start site from the 5’ RACE makes the proposed translational start site 
the most likely.  However it must be noted that in the absence of functional evidence 
the translational start site cannot be confirmed as upstream ATGs occur frequently in 
vertebrate mRNA (Rogozin et al., 2001) and the possibility of multiple sites of 
translation cannot be excluded (Kochetov et al., 2005). 
Measurement of TENP expression in embryonic brain and retinal tissues concur with 
the developmental down-regulation seen by Yan et al (Yan and Wang, 1998); 
expression seen at E10 is dramatically decreased by E16 and no expression is 
detected in adult brain or retinal tissues (Figure 3.5).  In contrast expression of TENP 
in the adult hen is restricted to the oviduct (Figure 3.6) suggesting at this stage TENP 
plays a different role. Expression is almost exclusively in the magnum with 
expression here around 400 x more than in the shell gland and almost 10,000x 
greater than in embryonic retina tissue.  The magnum is responsible for the 
production of egg white and the high level of expression here would suggest that 
TENP is primarily a component of egg white.  However, this study did detect some 
expression in other regions of the oviduct which would concur with the proteomic 
evidence for TENP in the other egg compartments e.g. the shell (Mann et al., 2006).  
Immunohistochemistry confirmed the presence of TENP as a protein in the tubular 
gland cells of the magnum region of the oviduct (Figure 3.10); this would support the 
secretion of TENP.  Interestingly TENP was not detected in the epithelial cells which 
may indicate that TENP is less involved in local protection of the oviduct.  In duck 
tissues TENP expression is also restricted to the magnum of the oviduct (Figure 3.6).  
TENP expression in the caecum had previously been reported by Chiang et al in 
2011 (Chiang et al., 2011) however when using a quantitative approach no 
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significant expression was measured in this tissue compared to other tissues (Figure 
3.6) which was further confirmed through IHC (Figure 3.10).  
Expression in the magnum of the oviduct did not differ significantly in relation to the 
position of the egg in the oviduct at the time of sampling or if it was a pause day 
when no egg was present, although there was a tendency for the level to be lower 
when the egg was in the magnum or had recently left it (P=0.051) (Figure 3.7).  This 
pattern of expression is typical of egg proteins and has been described previously for 
others including gallin (Gong et al., 2010) and ovalbumin (Muramatsu et al., 1994).  
In the magnum and shell gland there is significantly more TENP expression when the 
hen is in lay compared to when the oviduct is regressed (Figure 3.8) suggesting the 
expression of TENP is specifically up regulated during egg production when steroids 
are elevated and is likely to be under the control of gonadal steroids.  This was 
confirmed by the measurement of TENP expression after the administration of 
oestrogen and progesterone to juvenile hens, with the increase in expression greatest 
with the dose of oestrogen compared to that of progesterone. Most importantly the 
response was strongest when the animals had previously been primed with an 
oestrogenic compound and showing that oestrogen and progesterone act 
synergistically as one would expect of an oviduct gene controlled directly or 
indirectly by gonadal steroids.  Analysis for transcriptional factor binding sites 20kb 
upstream of the gene using MATCH (www.gene-regulation.com) did not identify 
any oestrogen or progesterone receptors so the effect may be secondary to 
stimulation of transcription factors by these steroids.   
These results strongly suggest that in the adult hen TENP’s role is as a major 
component of the egg.  However, local tissue activity, for example antimicrobial 
protection of the oviduct cannot be ruled out and it may serve both these roles.  It is 
also notable that proteomic analysis has recently identified TENP as a possible 
requisite host protein in infectious bronchitis virus (IBV) life cycles (Kong et al., 
2010b).  The relationship of TENP to the PLUNC/BPI family of proteins suggests a 
role for TENP in the innate defence of eggs against pathogens and the presence of 
LPS binding domains would make an antimicrobial role seem possible as 
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demonstrated with Ovocalyxin-36 (Gautron et al., 2011).  If this is the case it is 
interesting to note that TENP is present in all components of the egg and is a 
significant egg white component representing ~0.1-0.5% of the total protein, similar 
to the levels of ovoinhibitor, a multitype serine proteinase inhibitor which is present 
at 0.1-1.5% (Guerin-Dubiard et al., 2006).  However since this study began 
antimicrobial function has been demonstrated with TENP isolated from emu egg 
where it is a large component (~15%) (Maehashi et al., 2014).  In the emu egg there 
is very little lysozyme present and as such TENP is thought to play a large part in the 
defence of the egg.  The large number of known antimicrobial proteins already 
identified in the egg and the activity of emu TENP would make an antimicrobial role 
for chicken TENP seem plausible although experimental proof in the chicken does 
not yet exist. 
Despite the fact that chicken TENP is likely to be an antimicrobial agent it was not 
chosen as a candidate for feed trials due to the difficulties producing it in large 
quantities in our fungal expression system (see chapter 5).  In order for a protein to 
be a successful alternative to existing in-feed antibiotics it needs to be produced in 
large quantities, cheaply, otherwise it cannot be considered economically viable.  In 
addition to TENP being difficult to produce in our system the fact that it is a large 
protein makes it susceptible to enzymatic protein cleavage.  As the proposed strategy 
for peptide administration is in the feed the antimicrobial candidate must be able to 
withstand digestion in the intestine of the target organism.  One of the main enzymes 
in the gastrointestinal tract is pepsin, an in-silico digestion of the mature TENP 
protein revealed 136 pepsin cleavage sites at pH>2, focus was therefore shifted to the 
smaller peptides in this study, the ovodefensins.  However it is not to say that it 
might have other applications as an antimicrobial. 
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4.1. Introduction 
The egg has many mechanisms in place to protect itself from bacterial invasion; 
these can effectively be considered as either physical or chemical (Kovacs-Nolan et 
al., 2005).  An important part of the eggs chemical defence is provided by 
antimicrobial peptides (AMPs), otherwise known as host defence peptides (HDPs).  
A particular group of these, the ovodefensins, was recently shown to be a new family 
of egg specific defensins (Gong et al., 2010).  The family had been shown to be 
conserved across divergent avian species and was thought to be avian specific (Gong 
et al., 2010).   Proteomic methods had confirmed the presence of the chicken, turkey 
and duck members of the ovodefensin family in the egg (Odani et al., 1989, Mann, 
2007, Naknukool et al., 2008) and quantitative reverse transcriptase PCR confirmed 
that the expression of the chicken member, gallin was restricted to the oviduct of the 
hen (Gong et al., 2010).  In contrast classical defensins are widely distributed across 
many tissues and can be found in all vertebrates (van Dijk et al., 2008).  Only three 
of the classical chicken defensins are found in the egg; AvBD9, 10 and 11 (Herve et 
al., 2014).    It remained to be determined if the expression of other avian members 
of the ovodefensin family are also restricted to the oviduct, which would imply that 
the whole family was likely to be expressed principally for inclusion in the egg.  If 
this is the case ovodefensins are likely to be influenced by gonadal steroids and 
would be expected to show expression patterns in response to steroids typical of egg 
specific genes such as ovalbumin (Muramatsu et al., 1994) or TENP (Whenham et 
al., 2014).  Although the connection had not previously been made with classical 
defensins, ovodefensins were classed as a new branch of this family largely because 
of the conservation of a characteristic 6 cysteine motif, linked by 3 disulphide bonds 
and a common glycine residue attributed to all classical β-defensins (Gong et al., 
2010). Their position in the genome is also close to the β-defensin cluster on 
chromosome 3 (Gong et al., 2010).   The ovodefensins differ from classical defensins 
in the spacing of amino acids within the 6 cysteine motif, and are slightly shorter in 
length, the mature peptides ranging from only 39-41 amino acids, although they are 
still highly cationic as is expected with defensins.  Two cysteine motifs were 
observed in ovodefensins; C-X5-C-X3-C-X11-C-X3-CC and C-X3-C-X3-C-X11-C-
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X4-CC (Gong et al., 2010), which may be due to the fact that antimicrobial peptides 
are often under high selective pressure to evolve due to the ongoing arms race 
between pathogen and host, such as observed in classical β-defensins (Maxwell et al., 
2003).  Interestingly the 3D structure of the chicken ovodefensin gallin has recently 
been solved which confirmed the presence of the three-stranded antiparallel β-sheet 
observed in all classical β-defensins reinforcing its relationship with the β-defensins 
(Herve et al., 2014).  However, gallin contains an additional short two-stranded β-
sheet (Herve et al., 2014), this five-stranded arrangement supports the hypothesis that 
gallin, and presumably the other ovodefensins, form a structurally distinct sub-family 
of β-defensins.   
Due to an increase in antibiotic resistance there is an ever increasing need to find 
alternative strategies for microbial control.  Host defence peptides such as the 
defensins have been suggested previously as an interesting template for new classes 
of antimicrobial drugs as they often possess a wide spectrum of antimicrobial activity 
(Hancock, 1997, Hancock and Lehrer, 1998).  Cationic host defence peptides are 
small, typically containing a high abundance of positively charged and hydrophobic 
residues (Hancock and Sahl, 2006).  They have been studied not only for their direct 
antimicrobial activities but also for multifaceted immunomodulatory capabilities 
(Hancock and Sahl, 2006).  As it is hoped that host defence peptides such as 
ovodefensins may provide a new source of novel antimicrobials it is important to 
broaden our understanding of their biology and hopefully discover new molecules 
which may possess antimicrobial function.   
4.2. Objectives 
The aim of this chapter was to test the hypothesis that evolution is acting on spacing 
as well as sequence which may reveal the presence of further cysteine motifs and 
new molecules of the ovodefensin family in databases or the genomic sequences.  
The aim was to determine whether the family is avian specific as previously 
speculated.  This chapter will also examine the in greater detail the expression of the 
ovodefensin family both in terms of tissue, start site and steroid control. 
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4.3. Methods 
4.3.1. Discovery of new ovodefensin family members 
Available genome databases Ensembl (http://www.ensembl.org), PreEnsembl 
(http://pre.ensembl.org) and UCSC (http://genome.ucsc.edu/) were searched using    
TBLASTN and BlastP to locate potential homologs using the 41 amino acid mature 
peptide sequence of gallin (GenBank: CBE70283.1) and the previously published 39 
amino acid mature peptide sequence of taeniopygin 2 (Gong et al., 2010).  Further 
iterative searches were made with the homologues discovered.  Protein database Uni-
Prot (http://www.uniprot.org/) was also searched using BlastP to identify peptide 
sequences previously unidentified as ovodefensins. 
4.3.2. Phylogenetic analysis of the evolution of spacing between 
conserved residues.  
A distance matrix based on the amino acid sequence length between each of the 
cysteines and the conserved glycine residue was built for analysis by R for all known 
and newly discovered ovodefensins (Table 4.1).  Hierarchical clustering for each 
distance matrix was calculated using R (http://www.r-project.org/) which was then 
used to produce a cladogram of the phylogenetic relationships using the R ‘hclust’ 
function (Figure 4.1A).  Similarly cladograms based on spacing were produced 
separately for avian species (Figure 4.1C) and reptiles (Figure 4.1D).  The resulting 
ovodefensin ‘sub-families’ were used to propose new nomenclature for existing and 
newly discovered ovodefensin molecules (Table 4.2) which currently have trivial 
names based on  a range of criteria determined by the discoverer.  I propose that each 
gene has the prefix OvoD to identify it as an ovodefensin and is attributed a letter 
from A-F to identify the sub-family to which it belongs.  Within a sub-family each 
gene is given a numerical identifier allowing multiple forms of the same gene to be 
identified.  For example gallin would become Gallus gallus OvoDA1 and the 
additional copies OvoDA1_2 and OvoD1_3.  Through the use of this nomenclature 
meleagrin is Meleagris gallopavo OvoDA1 allowing it to be easily identified as a 
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Table 4.1: Distance matrix calculated from the inter cysteine and conserved glycine 
residues of all known Ovodefensin homologs using R.  Numbers 1-35 on each axis 
represent each of the Ovodefensin molecules; the numbers within the table 
represent the distance between each Ovodefensin spacing sequence.  Colour 
indicates the similarity of spacing between peptides 1-35 on the x and y-axis with 
green representing no difference and red those with the greatest difference. 
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Species Latin name 
Gene/ 
protein name 
Mature peptide sequence 
Chicken Gallus gallus OvoDA1 
LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASW
KWK 
Chicken Gallus gallus OvoDA1_2 
LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASW
KWK 
Chicken Gallus gallus OvoDA1_3 
LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASW
KWK 
Chicken Gallus gallus OvoDB1 
KRKGTCKGYCAPTCNKKDEWSFHQSCKKMYCCLLPLK
KGK 
Turkey Meleagris gallopavo OvoDA1 
QVLKYCPKIGYCSSKCSKAEVWAYSPDCKVHCCVPANQ
KWK 
Turkey Meleagris gallopavo OvoDA1_2 
QVLKYCPKIGYCSSKCSKAEVWAYSSDCKVHCCVPANR
KWK 
Turkey Meleagris gallopavo OvoDB1 
QHKGTCKGYCASACNKKDEWTFHQSCKKMYCCLPPPK
KGK 
Duck Anas platyrhynchos OvoDA1 
QVRKYCPKVGYCSSKCSKADVWSLSSDCKFYCCLPPGW
KGK 
Duck Anas platyrhynchos OvoDB1 
QKKGFCAGYCSYSCAKTDEWTFHQTCGKMYCCIPPPKK
GK 
Zebra finch Taeniopygia guttata OvoDA1 
KFRKTCAPMGYCSPKCRVMDLKYTSGDCKYSCCIPTAW
KGK 
Zebra finch Taeniopygia guttata OvoDA1_2 
KFRKTCAPMGYCSPKCRVMDLKYTSGDCKYSCCIPTAW
KGK 
Zebra finch Taeniopygia guttata OvoDB1 
QPKRSCRGHCSRTCGKGEREEHTEDCGGMHCCLTHRKR
K 
Rock pigeon Columba livia OvoDA1 
QVKKYWTYCPKEGHCSSKCDKMYTWTTSSDCKFYCCIP
YSWNGK 
Rock pigeon Columba livia OvoDB1 
QYKGVCPGYCSNMCDKMDEWGFSRSCRKMYCCIPLPK
KGK 
















Ficedula albicol OvoDB1 FCDGYCAHACGETEEWSFSPYCEELHCCIPSPKKGK 
Medium 
ground finch 





Geospiza fortis OvoDA1_2 
VRKTCAPVGYCSPKCRVMDLKYTSADCKYSCCIPTSWK
GK   
Medium 
ground finch 





Caretta caretta OvoDB1 EKKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK 
Chinese 
turtle 
Pelodiscus sinensis OvoDB1 KGCAGRCDWKCGKYEYETYTYDCPKSYCCLPLFKWK 
Chinese 
turtle 
Pelodiscus sinensis OvoDB1_2 KGCAGRCDWKCGKYEYETYTYDCPKSYCCLPLFKWK  
Painted turtle Chrysemys picta bellii OvoDB1 KGGCPGRCAKSCDKHEVASKTFDCKYMKCCTYPKKG 
Painted turtle Chrysemys picta bellii OvoDC1 QKKGCPGRCTSKCGKYEYPSKITYPNCKTLCCIASKRGK  
Painted turtle Chrysemys picta bellii OvoDC1_2 QKKGCPGRCTSKCGKYEYPSKITYPNCKTLCCIASKRGK 
Painted turtle Chrysemys picta bellii OvoDC2 QKKGCPGRCTSKCGKYEYPSKIPYPNCKALCCISSKKGK 
Anole Lizard Anolis carolinensis OvoDE1 KPSCSVDGGRCAKYCEKTEYASYVHDCPLCCFKYKK 
Anole Lizard Anolis carolinensis OvoDE2 KPSCSVDGGRCAKYCEKTEYASYVHNCPLCCFKYKK 
Anole Lizard Anolis carolinensis OvoDE2_2 KPSCSVDGGRCAKYCEKTEYASYVHNCPLCCFKYKK 
Anole Lizard Anolis carolinensis OvoDE2_3 KPSCSVDGGRCAKYCEKTEYASYVHNCPLCCFKYKK 
Anole Lizard Anolis carolinensis OvoDE3 KPSCSVDGGRCAKYCEKTEYGYYGYDCPLCCFKYKK 
Anole Lizard Anolis carolinensis OvoDF1 KGPSCSTYGGSCNPKGCAKGYTSYSTHDCKYCCVSP 
Anole Lizard Anolis carolinensis OvoDF2 KGPSCKEYGGICNPKSCAKGYSSYSTYDCKTCC 












Table 4.2 - All known and newly discovered ovodefensins 
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member of the same sub-family and a gallin ortholog.  This nomenclature will be 
used throughout the remainder of this thesis to aid clarity. 
In addition to this a cladogram was constructed using the programme Mega5 and the 
core peptide sequence from the conserved glycine until the fourth cysteine residue 
inclusively for sequences where the number of amino acids within this region was 
identical (Figure 4.1B).  Mega5 was also used to construct phylograms based on the 
whole mature peptide sequences for OvoDA family members (Figure 4.1E) and also 
OvoDB (Figure 4.1F). 
4.3.3. Animals and tissue collection 
To determine Gallus gallus OvoDA1 and OvoDB1 expression tissues were taken 
from sexually mature White Leghorn LSL hens (Lohmann) (see 2.4.2).   For analysis 
of Anas platyrhynchos OvoDB1 (dBPS1) and OvoDA1 (dBPS2) expression tissues 
were collected from sexually mature Pekin ducks (Cherry Valley) (2.4.4).  Combined 
expression of Meleagris gallopavo OvoDA1 (Meleagrin) and OvoDA2 and 
expression of OvoDB1 was determined using tissues from sexually mature turkeys 
(2.4.3).  Taeniopygia guttata OvoDA1 (Taeniopygin 1) and OvoDB1 (Taeniopygin 2) 
expression was measured using adult female zebra finches courtesy of Dr Karen 
Spencer, University of St Andrews, Scotland (see 2.4.5). 
In order to assess the effect of oviposition on Gallus gallus OvoDB1 expression 
magnum tissue was obtained from sexually mature White Leghorn hens with an 
ovum at various positions in the oviduct, see section 2.4.7 for details.    
Gallus gallus OvoDA1 and OvoDB1 expression was measured in hens that were in 
lay (n=11) and those where the oviduct had regressed due to incubation behaviour 
(n=11) to establish the effect of oviduct development, (section 2.4.8). 
4.3.4. RNA preparation 
RNA was extracted from tissues and processed as per the Ultraspec protocol (section 
2.5.1). 
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Species Accession no. Genome build/ location 
OvoDB1 
 
Gallus gallus EMBL: 
LN717248 
Nov’11; Chr 3; 106744444-
106744572 
OvoDA1_2 Meleagris gallopavo EMBL: 
LN717249 
Dec’09; Chr 2; 112968507-
112968850 
OvoDB1 Meleagris gallopavo EMBL: 
LN717250 




- melUnd1; Scaffold JH556573; 
2958896-2959015 
OvoDB1 Pelodiscus sinensis - PelSin_1.0; Scaffold JH212527; 
3638-3745 
OvoDB1_2 Pelodiscus sinensis - PelSin_1.0; Scaffold JH210373; 
9969-10076 
OvoDB1 Chrysemys picta 
bellii 
- Dec’11; Scaffold JH584573; 
2758224-2758331     
OvoDC1 Chrysemys picta 
bellii 
- Dec’11; Scaffold JH584573; 
2800433-2800549 
OvoDC1_2 Chrysemys picta 
bellii 
- Dec’11; Scaffold JH584573; 
2828206-2828322     
OvoDC2 Chrysemys picta 
bellii 
- Dec’11; Scaffold JH584573; 
2778988-2779104 
OvoDE1 Anolis carolinensis - May’10; Scaffold Un_GL343551; 
118450-118557 
OvoDE2 Anolis carolinensis - May’10; Scaffold Un_GL343551; 
106991-107098 
OvoDE2_2 Anolis carolinensis - May’10; Scaffold Un_GL343551; 
131862-131969 
OvoDE2_3 Anolis carolinensis - May’10; Scaffold Un_GL343551; 
142606-142713 
OvoDE3 Anolis carolinensis - May’10; Scaffold Un_GL343551; 
53724-53831 
OvoDF1 Anolis carolinensis - May’10; Scaffold Un_GL343551; 
64537-64644 
OvoDF2 Anolis carolinensis - May’10; Scaffold Un_GL343553; 
4868-4966 








- Aug’12; Scaffold JH736037; 4956-
5063 
OvoDA1 Ficedula albicol - FicAlb_1.4; Scaffold JH603338; 
1433524-1433405 
OvoDB1 Ficedula albicol - FicAlb_1.4; Scaffold JH603338; 
1441614-1441721 
OvoDA1 Geospiza fortis - Apr’12; Scaffold JH760839; 55-174 
OvoDA1_2 Geospiza fortis - Apr’12; Scaffold JH739967; 
2617679-2617798 
OvoDA1_3 Geospiza fortis - Apr’12; Scaffold JH739967; 
2632098-2632217 
 
Table 4.4 – Nomenclature and genome location of newly identified ovodefensins. 
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Common Name Latin Name Abbreviation 
Chicken Gallus gallus Gg 
Turkey Meleagris gallopavo Mg 
Duck Anas platyrhynchos Ap 
Zebra finch Taeniopygia guttata Tg 
Black swan Cygnus atratus Ca 
Rock Pigeon Columba livia Cl 
Budgerigar Melopsittacus undulatus Mu 
Collared flycatcher Ficedula albicol Fa 
Medium ground finch Geospiza fortis Gf 
Painted turtle Chrysemys picta bellii Cpb 
Loggerhead turtle Caretta caretta Cc 
Chinese soft-shell turtle Pelodiscus sinensis Ps 
Anole lizard Anolis carolinensis Ac 
American alligator Alligator mississippiensis Am 
 
Table 4.5 - A key for the abbreviations of the species Latin name.  
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4.3.5. Transcript detection and characterisation 
4.3.5.1. RT-PCR and sequencing 
1 µg samples of chicken, duck, turkey and zebra finch magnum RNA were reverse 
transcribed using a high capacity cDNA reverse transcription kit (Applied 
Biosystems, UK) according to the manufacturer’s protocol.  Primers (Chapter 2, 
Table 2.2) were designed to ensure complete coverage of each ovodefensin’s coding 
sequence.  PCR amplification was performed using standard conditions (section 
2.6.2).  Amplified PCR fragments were sequenced with the forward and reverse 
primers.  Sequences were assembled by Staden (Staden, 1996) to produce consensus 
sequences. 
4.3.5.2. 5’/3’ RACE 
5’/3’RACE (Roche Diagnostics 2
nd
 Generation, Mannheim, Germany) were carried 
out to determine the number of exons encoding Gallus gallus OvoDA1 (gallin) 
(section 2.8).  For 5’RACE primer OvoDA1SP2 was used for both amplification and 
sequencing.  For 3’RACE, OvoDA1SP5 was used for amplification and sequencing. 
Primer sequences for RACE can be found in Chapter 2, Table 2.2. 
4.3.6. Reverse transcription quantitative polymerase chain reaction 
(RT-QPCR).  
0.5 µg of cDNA was prepared (section 2.5.2) and used for RT-QPCR analysis as 
detailed in section 2.7.2.  Primer3 was used to design primers for quantification, 
sequences can be found in Chapter 2, Table 2.2.  Reactions containing no template 
were run as a control.  Lamin B-receptor (LBR) expression was measured in the 
same way to normalise concentrations (as described previously) (McDerment et al., 
2012, Whenham et al., 2014) in order to determine the absolute concentration of the 
different ovodefensin transcripts.  One way or two way ANOVA and least significant 
difference to test between the means were used as appropriate for statistical analysis 
of log transformed data. (Genstat 13th edition, VSN International Ltd, Oxon, UK). 
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4.3.7. Production and titres of polyclonal antibodies 
Production of antibodies was carried out by Dundee Cell Products Ltd, Dundee 
(section 2.11); titres of anti-GalOvoDB1 and anti-TaeOvoDB1 in the antisera were 
measured (section 2.11) for use in immunohistochemistry. 
4.3.8. Immunohistochemistry (IHC) 
Wax embedded tissues were prepared (section 2.12), a standard IHC protocol was 
then used; optimal staining was achieved at a 1:500 dilution for the polyclonal zebra 
finch anti-OvoDB1 (113_KGE _2.1) and 1:1000 for the chicken anti-OvoDB1 (108 
CNK-1.3). 
4.3.9. Sequencing and database submission 
All sequencing was carried out by GATC biotech (Konstanz, Germany) and 
consensus sequences were submitted to EMBL, Gallus gallus OvoDB1 (EMBL 
accession no. LN717248), Meleagris gallopavo OvoDA1_2 (EMBL accession no. 
LN717249), Meleagris gallopavo OvoDB1 (EMBL accession no. LN717250), 
Taeniopygia guttata OvoDA1 (EMBL accession no. LN717251), OvoDA1_2 (EMBL 
accession no. LN717252) and OvoDB1 (EMBL accession no. LN717253). Putative 
budgerigar, medium ground finch, anole lizard, american alligator, collared 
flycatcher, painted turtle and chinese soft-shelled turtle sequences were not submitted 
because they remain predicted but can be found in Table 4.2. 
4.4. Results 
4.4.1. Bioinformatic analysis and transcript confirmation 
TBLASTN similarity searches of available genomes located twenty four new 
ovodefensin homologues (Table 4.2, Table 4.4).  Hierarchical clustering based on the 
distance between each cysteine identifies six specific sub-families termed OvoDA-
OvoDF (Figure 4.1A).  In the chicken the first representative of OvoDB, a shorter 
cysteine motif (C-X3-C-X3-C-X11-C-X4-CC) was identified on chromosome 3, 
where OvoDA1 (C-X5-C-X3-C-X11-C-X3-CC) and the classical beta defensins are 
also located.  This was named OvoDB1 in accordance with the proposed 
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nomenclature outlined in 4.3.2 (Figure 4.1A, C, Table 4.3).  The first turkey 
representative of the OvoDB1 motif (Figure 4.1A, C, Table 4.3) was discovered on 
chromosome 2 the same chromosome as Meleagris gallopavo OvoDA1 (meleagrin).  
A further potential paralog of Meleagris gallopavo OvoDA1 was also located on this 
chromosome; the mature peptide sequence shares a 95% identity with OvoDA1 and 
was named Meleagris gallopavo OvoDA2 (Figure 4.1A, C, Table 4.4).  A budgerigar 
representative of sub-family B, Melopsittacus undulatus OvoDB1 (Figure 4.1A, C, 
Table 4.4) was discovered during this analysis however a representative from the 
same subfamily (A) as gallin has yet to be located for this species.  Three putative 
copies of a sub-family A ovodefensin were found in the April 2012 assembly of the 
medium ground finch genome; Geospiza fortis OvoDA1, OvoDA1_2 and OvoDA1_3 
(Figure 4.1A, C, Table 4.4).  A search of the flycatcher genome discovered a member 
from both the A and B sub-families, these were named Ficedula albicollis OvoDA1 
and OvoDB1 respectively (Figure 4.1A, C, Table 4.4).  For the first time reptile 
representatives of the ovodefensin family were identified.  Two copies of Pelodiscus 
sinensis OvoDB1(Figure 1A, D, Table 4) were identified in the Chinese soft-shell 
turtle genome.  In the painted turtle genome a sub-family B member was also 
located; Chrysemys picta bellii OvoDB1 (Figure 1A, D, Table 4) in addition to this a 
new cysteine spacing motif (C-X3-C-X3-C-X13-C-X3-CC), which we have termed 
sub-family C was uncovered.  Within this the painted turtle sub-family C contains 
two copies of the OvoDC1 gene and an OvoDC2 gene (Figure 4.1A, D, Table 4.4).  
TBLASTN searches of the American alligator genome identified two members of yet 
another new cysteine motif, sub-family D (C-X3-C-X3-C-X11-C-X3-CC); Alligator 
mississippiensis OvoDD1 and OvoDD2 (Figure 1A, D, Table 4).  Finally two further 
motifs were uncovered in the anole lizard genome; sub-family E (C-X6-C-X3-C-
X11-C-X2-CC) and F (C-X6-C-X4-C-X11-C-X2-CC).  Within sub-family E one 
copy of Anolis carolinensis OvoDE1 was located, three copies of OvoDE2 and one 
copy of OvoDE3 (Figure 1A, D, Table 4.4).  One copy of each of the sub-family F 
members was identified, OvoDF1, OvoDF2 and OvoDF3 (Figure 4.1A, D, Table 
4.4).   
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Figure 4.1:  Evolutionary relationship of ovodefensin homologues.  R ‘hclust’ 
was used to create a distance matrix and perform hierarchical clustering of all 
known ovodefensin members based on spacing between cysteine residues (A). This 
identifies six specific sub-families termed OvoDA-OvoDF.  A phylogram indicating 
the evolutionary history of sub-families OvoDA, OvoDB, OvoDD and OvoDE was 
inferred using the Neighbor-Joining method (Saitou and Nei, 1987) from the amino 
acid sequence of a core region from the conserved glycine residue until the fourth 
cysteine (B).  This suggested that the spacing with the cysteine motif of OvoDB 
evolved independently in avian and reptilian lineages and which are presented 
separately (C) and (D).  Mature peptide sequences from sub-families OvoDA (E) 
and OvoDB (F) were analysed individually in order to compare the full length of the 
molecule.   
For B, E and F the percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (1000 replicates) are shown next to the 
branches (Felsenstein, 1985). The branch lengths are proportional to the 
evolutionary distances which were computed using the Poisson correction method 
(Zuckerkandl and Pauling, 1965).  The units are the number of amino acid 
substitutions per site.  All positions containing gaps and missing data were 
eliminated. Evolutionary analyses were conducted in MEGA5 (Tamura et al., 2011).  
A key for the abbreviations of the species Latin name can be found in Table 4.5 and 
the sequences the alignments are based on in Table 4.2. 
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Genome build and chromosome/scaffold locations for each ovodefensin are outlined 
in Tables 4.3 and 4.4. 
Three homologs not previously classified as ovodefensins were also identified during 
this study.  Shapiro et al (Shapiro et al., 2013) produced a rock pigeon reference 
genome from which a putative sub-family A member was identified.  This had been 
named cygnin due to its homology with black swan cygnin and now propose the 
name Columba livia OvoDA1 (Figure 4.1A, C, Table 4.4).  From this genome a 
putative sub-family B member, named small basic protein was also located, the name 
Columba livia OvoDB1 (Figure 4.1A, C, Table 4.4) is proposed for this ovodefensin 
homolog.  In addition to this TEWP, a loggerhead turtle peptide was isolated from 
egg white and shown to be a defensin (Chattopadhyay et al., 2006), this peptide has 
the motif of a sub-family B ovodefensin and the name Caretta caretta OvoDB1 is 
adopted (Figure 4.1A, C, Table 4.4). 
4.4.2. 5’/3’ RACE 
5’/3’ RACE using magnum RNA and primers as specified in 4.3.5 resulted in a PCR 
product with 100% identity to the published Gallus gallus OvoDA1 (gallin) sequence 
(ENSGALG00000028311.1), the 5’ and 3’ sequence of which was derived by 
prediction.  Alignment with the chicken genome confirmed that Gallus gallus 
OvoDA1 is encoded for by two exons. 
4.4.3. Tissue expression 
Gallus gallus OvoDB1 expression was restricted to magnum and isthmus as 
previously documented with OvoDA1 (Gong et al., 2010); (Figure 10).  No 
expression was observed in any other tissue tested for either Gallus gallus OvoDA1 
(Figure 4.2) or OvoDB1 (Figure 4.3).  In contrast to this both Anas platyrhynchos 
OvoDA1 and OvoDB1 expression was greatest in the shell gland, although some 
expression was observed in both the magnum and the isthmus (Figure 4.10).  The 
combined expression of Meleagris gallopavo OvoDA1 and OvoDA1_2 and 
expression of OvoDB1 was high across all oviduct tissues, the greatest expression for 
these turkey ovodefensins  
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Figure 4.2:  Expression of Gallus gallus OvoDA1 mRNA in a range of adult 
tissues measured by RT-QPCR (n=4, mean ± sem). Expression was corrected for 
chicken LBR expression to normalise for any differences between tissues.  Tissues 
showing expression are framed in red. 
 
Figure 4.3:  Expression of Gallus gallus OvoDB1 mRNA in a range of adult 
tissues measured by RT-QPCR (n=4, mean ± sem). Expression was corrected for 
chicken LBR expression to normalise for any differences between tissues. Tissues 
showing expression are framed in red. 
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Figure 4.4:  Combined expression of Meleagris gallopavo OvoDA1 and 
OvoDA1_2 mRNA in a range of adult tissues measured by RT-QPCR (n=4, 
mean ± sem). Expression was corrected for turkey LBR expression to normalise for 
any differences between tissues.  Tissues showing expression are framed in red. 
 
Figure 4.5:  Expression of Meleagris gallopavo OvoDB1 mRNA in a range of 
adult tissues measured by RT-QPCR (n=4, mean ± sem). Expression was 
corrected for turkey LBR expression to normalise for any differences between 
tissues.  Tissues showing expression are framed in red. 
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Figure 4.6:  Expression of Anas platyrhynchos OvoDA1 mRNA in a range of 
adult tissues measured by RT-QPCR (n=3, mean ± sem). Expression was 
corrected for turkey LBR expression to normalise for any differences between 
tissues.  Tissues showing expression are framed in red. 
 
Figure 4.7:  Expression of Anas platyrhynchos OvoDB1 mRNA in a range of 
adult tissues measured by RT-QPCR (n=3, mean ± sem). Expression was 
corrected for duck LBR expression to normalise for any differences between tissues.  
Tissues showing expression are framed in red. 
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Figure 4.8:  Expression of Taeniopygia guttata OvoDA1 mRNA in a range of 
adult tissues measured by RT-QPCR (n=5, mean ± sem). Expression was 
corrected for zebra finch LBR expression to normalise for any differences between 
tissues.  Tissues showing expression are framed in red. 
 
Figure 4.9:  Expression of Taeniopygia guttata OvoDA1 mRNA in a range of 
adult tissues measured by RT-QPCR (n=5, mean ± sem). Expression was 
corrected for zebra finch LBR expression to normalise for any differences between 
tissues.  Tissues showing expression are framed in red. 
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Figure 4.10:  Expression of ovodefensin mRNA in a range of adult chicken (n=4, mean ± sem), turkey (n=4, mean ± sem), duck 
(n=3, mean ± sem) and zebra finch (n=5, mean ± sem) ovarian stroma and oviduct tissues measured by RT-QPCR (mean ± sem). 
Expression was corrected for chicken, turkey, duck or zebra finch LBR expression to normalise for any differences between tissues.  
Note: to accommodate the large differences in expression the data are presented on the log scale. 
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Figure 4.11:  Expression of Gallus gallus OvoDB1 mRNA in magnum tissue at different 
stages of egg formation measured by RT-QPCR (n=8, mean ± sem).  Gallus gallus 
OvoDB1 expression was corrected for LBR expression.  Pause represents a day when the 
hen did not ovulate so no egg is present. Magnum represents tissue taken when an egg is 
present in the magnum and early, mid and late describes the stage of shell formation in the 
shell gland and indicates the egg was not in the magnum when the sample was taken. 
ANOVA, P=0.269. 
 
Figure 4.12:  Expression of A) Gallus gallus OvoDA1 and B) Gallus gallus OvoDB1 in 
magnum tissue of laying (L) and out of lay (NL) birds measured by RT-QPCR (n=11, 
mean ± sem).  Non-laying hens were those where the oviduct had regressed due to the 
withdrawal of gonadotrophic support with the onset of incubation behaviour.  Expression was 
corrected using LBR expression. Note the large difference in the Y-axis scale between A and 
B.  Significance between laying state is indicated at P<0.001, (***). 
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was measured in the shell gland, magnum and isthmus (Figure 4.10).  Taeniopygia 
guttata OvoDA1 and OvoDB1 expression was also restricted to the oviduct with the 
highest expression being observed in the shell gland for both genes (Figure 4.10).  It 
should be noted that vagina tissue was not available for the zebra finch.  For all the 
ovodefensin transcripts analysed, no expression was detected in tissues outside the 
reproductive tract (Figures 4.2-4.9). 
There was no significant effect of the position of the egg in the oviduct or the lack of 
an egg in the oviduct on Gallus gallus OvoDB1 expression in the magnum (Figure 
4.11) (ANOVA, P=0.269). The level of Gallus gallus OvoDA1 and OvoDB1 
expression in the magnum was higher (P<0.001) in birds in-lay than in those with an 
oviduct in the regressed state (Figure 4.12).   
4.4.4. Immunohistochemistry 
The chicken anti-OvoDB1 antiserum (108 CNK-1.3) produced positive staining in 
the tubular gland cells of the magnum (Figure 4.13A, C).  The ciliated and non-
ciliated cells lining the magnum region of the oviduct did not react to the primary 
antibody. No staining was observed in the isthmus, shell gland or caecum (data not 
shown).  In contrast to this the zebra finch anti-OvoDB1 antiserum (113_KGE _2.1) 
produced positive staining in the tubular gland cells and surface epithelium of the 
magnum, isthmus and shell gland (Figure 4.14A, C, E).  No convincing staining was 
observed in the breast muscle (Figure 4.14G). 
4.5. Discussion 
Seven ovodefensins had previously been identified within divergent avian species 
and it had been observed that two cysteine motifs exist (Gong et al., 2010); however 
it was clear that there may be further divisions in structure and therefore possibly 
function (Table 4.3).  This study identified a further 25 ovodefensin members (Table 
4.4) through genome analysis, and attributed a further 3 previously known sequences 
to the group expanding the ovodefensin family to include reptile species for the first 
time.  It was first suggested by Gong et al. that the ovodefensins appeared to be a 
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Figure 4.13:  Only the tubular gland cells of the magnum (A and C) region of 
the oviduct convincingly stained positive with the chicken anti-OvoDB1 
antisera (108 CNK-1.3) whereas the surface epithelial cells (ciliated and non-
cilliated) stained negative (A and C).  The corresponding negative controls for A and 
C are shown in B and D. 
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Figure 4.14: The tubular gland cells and surface epithelium of the magnum (A), 
isthmus (C) and shell gland (E) regions of the oviduct stained positive with 
zebra finch anti-OvoDB1 antisera (113_KGE_2.1). The corresponding negative 
controls are shown in image B, D, and F.  Breast muscle (G and H) was not reactive 
to the primary antibody.  
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new family of defensin molecules, most likely belonging to the β-defensin group 
Gong et al., 2010).  However it was predicted that ovodefensins share the genomic 
organisation of mammalian β-defensins, being encoded for by two exons (Gong et 
al., 2010) rather than the four exons which encode for classical avian defensins (van 
Dijk et al., 2008).  This study confirmed the exon arrangement of Gallus gallus 
OvoDA1 by defining the transcription start site thus confirming the two exon 
predictions.  Where available, predictions of the newly discovered avian and reptilian 
ovodefensins also support the 2 exon arrangement.  In addition to an altered exon 
arrangement the ovodefensins differ from classical avian defensins in the spacing 
within the cysteine motif and therefore it is likely they form a new structural sub-
family of defensins.  This observation was supported by Hervé et al (2014) when the 
3D structure and specific cysteine pairing was solved and it was demonstrated that 
Gallus gallus OvoDA1 (gallin) contained an additional two stranded parallel β-sheet 
and no amino-terminal helix.  Now phylogenetic analysis of both the spacing and 
sequence of the ovodefensins suggests that multiple sub-families may exist within 
the family (Figure 4.1A, C, D).  These sub-families include four new ovodefensin-
like motifs OvoDC (C-X3-C-X3-C-X13-C-X3-CC), OvoDD (C-X3-C-X3-C-X11-C-
X3-CC), OvoDE (C-X6-C-X3-C-X11-C-X2-CC) and OvoDF (C-X6-C-X4-C-X11-
C-X2-CC) revealing that the ovodefensin family is much more diverse than was first 
thought.  All four new cysteine spacing motifs appear to be reptile specific (Figure 
4.1A, D) whereas of the originally identified motifs OvoDA, (C-X5-C-X3-C-X11-C-
X3-CC) was avian specific (Figure 4.1A, C) and OvoDB (C-X3-C-X3-C-X11-C-X4-
C) contained both avian and reptilian counterparts (Figure 4.1A, C, D). 
Phylogenetic analysis of spacing (Figure 4.1A) suggests that a common ancestor 
gave rise to two progenitor molecules which appear in turn to have independently 
evolved three cysteine motifs.  However sequence analysis (Figure 4.1B) suggests 
that the OvoDB cysteine motif has in fact evolved separately within both avian and 
reptilian lineages spacing is an important feature of the ovodefensin molecules. In a 
sense this seems like a form of convergent evolution, albeit the available repertoire 
of spacing is relatively limited.  In order to assess all the ovodefensin molecules 
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either spacing (Figure 4.1A) or a core region (Figure 4.1B) was used, however it is 
recognised that this may influence the outcome of the analysis depending on the 
evolutionary constraints of each selection.  In particular, analysis based on the core 
region of the molecule (Figure 4.1B) produced some unexpected outliers, for 
example within the OvoDA cluster the turkey molecules appear closer to the duck 
and swan than the chicken.  However when the full length peptides of the OvoDA 
sub-family are analysed separately (Figure 4.1E) a more classical species 
arrangement is observed.  This demonstrates the complex nature of what appears to 
be the co-evolution of sequence and spacing and the need for both aspects to be 
studied in combination.  Overall the evolution within birds, and now in this study 
another egg laying clade the reptiles, of a large repertoire of peptides that not only 
vary in sequence but the spacing between conserved cysteine residues suggests that 





 cysteine which varies from 3-6 amino acids in length for 
example has been demonstrated in Gallus gallus OvoDA1 to be important because of 
the basic residue in an otherwise hydrophobic region (Herve et al., 2014).  It has 
been difficult to find examples in the literature of situations where the amino acid 
distance between conserved residues of  a motif are changing or under selection, 
possibly because this is rare or because the methods of finding homologous genes 
relies heavily on the conservation of sequence, not pattern recognition. However 
approaches were developed to get round the problem in aligning large proteins where 
there were differences in spacing between conserved features important for protein 
secondary structure (Zhu et al., 1992) and these alignments appeared to have a better 
agreement with the accepted view of evolution than if this was not undertaken.  In 
large proteins this has been used to demonstrate the evolution by insertion of new 
domains in molecules which have effects on structure and the authors conclude that 
using structure is likely to be more robust than sequence when molecules cannot be 
unambiguously aligned (Jiang and Blouin, 2007).  In the case of the relatively small 
ovodefensins it also seems that this is the case.  
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RT-qPCR analysis on chicken, duck, turkey and zebra finch representatives of the 
ovodefensin family demonstrate that in all cases expression is restricted to the 
oviduct of the bird (Figures 4.2-4.9).  However, interestingly, levels and patterns of 
expression within the oviduct vary between genes and species.  As previously seen 
with Gallus gallus OvoDA1 (Gong et al., 2010), Gallus gallus OvoDB1 was 
expressed more highly in the magnum of the oviduct where the egg white is formed 
(Figure 4.10), however expression of Gallus gallus OvoDA1 was more than 40 times 
that of Gallus gallus OvoDB1 (Figure 4.12). In contrast to this both the duck and 
zebra finch ovodefensins were expressed most highly in the shell gland and the 
turkey ovodefensins had very high levels of expression in the magnum, isthmus and 
shell gland regions of the oviduct (Figure 4.10).  Immunohistochemistry confirmed 
the expression of Gallus gallus OvoDB1 (Figure 4.13) and Taeniopygia guttata 
OvoDB1 (Figure 4.14) at a peptide level in specific regions of the oviduct.  Gallus 
gallus OvoDB1 peptide distribution was restricted to the tubular gland cells of the 
magnum suggesting it is secreted into the egg white as previously seen with Gallus 
gallus OvoDA1.  In contrast Taeniopygia guttata OvoDB1 was expressed in both the 
tubular gland cells and surface epithelium of the magnum, isthmus and shell gland 
suggesting this may play a greater role in local protection of the oviduct as well as 
the innate defence of the egg.   
Gallus gallus OvoDB1 expression in the magnum of the oviduct did not differ 
significantly in relation to the position of the egg in the oviduct at the time of 
sampling (Figure 4.11); this was also the case for Gallus gallus OvoDA1 (Gong et 
al., 2010).  This expression profile is typical of egg proteins such as TENP 
(Whenham et al., 2014) or ovalbumin (Muramatsu et al., 1994).  Both Gallus gallus 
OvoDA1 and OvoDB1 expression in the magnum was significantly higher when the 
hen was in-lay compared to when the oviduct was regressed (Figure 4.12), 
suggesting that these genes are under the control of gonadal steroids, therefore being 
specifically up-regulated during egg production when steroid levels are elevated 
(Lague et al., 1975).  It is not possible to conclude if this is a direct effect of steroids 
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on the promoter or an indirect effect and indeed no classical oestrogen receptors were 
observed in the proximal promoter. 
This chapter has demonstrated that ovodefensins are avian and reptilian specific 
members of the β-defensin family.  Expression of avian members has been shown to 
be restricted to the oviduct and in the chicken are up-regulated in laying hens 
compared with hens with a regressed oviduct suggesting that gonadal steroids control 
expression.  Although the chicken ovodefensins show the classic signature of an egg 
specific gene, the pattern across the range of species examined is that of an oviduct 
specific family.  This coupled with the antimicrobial activity demonstrated in chapter 
5 suggests that ovodefensins have specifically evolved for a role in egg defence as a 
component of the eggs innate chemical defence; however they may also contribute to 
maintaining sterility in the oviduct through local tissue activity.  There is a large 
diversity within the ovodefensin family, with six motifs relating to spacing of the 
conserved cysteines discovered so far.  This suggests that evolution is acting not only 
on amino acid sequence but also spacing of the molecule.  This novel finding offers 
an additional avenue of investigation for the design of new antimicrobial compounds 
and makes the ovodefensins a promising family of molecules to take forward in this 
study.  Their small size makes them less susceptible to proteolytic cleavage than 
TENP and their conservation across divergent avian and reptilian species is 
suggestive of an important protective function.  With this in mind the next chapter 
will explore the antimicrobial function of this family and the prospects of these 
molecules for the modulation of gastrointestinal microflora. 
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5.1. Introduction 
Gallus gallus OvoDA1 (gallin), a chicken representative of the ovodefensin family 
was shown to be highly antibacterial against a laboratory-adapted strain of E. coli 
(Gong et al., 2010).  It has since been suggested that its direct antimicrobial actions 
are limited to E. coli (Herve et al., 2014), however Gallus gallus OvoDA1 is so far 
the only member of this novel family to be studied.  As it is hoped that host defence 
peptides such as ovodefensins may provide a new source of novel antimicrobials it is 
important to broaden our understanding of their capabilities including their activity 
against organisms of interest to the poultry industry such as Avian Pathogenic E.coli, 
Salmonella and Campylobacter.  Many defensin molecules are salt sensitive (Ganz, 
2003); and it is unclear if defensins are insensitive to pH.  Insensitivity to factors like 
pH and salt concentration would assist their use as antimicrobial agents that aim to 
control gut health in monogastrics where the withdrawal of in-feed antimicrobials 
has been causing problems (Bedford, 2000).  In order to overcome the cost 
associated with producing peptides in large quantities a fungal fermentation system 
has been used in this study (Chapter 2.14).   It is important to understand if this 
production method affects activity, therefore fungal derived recombinant peptide will 
be evaluated against the traditionally tested synthetic peptide. 
The purpose of this study was not to understand the role of the ovodefensins in the 
egg or oviduct but to determine whether or not they have the ability to modulate the 
gut microflora when administered orally through the feed and improve bird 
performance.  This question cannot be answered just by studying their effects against 
isolated organisms in vitro even if specific conditions of the target organ such as pH 
are considered.  However before progressing to the bird some promising evidence of 
activity is required in order to justify their use. 
The limitations of testing naturally occurring antimicrobial peptides in vitro has long 
been under scrutiny and the potency of their activity is often directly affected by the 
conditions they are tested under (Schwab et al., 1999).  Whether the peptide is tested 
under solid or liquid phase conditions or the absence/presence of salt, serum or 
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proteins in the test conditions have all been shown to affect activity (Schwab et al., 
1999).  The use of an ex vivo gut model allows the evaluation of promising 
candidates against a mixed community of microorganisms that directly resemble 
those conditions in which the peptide would need to work in terms of microbial 
microbiome structure, pH and metabolites.  The model used in this study was 
developed by Alimetrics, Finland (Apajalahti et al., 2009) and evaluates the 
microbial and environmental changes to ileal and caecal environments after dosing 
with recombinant peptide.   
5.2. Objectives 
To test the hypothesis that ovodefensin activity is not restricted to E.coli by testing 
the antimicrobial capabilities of novel ovodefensin family members including the 
newly identified chicken sub-family B member against a range of microrganisms.  
This study also examined the effect of factors which may influence ovodefensin 
activity if used as a feed additive such as salt and pH.  Finally an ex vivo gut model 
was used to investigate the hypothesis that ovodefensin peptides have the ability to 
modulate whole gut microbial communities. 
5.3. Methods 
5.3.1. Synthetic peptide production 
Gallus gallus OvoDA1 (LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASWKWK), 
OvoDB1 (KRKGTCKGYCAPTCNKKDEWSFHQSCKKMYCCLLPLKKGK) and Anas 
platyrhynchos OvoDA1 (QVRKYCPKVGYCSSKCSKADVWSLSSDCKFYCCLPPGWKGK) 
were synthesised (Almac Group, Gladsmuir, Scotland) (see 2.13).  Freeze dried 
peptides were reconstituted in 10% dimethyl sulfoxide (DMSO).  Synthetic peptide 
was used initially to screen peptides for activity in the in vitro assays. 
5.3.2. Recombinant peptide production 
Chemical synthesis of peptide is expensive and could not be used to produce 
sufficient yields for ex vivo and in vivo assays.  Due to cost chemical synthesis would 
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also not be a commercially viable method of production for a feed additive and 
therefore peptide was produced in a recombinant system. 
Recombinant Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1 were 
produced by Roal, Finland using a continuous fungal fermentation system.  
Trichoderma system expressing an empty vector was treated in the same way to act 
as a control in the in vitro and ex vivo evalution (see 2.14).   
Recombinant peptide was checked for antibacterial activity in the in vitro assay and 
used for the ex vivo assay and subsequently the in vivo trial detailed in Chapter 6. 
5.3.3. Antimicrobial assay 
A broth based antimicrobial assay (see 2.15) was used to determine the efficacy of 
Gallus gallus OvoDA1, OvoDB1 and Anas platyrhynchos OvoDA1.  Final 
concentrations of 0.5, 1, 2.5, 5, 10, 25, 50 and 100 µM were evaluated against E. coli 
K-12 strain DH5, avian pathogenic E. coli (APEC) O78:H9 strain χ7122, 
Salmonella enterica serovars Enteritidis (SE125109) and Typhimurium (ST4/74). 
For Staphylococcus aureus (8325-4) final concentrations of 10, 25, 50, 100, 150 and 
200 µM were used.   Results are expressed as a reduction in colony forming units per 
ml (CFU/ml) and where possible the effective dose 50 (ED50) was calculated using 
the DRC program in R (http://www.bioassay.dk/) (see 2.15.5). 
Neat purified recombinant Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1 
and control supernatant (see 5.3.2) were also evaluated in the antimicrobial assay 
before testing in the ex vivo model. 
Gallus gallus OvoDA1 was also evaluated against Camplybacter jejuni 11168 which 
is known to possess genes which confer resistance to cationic antimicrobial peptides 
as well as a mutant of this strain 11168H which lacks these genes (see 2.15.1 for 
details.  The same broth based assay as described previously was used with specific 
media and incubation conditions (see 2.15.1). 
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5.3.3.1. pH sensitivity 
The antimicrobial assay as outlined above (5.3.2) was adapted to test the effect of pH 
on the efficacy of Gallus gallus OvoDA1 against E. coli DH5.  The assay was 
carried out as before but using PBS at pH 6.4, 7.4 and 8.4; details can be found in 
appendix 1.  Gallus gallus OvoDA1 was tested at final concentrations of 1.9, 5.6, 
16.7 and 50 µM. 
5.3.3.2. Salt sensitivity 
The antimicrobial assay (5.3.2) was adapted to test the effect of salt sensitivity on 
Gallus gallus OvoDA1 efficacy.  PBS with NaCl concentrations of 50, 100 and 
150 mM, pH 6.4 were used; see appendix 1 for details. 
5.3.3.3. Bacterial metabolic state 
Some traditional antimicrobials are only able to kill replicating bacteria.  To 
determine if metabolic state has an effect on Gallus gallus OvoDA1 activity it was 
assessed against Avian Pathogenic E. coli in both a metabolically active and static 
state at 10 µM (see 2.15.4).  Ampicillin was used as positive control in these 
experiments as it is known to interfere with cell wall synthesis and therefore requires 
bacterial cells to be metabolically active. 
5.3.4. Viral plaque assay 
The antiviral activity of synthetic Gallus gallus OvoDA1, OvoDB1 and recombinant 
Taeniopygia guttata OvoDB1 was evaluated against a H1N1 Influenza A virus 
(A/WSN/33) using a eukaryotic MDCK cell monolayer (see 2.16).  Gallus gallus 
OvoDA1 and OvoDB1 were tested at 0.001, 0.01, 0.1, 1, 10 and 100 µM and 
recombinant Taeniopygia guttata OvoDB1 was used neat and diluted 1:2.  A known 
antiviral peptide (FluPep) (Nicol et al., 2012) was used as a positive control at 0.1, 1 
and 10 µg (see 2.16).  Results are expressed as a % reduction in viral plaques per 
well. 
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5.3.5. Macrophage infection assay 
The ability of Gallus gallus OvoDA1 at 1 and 10 µM to directly activate a 
macrophage-like cell line (HD11) was evaluated using Salmonella-gentamicin assay 
detailed in 2.17.  The assay measures the net total number of Salmonella 
phagocytised by the macrophages as well as the intracellular Salmonella replication 
of those phagocytised; extracellular Salmonella is eliminated from the final count 
using gentamicin.  Results are expressed as a % reduction in Salmonella colony 
forming units per well.  
5.3.6. Ex vivo gut model 
The method is adapted for poultry from work published on pigs (Apajalahti et al., 
2009).  The ex vivo model and analysis of environmental parameters including pH, 
gas production and short chain fatty acid (SCFA) profile was carried out by 
Alimetrics, Finland, I assisted with the DNA extraction/purification and RT-QPCR 
analysis of the microbial community.     
More information on this method can be found in chapter 2 (2.18).  Briefly, ileal or 
caecal contents from 30 4-week old chickens were pooled and the conditions of 
incubation were adjusted to mimic chicken ileal and caecal conditions as accurately 
as possible.  For the simulations, recombinant Gallus gallus OvoDA1 and 
Taeniopygia guttata OvoDB1 were tested at final concentrations of 50, 100 and 
200 µM, control supernatant was tested at a dose equivalent to 100 µM of 
recombinant peptide.  A negative control containing no additional supplement was 
included for comparison. 
After 10 hours, the volume of gas released from the vessels was recorded. After 
opening the simulation vessel, the pH of the fermentation medium was measured, 
this measurement was done immediately after the gas measurement to avoid pH 
shifts caused by the escape of CO2 from the medium. The medium was then sampled 
for the analysis of short chain fatty acids (SCFA) and bacterial density. The acids 
measured were acetic, propionic, butyric, iso-butyric, 2-methyl-butyric, valeric, and 
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lactic acid.  Total bacterial numbers and specific genus or species were enumerated 
using RT-qPCR. 
Treatments were compared to the negative control using ANOVA to identify 
significant differences and least significant difference was then used to test between 
means when significance of P<0.05 was observed in the ANOVA.  Bacterial counts 
were transformed (Log10) before analysis to normalise the data.  To demonstrate 
clearly if a significant difference was peptide specific or a result of background 
fungal components the data from LSD is also shown separately to compare the 
negative control, supernatant control and 100 µM treatments as these, at least 
theoretically contain the same amount weight/weight of background fungal 
components. 
5.4. Results 
5.4.1. Antimicrobial activity 
5.4.1.1. Synthetic peptide 
Gallus gallus OvoDA1 (gallin) peptide achieved a relatively large effect on E. coli 
DH5 with around a 98% reduction in CFU/ml at 100 µM (Figure 5.1A, Table 5.1), 
and is comparable to the results reported previously with E. coli BL21 (Gong et al., 
2010).  Gallus gallus OvoDA1 achieved around a 40% reduction in viability of avian 
pathogenic E. coli O78:H9 strain χ7122 when used at 50 or 100 µM (Figure 5.1A, 
Table 5.1) and a >90% reduction in viability against S. aureus 8325-4 a Gram-
positive organism, when used at 100 or 200 µM (Figure 5.1B, Table 5.1).   No 
reduction was observed against either of the Salmonella strains used in this study 
(Table 5.1).  A 35% reduction in viability of E. coli DH5 was achieved with 
100 µM Gallus gallus OvoDB1 (Figure 5.2), and a very small reduction was 
observed in APEC numbers (~3%) (Table 5.1).  No reduction was observed with 
Gallus gallus OvoDB1 against S. aureus or the Salmonella strains tested (Table 5.1).  
A duck representative of the ovodefensin family, Anas platyrhynchos OvoDA1 
(dBPS2) showed around an 80% reduction in viability of E. coli DH5 (Figure 5.3)  
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Figure 5.1: Gallus gallus OvoDA1 was incubated for 3 hours at 37°C with E.coli 
DH5, Avian Pathogenic E.coli χ7122 at 0.5-100 µM (A) or S.aureus 8325-4 at 
10-200 µM (B) in PBS and the number of surviving bacteria were counted (n=3, 
mean ± sem).  Results are represented as a reduction in CFU/ml when compared to 
a 10% DMSO control. 
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Figure 5.2: Gallus gallus OvoDB1 was incubated for 3 hours at 37°C with E.coli 
DH5 in PBS and the number of surviving bacteria were counted (n=3, mean ± 
sem).  Results are represented as a reduction in CFU/ml when compared to a 10% 
DMSO control. 
 
Figure 5.3: Anas platyrhynchos OvoDA1 was incubated for 3 hours at 37°C 
with E.coli DH5 in PBS and the number of surviving bacteria were counted 
(n=3, mean ± sem).  Results are represented as a reduction in CFU/ml when 
compared to a 10% DMSO control.  
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Table 5.1 – Summary of antimicrobial activity of synthetic Gallus gallus 
OvoDA1, Gallus gallus OvoDB1 and Anas platyrhynchos OvoDA1 and 
recombinant Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1.  Percent 
reduction in CFU/ml at 100 µM is shown for each peptide when activity is observed1.  
The ED50 value of synthetic peptides was calculated where a fall in viability greater 
than 50% was observed2. ‘X’ is used when an organism was not tested against that  
peptide.  Bacterial strains used were E. coli K-12 (DH5), avian pathogenic E. coli 
O78:H9 (χ7122), Salmonella enterica serovars Enteritidis (SE125109) and 
Typhimurium (ST4/74), Staphylococcus aureus (8325-4) and Campylobacter jejuni 
11168 wild type (WT) and 11168H mutant (mut).   
Synthetic 
         Gallus gallus  
            OvoDA1 
        Gallus gallus   
            OvoDB1 
    Anas platyrhynchos  






















DH5  99 3 35 - 87 53 
APEC 42 - 3 - - - 
S. aureus  99 16 - - - - 
S. enteritidis - - - - - - 
S. 
typhimurium 
- - - - - - 
C. jejuni 
(WT) 
10 - X X X X 
C. jejuni 
(mut) 
41 - X X X X 
Recombinant 
 Gallus gallus 
OvoDA1 
Taeniopygia guttata  

















DH5 83 - 98 -   
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Figure 5.4: Gallus gallus OvoDA1 was incubated for 3 hours at 37°C with 
Campylobacter jejuni 11168 (wild type) or Campylobacter jejuni 11168H 
(mutant) at 0.5-100 µM in PBS and the number of surviving bacteria were 
counted (n=1).  Results are represented as a reduction in CFU/ml when compared 
to a 10% DMSO control. Note: due to difficulty in culturing these strains the 
experiement was not repeated. 
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Figure 5.5: Gallus gallus OvoDB1 was incubated for 3 hours at 37°C with E.coli 
DH5 in PBS at a range of pH (A) and NaCl concentration (B)  and the number 
of surviving bacteria were counted (n=3, mean ± sem).  Results are represented 
as a reduction in CFU/ml when compared to a 10% DMSO control. 
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Figure 5.6: Gallus gallus OvoDA1 was incubated for 3 hours at 37°C with 
metabolically active Avian Pathogenic E. coli χ7122 or metabolically static 
Avian Pathogenic E. coli χ7122 at 10 µM and the number of surviving bacteria 
were counted (n=3, mean ± sem).  Results are represented as a reduction in 
CFU/ml when compared to a 10% DMSO control. 
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but no convincing activity was seen against any of the other bacterial strains tested 
(Table 5.1). 
Gallus gallus OvoDA1 achieved a slight reduction in wild type Campylobacter jejuni 
CFU/ml (9.8%) at 100 µM (Figure 5.4); however at the same concentration a 41% 
reduction was observed in the mutant strain which lacks known cationic peptide 
resistance genes (Figure 5.4). 
Gallus gallus OvoDA1 potency as measured by ED50 did not differ significantly due 
to pH (P=0.42), the ED50 of Gallus gallus OvoDA1 at pH 6.4, 7.4 and 8.4 was 
7.38 µM, 3.57 µM and 3.67 µM respectively (Figure 5.5A).  The potency of Gallus 
gallus OvoDA1 at ED50 level was also not affected by salt concentration (P=0.49), 
the ED50 of Gallus gallus OvoDA1 at 50, 100 and 150 mM NaCl was 3.55 µM, 
3.88 µM, and 3.27 µM respectively (Figure 5.5B). However at higher concentrations 
of Gallus gallus OvoDA1 antibacterial activity appeared to be diminished in a 
manner sensitive to the salt concentration (Figure 5.5B). 
The metabolic state of APEC did not affect the antibacterial activity of Gallus gallus 
OvoDA1 with a 10% reduction being observed in both the metabolically active and 
static bacteria (Figure 5.6).  The difference in metabolic states can be observed 
clearly by the antibacterial effect of ampicillin which resulted in nearly a 100% 
reduction in CFU/ml when the cells were metabolically active and 10% when the 
bacteria was in a static state (Figure 5.6). 
5.4.1.2. Recombinant peptide 
Neat recombinant Gallus gallus OvoDA1 achieved an 83% reduction in E. coli 
DH5, Taeniopygia guttata OvoDB1 also showed potent antimicrobial activity with 
a 98% reduction in CFU/ml (Table 5.1).  No antibacterial activity was detected for 
the supernatant control. 
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5.4.2. Anti-viral activity 
No anti-viral activity was observed for Gallus gallus OvoDA1, OvoDB1 or 
recombinant Taeniopygia guttata OvoDB1 against Influenza A/WSN/33 in the assay 
used.  On average Gallus gallus OvoDA1 resulted in a 6% increase in viral plaques 
when compared to the control.  Gallus gallus OvoDB1 gave a 5% increase and 
recombinant Taeniopygia guttata an 8% increase; however these results were not 
statistically significant due to variability in plaque number.   No toxicity was 
observed to the eukaryotic cell line used for either of the synthetic peptides or 
recombinant form.  FluPep (see 2.16) achieved around an 88% reduction at 100 µg. 
5.4.3. Macrophage infection assay 
Administration of Gallus gallus OvoDA1 to HD11 cells resulted in a 4% increase in 
extracellular Salmonella in the first assay.  As this result did not indicate an ability to 
activate macrophage activity the experiment was not repeated due to the large 
quantity of peptide required. 
5.4.4. Ex vivo gut microbiome modulation 
5.4.4.1. Ileum  
A significant effect was observed on the amount of gas in the ex vivo ileum 
(ANOVA, P<0.001) (Figure 5.7A).  However, although an increase was recorded 
when treated with Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1, 
supernatant alone also resulted in an increase in gas (Figure 5.7B).  Ileum pH was 
significantly reduced in all treatments including the supernatant control (ANOVA, 
P<0.001) (Figure 5.7C and 5.7D).  Acetic acid concentration (mM) significantly 
increased in all treatments including the supernatant control (ANOVA, P<0.001) 
(Figure 5.8A and 5.8B), however the relative amount of acetic acid (%) 100 µM 
Gallus gallus OvoDA1 resulted in a significant reduction whereas the supernatant 
resulted in a significant increase when compared with the negative control (Figure 
5.8C and 5.8D).  A significant effect on lactic acid (mM) was observed (ANOVA, 
P<0.001).  100 µM Gallus gallus OvoDA1 resulted in a significant increase in lactic 
acid compared with both the control and the supernatant (Figure 5.9A and 5.9B).  
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Figure 5.7:  Effect of treatment on gas production and pH in the ileum digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on gas 
production (ANOVA, P<0.001) (A, B) and pH (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C) show data for all treatments.  The significance where 
indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, D) are extracted from the data on the left 
and represent the data where 100µM of each peptide was used and where the supernatant concentration was equal.  This therefore represents a more appropriate 
comparison than comparing all data as at this concentration the supernatant provides a weight/weight control for background fungal components.  In this panel 
comparisons are represented by letters (a-c) where columns with different letters are significantly different to at least P<0.05.   
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Figure 5.8:  Effect of treatment on acetic acid in the ileum digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on acetic acid concentration 
(ANOVA, P<0.001) (A, B) and percentage (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C) show data for all treatments.  The significance where indicated 
is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, D) are extracted from the data on the left and 
represent the data where 100µM of each peptide was used and where the supernatant concentration was equal.  This therefore represents a more appropriate 
comparison than comparing all data as at this concentration the supernatant provides a weight/weight control for background fungal components.  In this panel 
comparisons are represented by letters (a-c) where columns with different letters are significantly different to at least P<0.05.   
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Figure 5.9:  Effect of treatment on lactic acid in the ileum digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on lactic acid concentration (ANOVA, P<0.001) 
(A, B) and percentage (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C, E) show data for all treatments.  The significance where indicated is in comparison with the control; 
P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, D, F) are extracted from the data on the left and represent the data where 100µM of each peptide was 
used and where the supernatant concentration was equal.  This therefore represents a more appropriate comparison than comparing all data as at this concentration the supernatant 
provides a weight/weight control for background fungal components.  In this panel comparisons are represented by letters (a-c) where columns with different letters are significantly different 
to at least P<0.05.  The ratio of lactic and acetic acid (ANOVA, P<0.001) illustrates the opposing changes in environment between peptide and supernatant treatment. 
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Figure 5.10:  Effect of treatment on propionic acid and butryric acid in the ileum digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on propionic acid 
concentration (ANOVA, P<0.001) (A, B) and percentage (ANOVA, P<0.001) (C, D).  No significant effect was observed for butyric acid concentration (ANOVA, P=0.564) (E) or percentage 
(ANOVA, P=0.502) (F).  Graphs A, C, E and F show data for all treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and 
P<0.0001 (****).  Graphs B and D are extracted from the data to their left and represent the data where 100µM of each peptide was used and where the supernatant concentration was equal.  
This therefore represents a more appropriate comparison than comparing all data as at this concentration the supernatant provides a weight/weight control for background fungal 
components.  In this panel comparisons are represented by letters (a,b) where columns with different letters are significantly different to at least P<0.05. 
Chapter 5                                                Antimicrobial function of the ovodefensin family 
~ 144 ~ 
 
 
Figure 5.11:  Effect of treatment on isovaleric and valeric acid in the ileum digesta (n=5, mean ± sem).  Analysis of variance showed no 
significant effect on isovaleric acid concentration (ANOVA, P=0.479) (A) or valeric acid concentration (ANOVA, P0.317) (B).  However the percentage of 
valeric acid in the ileum digesta was significantly altered (ANOVA, P=0.007) (C, D).  Graphs on A-C show data for all treatments.  The significance 
where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graph D is extracted from the data in C 
and represents the data where 100µM of each peptide was used and where the supernatant concentration was equal.  This therefore represents a more 
appropriate comparison than comparing all data as at this concentration the supernatant provides a weight/weight control for background fungal 
components.  In this panel comparisons are represented by letters (a) where columns with different letters are significantly different to at least P<0.05. 
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Figure 5.12:  Effect of treatment on total short chain fatty acid (SCFAs) and volatile fatty acids (VFAs) in the ileum digesta (n=5, mean ± sem).  
Analysis of variance showed a significant effect on total SCFA (ANOVA, P<0.001) (A, B) and VFA concentration (ANOVA, P<0.001) (C, D).  Graphs on 
the left hand side (A, C) show data for all treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), 
P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, D) are extracted from the data on the left and represent the data where 100µM of each 
peptide was used and where the supernatant concentration was equal.  This therefore represents a more appropriate comparison than comparing all 
data as at this concentration the supernatant provides a weight/weight control for background fungal components.  In this panel comparisons are 
represented by letters (a-c) where columns with different letters are significantly different to at least P<0.05. 
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Figure 5.13:  Effect of treatment on total bacterial numbers, E. coli, Lactobacillus species and Lactobacillus reuteri in the ileum digesta (n=5, mean ± sem).  Analysis of variance 
showed no significant effect on total bacteria (ANOVA, P=0.413) (A) or E. coli (ANOVA, P0.354) (B).  However the total number of Lactobacillus species in the ileum digesta was significantly 
altered (ANOVA, P<0.001) (C, D) with significant effects being observed in L. reuteri numbers in particular (ANOVA, P<0.001) (E, F).  Graphs A-C and E show data for all treatments.  The 
significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs D and F are extracted from the data to their left and 
represent the data where 100µM of each peptide was used and where the supernatant concentration was equal.  This therefore represents a more appropriate comparison than comparing all 
data as at this concentration the supernatant provides a weight/weight control for background fungal components.  In this panel comparisons are represented by letters (a-b) where columns 
with different letters are significantly different to at least P<0.05. 
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Taeniopygia guttata OvoDB1 at 100 µM was significant from the control however it 
was not significantly different to the supernatant control.  Treatment also had a 
significant effect on the percentage of lactic acid in the ex vivo ileum (ANOVA, 
P<0.001); lactic acid significantly increased when treated with 100 µM Gallus gallus 
OvoDA1 however the supernatant control resulted in a significant reduction in % 
lactic acid (Figure 5.9C and 5.9D).  These significant changes in acetic acid and 
lactic acid (ANOVA, P<0.001) are shown as a ratio in Figures 5.9E and 5.9F for 
clarity.  A significant effect was observed on propionic acid concentration (ANOVA, 
P<0.001) (Figure 5.10A) and percentage (ANOVA, P<0.001) (Figure 10C). However 
when individual doses were compared neither Gallus gallus OvoDA1 or Taeniopygia 
guttata OvoDB1 were significant from either the negative or supernatant controls 
when included in the feed at 100 µM (Figure 5.10B and 5.10D).  Butyric acid 
concentration and percentage also did not significantly differ due to treatment 
(ANOVA, P=0.564 and P=0.502 respectively) (Figure 5.10E and 5.10F).  Isovaleric 
acid concentration did not significantly differ due to treatment (ANOVA, P=0.479) 
(Figure 5.11A) nor did valeric acid (ANOVA, P=0.317) (Figure 5.11B).  When 
valeric acid was analysed as a percentage of the total SCFAs a significant difference 
was observed (ANOVA, P=0.007).  Further analysis revealed that this significance 
was only the highest (200 µM) concentrations of Gallus gallus OvoDA1 (P<0.01) 
and Taeniopygia guttata OvoDB1 (P<0.01).  Treatment had a significant effect on 
total short chain fatty acids (SCFA) (ANOVA, P<0.001) (Figure 5.12A). Although 
both peptide treatment and supernatant resulted in an increase in SCFAs, treatment 
with 100 µM Gallus gallus OvoDA1 resulted in significantly more SCFAs than the 
supernatant alone (Figure 5.12B).  Total volatile fatty acids also significantly 
increased (ANOVA, P<0.001) (Figure 5.12C) however both the peptide treatments 
and supernatant behaved similarly (Figure 5.12D).  Isobutyric and 2-methyl-butyric 
acid were not measured in the ileum as they are not major components in this region. 
The total number of bacteria in the ileum did not significantly differ for any of the 
treatments (ANOVA, P=0.413) (Figure 5.13A) nor did total Escherichia coli 
numbers in any of the treatments (ANOVA, P=0.354) (Figure 5.13B).  Total 
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Lactobacillus species significantly increased (ANOVA, P<0.001) (Figure 5.13C), 
and when 100 µM treatments were analysed separately to account for background 
fungal components they significantly increased compared to both the supernatant and 
the negative control (Figure 5.13D).  The supernatant did not significantly differ 
from the negative control suggesting the increase in Lactobacillus was due to the 
peptide (Figure 5.13D).  The level of significance observed in the ANOVA of this 
data is due to a highly significant increase in Lactobacillus species when 200 µM 
Gallus gallus OvoDA1 was used (P<0.0001).  In particular Lactobacillus reuteri 
showed a significant increase when recombinant peptide was administered 
(ANOVA, P<0.001) (Figure 5.13C), this was significant when compared with the 
supernatant (Figure 5.13D). 
5.4.4.2. Caeca 
All treatments including the supernatant control resulted in an increase in the amount 
of caecal gas (ANOVA, P<0.001) (Figure 5.14A and 5.14B) and overall there was a 
reduction in caecal pH (ANOVA, P<0.001) (Figure 5.14C), however the greatest pH 
reduction was observed with the control supernatant (Figure 5.14D).  There was an 
overall increase in acetic acid concentration (ANOVA, P<0.001) (Figure 5.15A) and 
percentage (ANOVA, P<0.001) (Figure 5.15C) in the caeca.  However this 
observation was observed for both the peptide and supernatant treatments (Figure 
5.15B and 5.15D).  Both propionic acid (ANOVA, P<0.001) (Figures 5.16A-D) and 
butyric acid (ANOVA, P<0.001) (Figures 5.17A-D) concentration in the caeca 
increased under all test conditions; however this was not peptide specific.  Isobutyric 
acid (Figures 5.18A) and 2-methyl-butyric acid (Figures 5.18C) showed a significant 
decrease in the caecal model (ANOVA, P<0.001; P=<0.001), independent of whether 
peptide or supernatant was added (Figure 5.18B and 5.18D).  There was a significant 
effect on valeric acid concentration (ANOVA, P<0.001) and percentage (ANOVA, 
P=0.002) (Figures 5.19A and 5.19C) however this did not differ upon dosing with 
peptide or supernatant control (Figures 5.19B and 5.19D).  Isovaleric acid decreased 
overall (ANOVA, P<0.001) but this was not peptide specific (Figure 5.19E and 
5.19F).  Total short chain fatty acids increased overall (ANOVA, P<0.01) (Figures  
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Figure 5.14:  Effect of treatment on gas production and pH in the caecal digesta (n=5, mean ± sem).  Analysis of variance showed a significant 
effect on gas production (ANOVA, P<0.001) (A, B) and pH (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C) show data for all treatments.  
The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, 
D) are extracted from the data on the left and represent the data where 100µM of each peptide was used and where the supernatant concentration was 
equal.  This therefore represents a more appropriate comparison than comparing all data as at this concentration the supernatant provides a 
weight/weight control for background fungal components.  In this panel comparisons are represented by letters (a-d) where columns with different 
letters are significantly different to at least P<0.05. 
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Figure 5.15:  Effect of treatment on acetic acid in the caecal digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on acetic 
acid concentration (ANOVA, P<0.001) (A, B) and percentage (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C) show data for all 
treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on 
the right (B, D) are extracted from the data on the left and represent the data where 100µM of each peptide was used and where the supernatant 
concentration was equal.  This therefore represents a more appropriate comparison than comparing all data as at this concentration the supernatant 
provides a weight/weight control for background fungal components.  In this panel comparisons are represented by letters (a-c) where columns with 
different letters are significantly different to at least P<0.05. 
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Figure 5.16:  Effect of treatment on propionic acid in the caecal digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on 
propionic acid concentration (ANOVA, P<0.001) (A, B) and percentage (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C) show data for all 
treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on 
the right (B, D) are extracted from the data on the left and represent the data where 100µM of each peptide was used and where the supernatant 
concentration was equal.  This therefore represents a more appropriate comparison than comparing all data as at this concentration the supernatant 
provides a weight/weight control for background fungal components.  In this panel comparisons are represented by letters (a-c) where columns with 
different letters are significantly different to at least P<0.05. 
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 Figure 5.17:  Effect of treatment on butyric acid in the caecal digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on 
butyric acid concentration (ANOVA, P<0.001) (A, B) and percentage (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C) show data for all 
treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on 
the right (B, D) are extracted from the data on the left and represent the data where 100µM of each peptide was used and where the supernatant 
concentration was equal.  This therefore represents a more appropriate comparison than comparing all data as at this concentration the supernatant 
provides a weight/weight control for background fungal components.  In this panel comparisons are represented by letters (a-c) where columns with 
different letters are significantly different to at least P<0.05. 
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Figure 5.18:  Effect of treatment on isobutyric and 2Me-butyric acid in the caecal digesta (n=5, mean ± sem).  Analysis of variance showed a 
significant effect on isobutyric acid (ANOVA, P<0.001) (A, B) and 2Me-butyric acid concentration (ANOVA, P<0.001) (C, D).  Graphs on the left hand 
side (A, C) show data for all treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and 
P<0.0001 (****).  Graphs on the right (B, D) are extracted from the data on the left and represent the data where 100µM of each peptide was used and 
where the supernatant concentration was equal.  This therefore represents a more appropriate comparison than comparing all data as at this 
concentration the supernatant provides a weight/weight control for background fungal components.  In this panel comparisons are represented by 
letters (a-d) where columns with different letters are significantly different to at least P<0.05. 
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Figure 5.19:  Effect of treatment on valeric and isovaleric acid in the caecal digesta (n=5, mean ± sem).  Analysis of variance showed a significant effect on both valeric acid 
concentration (ANOVA, P<0.001) (A, B) and percentage (P=0.002) and isovaleric acid concentration (ANOVA, P<0.001) (C, D).  Graphs on the left hand side (A, C, E) show data for all 
treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, D, F) are extracted from 
the data on the left and represent the data where 100µM of each peptide was used and where the supernatant concentration was equal.  This therefore represents a more appropriate 
comparison than comparing all data as at this concentration the supernatant provides a weight/weight control for background fungal components.  In this panel comparisons are represented 
by letters (a-d) where columns with different letters are significantly different to at least P<0.05. 
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Figure 5.20:  Effect of treatment on total short chain fatty acid (SCFAs) and volatile fatty acids (VFAs) in the caecal digesta (n=5, mean ± 
sem).  Analysis of variance showed a significant effect on total SCFA (ANOVA, P<0.001) (A, B) and VFA concentration (ANOVA, P<0.001) (C, D).  
Graphs on the left hand side (A, C) show data for all treatments.  The significance where indicated is in comparison with the control; P<0.05 (*), P<0.01 
(**), P<0.001 (***) and P<0.0001 (****).  Graphs on the right (B, D) are extracted from the data on the left and represent the data where 100µM of each 
peptide was used and where the supernatant concentration was equal.  This therefore represents a more appropriate comparison than comparing all 
data as at this concentration the supernatant provides a weight/weight control for background fungal components.  In this panel comparisons are 
represented by letters (a-c) where columns with different letters are significantly different to at least P<0.05.  
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Figure 5.21:  Effect of treatment on the total number of bacteria, total Bacteroides, Bifidobacterium and Lactobacillus species in 
the caecum digesta (n=5, mean ± sem).  No significant effect was observed on total number of bacteria (ANOVA, P=0.801) (A), 
Bacteroides (ANOVA, P=0.979) (B), Bifidobacterium (ANOVA, P=0.239) or Lactobacillus species (ANOVA, P=0.609). 
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Figure 5.22: Effect of treatment on Megamonas hypermegale, Clostridial cluster IV and Clostridial cluster XIVa in the caecal 
digesta (n=5, mean ± sem). No significant changes were observed in Megamonas hypermegale (ANOVA, P=0.598) (A), Clostridial cluster 
IV (ANOVA, P0.570) (B) or Clostridial cluster XIVa (ANOVA, P=0.370) (C) in the caecal digesta. 
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5.20A) but peptide treatment did not differ from the supernatant control (Figure 
5.20B).  Volatile fatty acids were also significantly increased (ANOVA, P<0.001) 
(Figure 5.20C), however again this was not peptide specific when compared with the 
supernatant control (Figure 5.20D).  Lactic acid concentrations were measured but 
not shown as levels were extremely low as expected with caecal contents (Rinttila 
and Apajalahti, 2013). 
No significant changes in total bacteria numbers (ANOVA, P=0.801) (Figure 5.21A) 
or any specific species was measured in the caecal contents.  Total Bacteroides 
(ANOVA, P=0.979) (Figure 5.21B), Bifidobacterium (ANOVA, P=0.239) (Figure 
5.21C) and Lactobacillus (ANOVA, P=0.609) (Figure 5.21D) species, Megamonas 
hypermegale (ANOVA, P=0.598) (Figure 5.22A) and Clostridial clusters IV and 
XIVa (ANOVA, P=0.570 and P=0.370 respectively) (Figures 5.22B and 5.22C) 
measured using RT-qPCR were not significant. 
5.5. Discussion 
In support of an egg defence role, Gallus gallus OvoDA1 was previously shown to 
have antimicrobial activity against E. coli (Gong et al., 2010), an observation that 
was confirmed by Hervé et al (2014).  The data outlined in this study also 
demonstrated antimicrobial activity of Gallus gallus OvoDA1 against laboratory-
adapted and pathogenic E. coli (Figure 5.1A), and in agreement with the former 
publication (Herve et al., 2014), no activity was found against Salmonella serovars 
Enteritidis and Typhimurium (Table 5.1).  However this study did demonstrate 
antimicrobial activity of Gallus gallus OvoDA1 against S. aureus (Figure 5.1B).  
Although it had been previously documented that Gallus gallus OvoDA1 did not 
possess antimicrobial activity against S. aureus (Herve et al., 2014) both the method 
used to measure antimicrobial activity and the strain differ. This is the first time 
activity has been recorded for a Gram-positive organism with an ovodefensin, and 
indeed for an organism other than E. coli demonstrating the need for more in depth 
analysis of the spectrum of activity of the ovodefensins.   
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For the first time this study examined the antimicrobial activity of two other avian 
members of the ovodefensin family, Gallus gallus OvoDB1 and Anas platyrhynchos 
OvoDA1.  Gallus gallus OvoDB1 represents a member of the sub-family B cysteine 
motif (C-X3-C-X3-C-X11-C-X4-CC) whereas Anas platyrhynchos OvoDA1 
contains the same sub-family A cysteine motif as Gallus gallus OvoDA1 (C-X5-C-
X3-C-X11-C-X3-CC).  Although Gallus gallus OvoDB1 possessed antimicrobial 
activity against E.coli DH5 (35% reduction in CFU/ml) (Figure 5.2) it was not as 
potent as OvoDA1 from the same species at the same concentration (100 µM) and no 
activity was recorded against APEC, S. aureus or either of the Salmonella strains 
tested in this study (Table 5.1).  Anas platyrhynchos OvoDA1 demonstrated good 
activity against E.coli DH5 (>80% reduction) (Figure 5.3) yet no activity was 
recorded against any of the other strains used in this study (Table 5.1).  The 
antimicrobial results from this study suggest that the family is as diverse in its 
activity as it is in sequence which questions whether the sequence or perhaps spacing 
within the cysteine motifs of these molecules affects their ability to kill 
microorganisms, perhaps evolving to counter the specific challenges each organism 
faces.   However both Gallus gallus and Anas platyrhynchos OvoDA1 are from the 
same sub-family suggesting that spacing alone does not define direct antimicrobial 
activity.  Another possibility for differing levels of activity is charge which varies 
from +4 to +10 within the currently identified ovodefensin members. However when 
considering that Gallus gallus OvoDA1 has a charge of +7, Gallus gallus OvoDB1 a 
charge of +10 and Anas platyrhynchos OvoDA1 +6 charge alone does not seem to 
explain the differences in activity noted. 
For use as a feed additive to be plausible the peptides need to be produced in large 
quantities economically.  The company involved in this project (AB Vista) 
(https://www.abvista.com/) have a large amount of expertise in the recombinant feed 
additive field and their technology allowed both of these issues to be addressed 
through a fungal fermentation system.  However the recombinant product produced 
needs to be active.  Gallus gallus OvoDA1 was the most active in the in vitro tests 
conducted and was therefore used for production in this system.  Taeniopygia guttata 
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OvoDB1 was identified as the avian ovodefensin differing most from Gallus gallus 
OvoDA1 in terms of sequence, peptide length and spacing in Chapter 3 and it was 
therefore decided that it would also be produced in the fungal system.  Both neat 
recombinant Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1 showed 
potent activity against E.coli DH5 in the antibacterial assay.  Gallus gallus 
OvoDA1 achieved an 83% reduction in CFU/ml and Taeniopygia guttata OvoDB1 
reduced E.coli DH5 by 98%.  These results show that recombinant ovodefensin 
peptides have antibacterial activity and could potentially be used as a feed additive. 
As Gallus gallus OvoDA1 was the most potent ovodefensin in these experiments it 
was tested against a pathogen of significant interest to the poultry industry, 
Campylobacter jejuni.  Campylobacter is the leading cause of food poisoning in the 
UK with Campylobacter poisoning results in approximately 100 deaths each year 
and costs the UK economy about £900 million (WHO, 2011).  Gallus gallus 
OvoDA1 only resulted in a 10% reduction in the wild type strain of this organism.  
However this particular strain is known to possess genes which are thought to confer 
resistance to positively charged antimicrobial peptides (unpublished) and when 
Gallus gallus OvoDA1 was tested against a mutant strain with these genes removed 
an impressive 41% reduction was observed.  This is an important observation as only 
approximately 50% of Campylobacter strains possess these particular genes (Mark 
Stevens, March 2014, personal communication) and therefore this ovodefensin 
peptide may be effective against other Campylobacter strains too.  However further 
testing against a larger panel of Campylobacter strains would need to be undertaken 
to determine the true effectiveness of this peptide as it is possible that other genes in 
different strains may also convey resistance to direct antibacterial activity of charged 
peptides. 
If administered as a feed additive then the recombinant peptide would need to work 
under a variety of environmental conditions. Gallus gallus OvoDA1 was therefore 
assessed in further detail.  The pH of the target region of the intestine, the small 
intestine is around pH 6.4 (Mabelebele et al., 2014) so pH was chosen as a factor for 
study.  Altering pH did not significantly affect the ED50 of Gallus gallus OvoDA1 
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(Figure 5.5A) however it is clear from the graph that overall potency of the peptide 
did diminish at pH 6.4.  Although there was a small reduction in potency it is 
promising that the activity of the peptide was not drastically reduced suggesting that 
the peptide is not inactivated at lower pH.   
Salt sensitivity of classical mammalian defensins such as mouse β-defensin 1 (Bals et 
al., 1998) has been well documented and it is suggested that this is a feature common 
to all defensin molecules (Ganz, 2003), it was therefore important to test the effect of 
salt on ovodefensin activity.  Again Gallus gallus OvoDA1 was chosen for this work.  
Salt concentrations were chosen to approximately reflect the natural environment of 
the peptide, the egg (50 mM) (Bell and Freeman, 1984), the standard assay 
conditions (100 mM) and physiological salt concentrations of the chicken milieu 
(150 mM) (Bell and Freeman, 1984).  Salt concentration did not significantly affect 
the ED50 value however it is clear that salt concentration did significantly affect the 
maximal potency of the peptide (Figure 5.5B) resulting in reduction in overall kill of 
32% at the highest concentration tested and a maximum reduction in killing of 58% 
at 16.7 µM. 
The metabolic state of APEC did not affect antibacterial activity of Gallus gallus 
OvoDA1 suggesting that the mode of action of this peptide does not require the cell 
to be replicating.  This is consistant with the proposed model of defensin activity 
which involves electrostatic interaction with the cell membrane.  The diminished 
activity of ampicillin in this assay demonstrates the fact that the bacterial cells were 
in metabolically static state and unable to replicate as this is a vital process for 
ampicillin activity because it interferes with cell wall synthesis (Kong et al., 2010).  
The effect of metabolic state would likely have been clearer had E.coli DH5 been 
used as the peptide is more potent against this strain.  However the results suggest 
that metabolic state is not important for activity which widens the potential use of 
this peptide if it was to be considered for purposes other than a feed additive. 
Some defensins show antiviral activity and it was therefore of interest to see if the 
ovodefensins possessed this property.  A/WSN/33 is a human H1N1 strain isolated 
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post mortem from a casualty of the 1918 Spanish influenza pandemic (Taubenberger, 
2006).  This particular strain does not have the ability to infect birds however it can 
be used as a model organism as some H1N1 do possess this ability and it was 
necessary to choose a strain that was able to infect the MDCK cells commonly used 
in this assay.  None of the peptides tested were able to reduce the number of viral 
plaques formed in this assay.  This does not rule out the ability of ovodefensins to 
kill viruses as antiviral peptides have differing spectrums of activity and it may be 
that ovodefensins are effective against other viruses.  Importantly it was also noted 
that, at least under visual inspection, no toxicity was observed to the eukaryotic 
MDCK cells used in the assay with cell monolayers remaining intact in the presence 
of peptide when no virus was added.  As viruses are not the primary target for a feed 
additive it was decided that antiviral work would be taken no further. 
As some defensins are documented to have immunomodulatory activities (see 
Chapter 1, Figure 1.4) a small macrophage infection assay was carried out to 
examine this function.  Gallus gallus OvoDA1 did not improve the ability of HD11 
macrophage-like cells to phagocytise Salmonella.  However this was a pilot assay 
and the mechanisms of immunomodulatory activity are complex and likely to require 
other effector molecules which will be discussed in more detail in Chapter 7.  This 
assay can therefore only tell us that the peptide is unable to directly activate HD11 
cells under these conditions. It cannot rule out immunomodulatory activities; 
however a vast amount of work would be required to evaluate these modes of action 
in more detail that could not be achieved in the timescale of this thesis. 
The ex vivo gut model produced some very promising results, particularly in the 
ileum, and it would appear that ovodefensins, in particular Gallus gallus OvoDA1 
are able to modulate the gut microbiome and environment in a dose dependent 
manner.  Although no major significant changes when compared to the supernatant 
were observed in the caeca the changes in the ileum were indicative of a positive 
shift in the microbiome and correlate well with Alimetrics’ in-house performance 
indexes.  In particular the increase in Lactobacillus species (Figure 5.13D) is 
promising.  It is generally accepted that this genus is associated with good gut health, 
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and L. reuteri (Figure 5.13F) is currently used as a probiotic to this end (Spinler et 
al., 2008).  It was particularly promising that this effect was specific to the treatments 
containing peptide and is therefore unlikely to be due to any residual background 
fungal components.  The increase in lactic acid in this region (Figure 5.9A) also 
supports this change in the microbial community.  Other indicators of good gut 
health such as a reduction in pH and an increase in butyric acid (Rinttila and 
Apajalahti, 2013) were also recorded in the study; however, as the control 
supernatant had the same effect we are unable to attribute this change to the peptide.  
This matters if trying to determine the exact effect of the ovodefensin peptide in gut 
modulation however the aim of this PhD thesis was to identify a product which could 
be used as a feed additive to modulate gut health.  To this end the ‘ovodefensin 
product’ showed a number of promising changes to the parameters measured and the 
lack of obvious toxicity observed in the viral and macrophage infection assay suggest 
that the product would be safe.  Therefore Gallus gallus OvoDA1 and Taeniopygia 
guttata OvoDB1 were used for large scale production and in vivo analysis; the results 
of this trial are documented in Chapter 6. 
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6.1. Introduction 
The efficacy and cost effectiveness of traditional antibiotics made them a popular 
choice for controlling enteric disease and promoting growth in livestock (Bedford, 
2000).  As discussed in Chapter 1 many concepts, including the use of antimicrobial 
peptides (AMPs), have been suggested as potential substitutes for the recently 
outlawed antibiotic compounds.  However, discovery of novel candidates and cost of 
production has proved problematic (Hancock and Sahl, 2006).  The identification of 
a large number of AMPs and the use of the recombinant production system outlined 
in this thesis has begun to address these issues and the ex vivo gut model outlined in 
chapter 5 revealed the potential for the use of AMPs as intestinal modulators.  It is 
also clearly desirable that new strategies for disease control in animals have no ties to 
human treatment so that if resistance did develop, although unlikely, there would not 
be an effect on human medicine.  Despite promising results in vitro there has been 
few trials exploring the use of AMPs in vivo (Kogut et al., 2010, Kogut et al., 2013) 
and as such there is clearly a requirement to test their efficacy in poultry. 
In order to assess if the inclusion of AMPs in feed are having a beneficial effect on 
the growth and health of poultry several parameters were assessed.  The major 
indicator of a successful trial is the increase in growth performance as this was a key 
outcome of the previously used antibiotic growth promoters and directly affects the 
profitability of the industry (Bedford, 2000, Miles et al., 2006).  To assess this body 
weight was recorded, and as birds were fed ab libitum feed intake was also recorded 
to calculate the food conversion ratio (FCR) and prevent false positives if there was 
an increase in feed intake. 
If an effect was observed, understanding the mechanisms behind it would be 
extremely complex as many factors influence growth including gut integrity, 
intestinal microbiota and the health/immune status of the bird (Whittow, 1999).  
Examining all these factors in detail was not possible due to constraints on time and 
resources however it was hypothesised that the microbiota of the bird may be 
affected both directly and indirectly by ovodefensins due to their known antibacterial 
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activity and proposed immunomodulatory capabilities.  If this was the case then 
examining the microbial composition of the gastrointestinal tract (GIT) and 
environmental factors including pH, gas production and bacterial metabolites are a 
good indicator of such effects (Apajalahti, 2005).  Additionally there is evidence to 
suggest that the bacterial composition of the GIT and in particular the resulting 
fermentation products directly affect the performance of the bird either by affecting 
the immune response e.g. increasing endogenous defensin expression (Sunkara et al., 
2011) or by altering the efficiency of nutrient absorption (Rinttila and Apajalahti, 
2013).   
It is important to note, however, that the approach taken aimed first and foremost to 
determine if the in-feed inclusion of ovodefensins improve bird growth as 
determined by body weight.  The experiment also aimed elucidate some of the 
mechanisms behind a change in growth performance; however the trial would still be 
deemed successful if an increase in body weight was observed in the absence of a 
change in the GIT microbiota or environment. 
6.2. Objectives 
To test the hypothesis that the inclusion of ovodefensin peptide in poultry feed can 
improve growth performance of broilers through the modulation of the gut 
microbiome and environmental profile e.g short chain fatty acid profile. 
6.3. Methods 
Gallus gallus OvoDA1 and Taeniopygia guttata OvoDB1 were included in the feed 
at 0.0047, 0.047 and 0.47 g/kg and 0.0045, 0.045 and 0.45 g/kg respectively.  Peptide 
was produced using a recombinant fungal system as outline in 2.14.  The negative 
control for this experiment was the absence of peptide from the feed. 
Trial design was carried out jointly by Alimetrics and AB Vista and myself; I carried 
out the feed formulation under the supervision of AB Vista.  This experimental feed 
trial was carried out at Alimetrics, Finland; sample collection was carried out 
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according to my instructions and I assisted with DNA purification and bacterial 
analysis.  I carried out all the analysis shown in this thesis. 
A brief outline of the feed trial methodology is outlined below, full details can be 
found in Chapter 2 (2.19). 
6.3.1. Animals and housing 
Newly-hatched male Ross 508 broiler chicks (HKScan, Finland) were randomly 
allocated into the feeding treatments with 17 chicks per pen, 8 replicate pens and 
1088 birds in total.   Feed and water were available ad libitum at all times during the 
trial.     
All welfare standards complied with The Finnish Act on Animal Experimentation. 
6.3.2. Feed formulation 
The diet was a wheat-soya based commercial-type mash feed for broiler chicks. A 
starter formula was used during the 3-week trial.  The main feed ingredients were 
analysed for basic nutrients and amino acid profiles for the final formulation which 
can be found in Chapter 2, Table 2.3. 
The test substances were carefully mixed by hand into 5 kg premixes with wheat.  
Each premix batch replaced 5 kg of wheat from the final formula.  
6.3.3. Sample collection 
The chicks were weighed on days 1, 11 and 21. Correspondingly, feed intake per pen 
and the feed conversion ratio (FCR) were measured for the following periods: days 
1-11, days 11-21 and days 1-21.  The birds were monitored on a daily basis and any 
dead birds or birds euthanized because of health problems were weighed. Daily 
mortality was recorded and FCR was calculated both corrected and uncorrected for 
mortality. 
On day 11, two birds per pen were weighed and euthanized by cervical dislocation. 
The abdominal cavity was opened, and the entire ileum and the paired caeca 
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removed, packed in individual plastic bags, frozen immediately and stored at -20°C 
until analysis.  On the day 21, a similar set of samples were collected, and all the 
remaining birds were weighed and euthanized. 
Treatments were compared for significance using ANOVA, where significance was 
observed the Least Significant Difference test was used to determine significance 
between treatments. 
6.3.4. Metabolite and intestinal environment analysis 
The SCFAs were analysed as free acids by gas chromatography, using pivalic acid as 
an internal standard, as described elsewhere in detail (Holben et al., 2002).  Total 
SCFAs, acetic, propionic, butyric, iso-butyric, 2Me-butyric, valeric, isovaleric and 
lactic acid were measured from the highest dose of each peptide and treatments were 
compared using a Kruskal-Wallis test as the data could not be normalised using 
typical transformations.  Where significance was observed a Mann-Whitney ranked 
test was used to compare peptide treatments with the control. 
6.3.5. Microbiome analysis 
Bacterial numbers were measured using quantitative real time PCR.  In this study, all 
results are expressed as the number of ribosomal RNA (rRNA) gene copies per 1 g of 
digesta.  Measurements were made for the highest dose of each peptide treatment and 
the negative control and significance was tested using Kruskal-Wallis as the data 
could not be normalised using typical transformations.  Where significance was 
observed a Mann-Whitney ranked test was used to compare peptide treatments with 
the control. 
6.4. Results 
6.4.1. Growth performance 
A significant effect was observed on mean body weight gain (ANOVA, P=0.044). 
Gallus gallus OvoDA1 resulted in a significant dose dependant increase in mean 
body weight gain; it achieved a maximum 55.3 g increase when compared to the  
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Figure 6.1:  Effect of treatment on mean body weight gain from hatch to day 21 
(n=136, mean ± sem).  Analysis of variance showed a significant effect on mean 
body weight gain (ANOVA, P=0.044).  The significance where indicated is in 
comparison to with the control; P<0.05 (*). 
 
Figure 6.2:  Effect of treatment on food consumption from hatch to day 21 
(n=136, mean ± sem).  Analysis of variance showed there was no significant effect 
on food consumption (ANOVA, P= 0.540). 
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Figure 6.3:  Effect of treatment on food conversion ratio (FCR) from hatch to 
day 21 (A) and day 2-11 (B) (n=136, mean ± sem).  Analysis of variance showed 
no significant effect on FCR over the course of the whole experiment, days 0-21 
(ANOVA, P=0.071).  However a significant effect on FCR was observed from day 2-
11 (ANOVA, P=0.029)  The significance where indicated is in comparison to the 
control; P<0.05 (*).  
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control over the total 21 day duration of the experiment (P<0.05) (Figure 6.1).  
Inclusion of Taeniopygia guttata OvoDB1 at the lowest (0.0045 g/kg) and highest 
dose (0.45 g/kg) in the feed also resulted in a significant increase in body weight 
when compared with the control resulting in a maximal increase of 62.1 g at 21 days 
(P<0.05).  However no increase in body weight was observed at the middle dose 
(0.045 g/kg).  The increase in body weight was not due to an increase in feed 
consumption as this did not significantly differ throughout the experiment (ANOVA, 
P=0.540) (Figure 6.2). 
Feed conversion ratio (FCR) did not significantly differ during the course of the 
experiment, days 0-21 (ANOVA, P=0.071) (Figure 6.3A) but it approached 
significance, however a significant decrease in FCR was observed during the earlier 
growth phase of the experiment, days 2-11(ANOVA, P= 0.029) (Figure 6.3B). 
6.4.2. Environmental analysis 
6.4.2.1. Ileum 
No significant difference in total SCFAs was observed at day 11 in the ileum 
(P=0.46) (Figure 6.4A).  There was also no significant difference in acetic acid 
concentration (P=0.869) (Figure 6.4B) or lactic acid (P=0.452) (Figure 6.4C).  All 
other parameters measured were too low to be reliably tested for significance at 
either day 11 or day 21. 
There was also no significant effect on total SCFAs (P=0.946) (Figure 6.5A), acetic 
acid (P=0.966) (Figure 6.5B) or lactic acid (P=0.877) (Figure 6.5C) at day 21.     
6.4.2.2. Caeca 
At day 11 there was no significant effect of total SCFAs, however the effect did 
verge on significance (P=0.056) (Figure 6.6A).  There was also no significant effect 
on lactic acid concentration (P=0.806) (Figure 6.6B), butyric acid (P=0.234) (Figure 
6.6C), or propionic acid concentration (P=0.081) (Figure 6.7A).  However a 
significant effect was observed on the concentration of acetic acid in the caeca at day  
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Figure 6.4:  Effect of treatment on total short chain fatty acids, acetic acid and lactic acid in broiler ileum digesta at day 11 (n=16, 
mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total short chain fatty acids (P=0.46) (A), acetic acid 
(P=0.869) (B) or lactic acid (P=0.452) (C).   
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Figure 6.5:  Effect of treatment on total short chain fatty acids, acetic acid and lactic acid in broiler ileum digesta at day 21 (n=16, 
mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total short chain fatty acids (P=0.946) (A), acetic acid 
(P=0.966) (B) or lactic acid (P=0.877) (C).  
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Figure 6.6:  Effect of treatment on total short chain fatty acids, acetic acid and lactic acid in broiler caecal digesta at day 11 
(n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total short chain fatty acids (P=0.056) (A), lactic 
acid (P=0.806) (B) or butyric acid (P=0.234) (C).
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Figure 6.7:  Effect of treatment on total short chain fatty acids, acetic acid and 
lactic acid in broiler caecal digesta at day 11 (n=16, mean ± sem).  Analysis by a 
Kruskal-Wallis test showed no significant effect on propionic acid (P=0.081) (A), 
however a significant effect was observed for acetic acid (P=0.036).  The 
significance where indicated is in comparison to with the control; P<0.05 (*). 
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Figure 6.8:  Effect of treatment on total short chain fatty acids, acetic acid and propionic acid in broiler caecal digesta at day 21 
(n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total short chain fatty acids (P=0.421) (A), acetic 
acid (P=0.193) (B) or propionic acid (P=0.312) (C).  
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Figure 6.9:  Effect of treatment on butyric acid and lactic acid in broiler caecal 
digesta at day 21 (n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed 
no significant effect on butyric acid (P=0.076) (A), however a significant effect was 
observed for lactic acid (P=0.006).  The significance where indicated is in 
comparison to with the control; P<0.01 (**). 
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11 (P=0.036) (Figure 6.7B).  A Mann-Whitney test showed that there was a 
significant increase in acetic acid when Gallus gallus OvoDA1 was included in the 
feed (P=0.042), however no significant effect was observed with Taeniopygia guttata 
OvoDB1 compared with the control (P=0.983).  As with day 11 SCFAs there was no 
significant effect on total SCFAs at day 21 in the caeca (P=0.421) (Figure 6.8A).  
There was also no significant effect observed on acetic acid concentration (P=0.193) 
(Figure 6.8B) or propionic acid concentration (P=0.312) (Figure 6.8C).  Changes in 
the level of butyric acid in the caeca at day 21 approached significance (P=0.076) 
(Figure 6.9A).  When treatments were individually compared with the control there 
was no significant effect of Gallus gallus OvoDA1 (P=0.751) but again there was a 
trend for a reduction in butyric acid after Taeniopygia guttata OvoDB1 treatment 
(P=0.076).  There was a highly significant effect on lactic acid concentration at day 
21 in the caeca (P=0.006) (Figure 6.9B).  When treatments were analysed 
individually there was no significant effect of Taeniopygia guttata OvoDB1 
treatment (P=0.471) but there was a significant reduction in lactic acid concentration 
when Gallus gallus OvoDA1 was included in the diet (P=0.012). 
6.4.3. Microbiome analysis 
6.4.3.1. Ileum 
Microbiome analysis of day 11 ileum digesta showed no significance in the total 
number of bacteria P=0.49) (Figure 6.10A) between treatments.  Specifically there 
was no significant change in the number of total Lactobacillus (P=0.43) (Figure 
6.10B) or Enterococcus species (P=0.847) (Figure 6.10C).  There was also no 
significant change in Lactobacillus reuteri (P=0.778) (Figure 6.11A), Clostridium 
perfringens (P=0.715) (Figure 6.11B), Escherichia coli (P=0.759) (Figure 6.11C) or 
Streptococci (P=0.097) (Figure 6.11D).  Eimeria levels in the ileum were measured 
but were undetectable in almost all samples. 
Day 21 ileal digesta results indicated no significant changes in total numbers of 
bacteria (P=0.544) (Figure 6.12A).  There were also no significant differences in 
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Figure 6.10:  Effect of treatment on total bacteria, Lactobacillus and Enterococcus in broiler ileum digesta at day 11 (n=16, mean 
± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total bacteria (P0.49) (A), Lactobacillus species (P=0.43) (B) or 
Enterococcus numbers (P=0.847) (C). 
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Figure 6.11:  Effect of treatment on Lactobacillus reuteri, Clostridium perfringens, E. coli and Streptococcus in broiler ileum 
digesta at day 11 (n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on Lactobacillus reuteri (P0.778) 
(A), C. perfringens (P=0.715) (B), E. coli (P=0.759) (C) or Streptococcus numbers (P=0.097) (D). 
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Figure 6.12:  Effect of treatment on total bacteria, Lactobacillus and Enterococcus in broiler ileum digesta at day 21 (n=16, mean 
± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total bacteria (P0.544) (A), Lactobacillus species (P=0.803) (B) 
or Enterococcus numbers (P=0.221) (C). 
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Figure 6.13:  Effect of treatment on Lactobacillus reuteri, Clostridium perfringens, E. coli and Streptococcus in broiler ileum digesta at day 21 
(n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on Lactobacillus reuteri (P0.434) (A) however there was a highly 
significant effect on C. perfringens levels (P=0.002) (B).  There was also no significant difference in E. coli (P=0.202) (C) or Streptococcus numbers 
(P=0.332) (D).  The significance where indicated is in comparison to with the control; P<0.01 (**) and P<0.001 (***). 
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Lactobacillus species (P=0.803) (Figure 6.12B), Enterococcus (P=0.221) (Figure 
6.12C) or Lactobacillus reuteri (P=0.434) (Figure 6.13A).  A highly significant 
change was observed in the level of Clostridium perfringens in the ileum at day 11 
(P=0.002) (Figure 13B) that was still significant when a Bonferroni correction was 
applied.  Both treatment with 0.47 g/kg Gallus gallus OvoDA1 and 0.45 g/kg 
Taeniopygia guttata OvoDB1 resulted in a highly significant reduction in C. 
perfringens (P=0.0016 and P=0.006 respectively).  No significant changes were 
observed in E. coli (P=0.202) (Figure 6.13C) however from the graph there did 
appear to be some large inter group differences so individual treatments were 
assessed and the effect of Gallus gallus OvoDA1 approached significance (P=0.062).  
No significant changes were observed for Streptococcus (P=0.332) (Figure 6.13D).  
As in the day 11 ileal digesta Eimeria was below the level of detection of this assay.  
6.4.3.2. Caeca 
Analysis of day 11 caecal contents did not show a significant different in the total 
number of bacteria (P=0.599) (Figure 6.14A).  There was also no significant change 
in Lactobacillus (P=0.255) (Figure 6.14B), Bifidobacterium (P=0.249) (Figure 
6.14C) or Coriobacteriaceae species (P=0.200) (Figure 6.14D).  However there was 
a significant effect on Clostridial cluster IV organisms in the caeca (P=0.044) (Figure 
6.15A).  Specifically when treated with Gallus gallus OvoDA1 there was a 
significant increase in Clostridial cluster IV organisms (P=0.029), however no 
changes were observed with Taeniopygia guttata OvoDB1 treatment (P=0.429).  
Although not significant there was also a trend for an increase in Clostridial cluster 
XIVa (P=0.076) (Figure 6.15B).  No changes were observed in the caeca at day 11 
for E. coli (P=0.129).  Both Eimeria and Megamonas hypermegale were too low to 
be measured accurately in this assay. 
The total number of bacteria did not significantly differ at day 21 in the caeca 
(P=0.324) (Figure 6.16A).  There was also no change in total Lactobacillus species 
(P=0.137) (Figure 6.16B).  There was a highly significant effect on Bifidobacterium 
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Figure 6.14:  Effect of treatment on total bacteria, Lactobacillus, Bifidobacteria and Coriobacteriaceae in broiler caecal digesta at 
day 11 (n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total bacteria (P0.599) (A), Lactobacillus 
species (P=0.255) (B), Bifidobacteria (P=0.249) (C) or Coriobacteriaceae numbers (P=0.200) (D). 
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Figure 6.15:  Effect of treatment on Clostridial cluster IV, Clostridial cluster XIVa and E. coli in broiler caecal digesta at day 11 
(n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed a significant effect on Clostridial cluster IV (P0.044) (A) and the effect on 
Clostridial cluster XIVa verged on significance (P=0.076) (B).  There was no significant effect on E.coli (P=0.129) (C).   
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Figure 6.16:  Effect of treatment on total bacteria, Lactobacillus, Bifidobacteria and Coriobacteriaceae in broiler caecal digesta at day 21 
(n=16, mean ± sem).  Analysis by a Kruskal-Wallis test showed no significant effect on total bacteria (P0.324) (A) or Lactobacillus species (P=0.137) 
(B).  There was a highly significant effect on Bifidobacteria numbers in the caeca (P=0.001) (C) at day 21.  No significant effect was observed on 
Coriobacteriaceae numbers (P=0.893) (D).   
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Figure 6.17:  Effect of treatment on Clostridial cluster IV, Clostridial cluster XIVa and E. coli in broiler caecal digesta at day 21 (n=16, mean ± 
sem).  Analysis by a Kruskal-Wallis test showed no significant effect on Clostridial cluster IV (P0.395) (A) or Clostridial cluster XIVa (P=0.455) (B).  
However there was a significant effect on E.coli numbers in the caeca at day 21 (P=0.013) (C).  The significance where indicated is in comparison to 
with the control; P<0.05 (*). 
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levels in the caeca at day 21 (P=0.001) (Figure 6.16C) which was still significant 
when a Bonferroni correction was applied.  When treatments were compared with the 
control Gallus gallus OvoDA1 resulted in a significant reduction in Bifidobacterium 
(P=0.027) whereas the effect of Taeniopygia guttata OvoDB1 was not significant 
(P=0.189).  However the effect of Gallus gallus OvoDA1 versus the control did not 
explain the large significance observed in the data and when the two peptides were 
compared with eachother a highly significant difference between treatments was 
observed (P=0.0004).  At day 21 no significant changes were observed in 
Coriobacteriaceae (P=0.893) (Figure 6.16D), Clostridial cluster IV (P=0.395) 
(Figure 6.17A) or Clostridial cluster XIVa (P=0.455) (Figure 6.17B).  There was a 
significant effect on E. coli numbers (P=0.013) (Figure 6.17C); compared with the 
control Gallus gallus OvoDA1 resulted in a significant reduction (P=0.046) whereas 
there was no difference after Taeniopygia guttata OvoDB1 treatment (P=0.141).  
Megamonas hypermegale and Eimeria were still below the limits of detection in the 
caeca at day 21.  
6.5. Discussion 
Ovodefensin peptide treatment had a significant effect on mean body weight gain 
over the duration of the experiment (Figure 6.1).  Gallus gallus OvoDA1 resulted in 
a dose dependant increase in mean body weight; for inclusion at both 0.047 and 
0.47 g/kg the increase was significant when compared to the un-supplemented diet.  
Taeniopygia guttata OvoDB1 feed supplementation also resulted in an increase in 
body weight when compared with the control at 0.0045 and 0.45 g/kg.  The increase 
in body weight was not due to an increase in feed consumption as this did not alter 
over the course of the experiment (Figure 6.2).  Strangely there was no significant 
increase in body weight with the middle dose (0.045 g/kg) of Taeniopygia Guttata 
OvoDB1 despite the fact that there was an increase with the lowest dose as well as a 
reduction in FCR.  This may suggest some benefit to examining lower doses of 
ovodefensin peptide inclusion; perhaps at lower doses the peptide results in less of an 
immunomodulatory response.  As this response requires expenditure of energy 
(Whittow, 1999) effective dosing of peptide may require finding an appropriate 
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balance between energy spent on altering the gut microflora and that which is gained 
through this microbiome alteration.  However it should be noted that despite there 
being a large amount of replication within the experiment this is the first time these 
peptides have been tested in this way and a repeat of this work will need to be carried 
out to confirm that this is a true observation.  Currently if these results are corrected 
using the Bonferroni method most would fall below the criteria of significance but 
the results give an indication of which parameters may be important to assess in the 
future.  That said, even with that stringent correction there are some cases in these 
experiments where significance is achieved.  In the final chapter recommendations 
for future feed trials and further analysis on the current samples in order to determine 
the true effects of these peptides will be discussed. 
Observations from the analysis of both the environmental profile of the 
gastrointestinal tract e.g. pH and metabolites as well as the microbiome showed 
beneficial effects, particularly in the caeca.  At day 11 peptide inclusion resulted in a 
significant increase in butyrate producing Clostridial cluster IV (Figure 6.15A) and 
an increase in Clostridial cluster XIVa that approached significance (Figure 6.15B) 
(P=0.076).  Butyrate is produced through bacterial fermentation of undigested 
carbohydrates (Pryde et al., 2002) and it has been suggested that it can induce 
endogenous defensin expression (Sunkara et al., 2011) which may in turn promote 
beneficial modulation of the gastrointestinal microbiome.  In support of this 
observation there was a strong trend (Figure 6.9A) in the increase of butyrate levels 
in the caeca by day 21.  It was not possible in this thesis to measure endogenous 
expression of defensins due to time but tissue samples were collected for this purpose 
and it would be interesting to see if stimulating butyrate production in vivo results in 
an increase in AvBD9 and AvBD14 as previously described when butyrate was 
administered directly to the bird through the feed (Sunkara et al., 2011).   By day 21 
there was also a highly significant decrease in Bifidobacterium in the caeca (Figure 
6.16C).  Analysing treatments individually demonstrated that only Gallus gallus 
OvoDA1 produced a significant effect when compared with the control.  Interestingly 
the most statistically significant difference in Bifidobacterium was observed when 
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comparing peptide treatments with each other possibly suggesting they have 
opposing effects on this organism.  Bifidobacterium metabolise simple carbohydrates 
and can help utilise those carbohydrates which have escaped host digestion (Willey 
et al., 2008).  Bifidobacterium is generally considered a beneficial commensal of the 
GIT and is often used as a probiotic as it is associated with pathogen exclusion, 
particularly competitive exclusion of gram negative organisms, and has also been 
implicated in maintenance of the intestinal barrier (Griffiths et al., 2004).  However, 
although these organisms are generally considered beneficial they metabolise fairly 
simple carbohydrates and therefore high numbers in the caeca can be an indication of 
poor nutrient absorption further up in the GIT (Rinttila and Apajalahti, 2013).  
Therefore the highly significant reduction of these organisms in the caeca suggest 
that nutrient absorption is improved in the peptide treated birds meaning that less 
unabsorbed sugars are reaching the caeca.  At day 21 there was also a highly 
significant effect on lactic acid concentration in the caeca (Figure 6.9B), Gallus 
gallus OvoDA1 in particular resulted in a large reduction in lactic acid; as lactic acid 
is a major end product of Bifidobacteria metabolism (Willey et al., 2008) this 
correlates nicely with the reduction in numbers of this organism.   
No significant changes were observed in the ileum for any of the SCFA profiles 
measured in this study.  However as previously discussed the reduction of 
Bifidobacterium and lactic acid in the caeca is indicative of improved nutrient 
absorption in the higher gastrointestinal tract.  It may be that these improvements 
could not be identified from the parameters measured or it may be that these changes 
were happening more proximally in the GIT, for example in the jejunum where a 
large amount of nutrient digestion and absorption takes place (Whittow, 1999).  At 
day 11 there was a reduction in Streptoccocus in the ileum which approached 
significance (Figure 6.11D).  Although Streptococcus is considered a commensal 
organism in the gut it can be an opportunistic pathogen (Willey et al., 2008) and a 
reduction in this genus could therefore be considered beneficial.  At day 21 no 
significance was detected in E. coli levels in the ileum when Kruskal Wallis was 
used to analyse the data (Figure 6.13C), however the graph indicated that there was a 
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strong tendency for a reduction in E. coli numbers when Gallus gallus OvoDA1 was 
administered.  Therefore a Mann-Whitney test was used to test the significance 
between the negative control and Gallus gallus OvoDA1, this showed that the trend 
approached significance (Figure 6.13C).  Most strikingly peptide administration had 
a very significant effect on the number of Clostridium perfringens organisms in the 
ileum at day 21 (Figure 6.13B) with numbers being reduced with both peptides.  
Clostridium perfringens is the causative agent of necrotic enteritis (McDevitt et al., 
2006) and has been of particular concern to the poultry industry since the ban on 
antibiotic growth promoters in the last decade (Dahiya et al., 2006). Any reduction in 
this organism could have considerable benefits to the poultry industry both in terms 
of the health and performance of the flock and consequently welfare and profit. 
The observations made in this chapter suggest that the in-feed inclusion of 
ovodefensin peptides could present an interesting alternative to traditional antibiotic 
growth promoters (AGPs).  The increase in body weight  observed paralleled that 
achieved, a maximal increase of 62.1 g at 21 days with the AGPs (Miles et al., 2006) 
and the changes observed in both the environmental profile and microbiome were 
indicative of improved nutrient absorption and a healthy microbiota.  Further work 
will need to be carried out to determine if these observations are reproducible and 
whether they offer protection from disease in a challenge situation; this will be 
discussed in detail in the next chapter. 
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7.1. Final discussion 
In this final chapter the major findings of this research will be summarised and the 
potential implications of the work will be discussed.  In particular directions for 
future research with a focus on commercialisation and understanding the 
mechanisms behind the changes observed in the in vivo peptide trial will be 
addressed.   
7.1.1. General discussion 
7.1.1.1. TENP 
The work outlined in Chapter 3 gives new insights into the comparative biology and 
expression of TENP, demonstrating its conservation among avian species and 
describing for the first time its expression in the adult hen.  The results strongly 
suggest that in the adult TENP plays a major role in the egg, most probably in 
antimicrobial innate defence.  It is possible that TENP may also act locally in the 
oviduct providing antimicrobial protection; however, immunohistochemistry showed 
no TENP protein in the epithelial cells suggesting that its major role is within the 
egg.  Chapter 3 also described in detail the transcript encoding TENP in the adult, 
showing that both BPI domains are expressed and revealing an alternative 
translational start site and frameshift event compared with the previously published 
sequence (Yan and Wang, 1998).  In the adult TENP has the clear signature of an 
egg specific protein; its expression is restricted to the oviduct, diminished when the 
bird is out of lay and enhanced in response to gonadal steroids.  This is particularly 
interesting because in the embryo TENP is expressed in brain and retinal tissues and 
at least in the brain may play a transient role in development (Yan and Wang, 1998).  
The dual purpose of TENP makes it an extremely interesting candidate for future 
research as it could provide insight into the biology of not only the egg but the chick 
as well.  
It was decided that TENP would not be the focus of feed trials in this project due to 
its large size and efforts in protein production and assessment of antimicrobial 
activity were directed elsewhere.  However since this work was completed 
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antimicrobial activity has been demonstrated for emu TENP (Maehashi et al., 2014) 
and it would be extremely interesting to see if chicken TENP also possessed 
antimicrobial activity.  The large size and consequent multiple protease cleavage 
sites of TENP make it unsuitable as a feed additive; however if shown to be 
antimicrobial it may be useful in other applications such as carcass washing where 
the route of application is topical, or outside of the poultry industry in functions such 
as wound healing or catheter sterilisation (Easton et al., 2009).  TENPs proposed 
mechanism of action is through LPS binding (Beamer et al., 1998); it may therefore 
provide a useful synergistic relationship with molecules such as the ovodefensins 
which are proposed to rely on electrostatic interactions as typical of β-defensins 
(Ganz, 2003).    
7.1.1.2. The ovodefensin family 
In this thesis it was shown that the ovodefensins are a structurally distinct family of 
positively charged β-defensins which are conserved across avian and reptilian 
species.  Within the ovodefensin family unique cysteine spacing motifs were 
identified which divide this group into six sub-families which were used to propose 
new nomenclature.  Evolutionary analysis suggests that one cysteine motif (OvoDB) 
has evolved independently in both birds and reptiles demonstrating unique evolution 
of spacing within this family as well as classical evolution of sequence.  RT-qPCR 
analysis confirmed that at least in the avian species examined in this study, 
expression was restricted to the oviduct as previously documented for Gallus gallus 
OvoDA1 (gallin) (Gong et al., 2010).  However it was apparent that whilst the level 
of expression in each oviduct region varied between species it was fixed for each 
complement of ovodefensins within a species.  This finding poses the question; what 
is driving the evolution of ovodefensins and specifically what might be driving 
expression?  For example it could be hypothesised that the environment in which a 
given species lays its eggs affects which regions of the egg most require antibacterial 
protection, and ovodefensin expression would be up-regulated accordingly.  The 
results in Chapter 4 show that duck ovodefensins are expressed most highly in the 
shell gland.  It could therefore be theorised that the wet environments encountered by 
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waterfowl result in greater antimicrobial requirement for the egg shell since bacterial 
contact is likely heightened, however this does not explain the high expression of 
turkey ovodefensins in the shell gland.  Of course environmental observations alone 
cannot prove the hypothesis and indeed even with a large number of ovodefensins if 
would be difficult to do so as environmental pressures are often multifaceted and 
complex.  Nonetheless the ongoing ‘arms race’ between host and pathogen is a 
strong driver of evolution and immune genes such as AMPs are often under positive 
selection and therefore evolve more rapidly (Kosiol et al., 2008).  Therefore 
particular pathogens of the host environment may be playing a role in how the 
ovodefensins within any given species evolve.  In this thesis it was only possible to 
test the antimicrobial capabilities of a few peptides against a small range of bacterial 
species but it was evident that the spectrum of activity and efficacy varied.  It would 
be interesting to test a much wider range of peptides and microbial species in order to 
determine if any connection could be made between species and activity.  It would be 
of particular interest to test ovodefensins against known pathogens isolated from the 
host species.  However this could prove problematic, particularly when trying to 
obtain strains from species such as the zebra finch.  By increasing the range of 
peptides and microbes tested it may also be possible to shed light on how factors 
such as charge and spacing affect activity.  In this respect the large number and 
diversity of naturally occurring ovodefensins presents an interesting opportunity to 
study functional evolution.  On the other hand the fact that both sequence and motif 
spacing appear to be important features of these molecules also provides an 
interesting and novel approach in designing variants with improved activity.   
In vitro ovodefensin activity appears to be fairly limited, however Gallus gallus 
OvoDA1 was the most potent peptide in this investigation demonstrating a large 
reduction in both E. coli and S. aureus and showing little sensitivity to factors such 
as salt concentration and pH.  It would therefore seem appropriate to use Gallus 
gallus OvoDA1 as a template for designing variants with improved activity.  In 
addition since this work was carried out the structure of Gallus gallus OvoDA1 has 
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been resolved using 3D-NMR (Herve et al., 2014) which provides the knowledge to 
make more informed changes to the molecule. 
 
Figure 7.1: Primary sequence of Gallus gallus OvoDA1. Conserved cysteine 
residues are shown in red and numbered, exposed lysine residue K8 in blue and 
conserved glycine residue G10 in green. Regions between C1-C2 and C4-C5 are 
underlined. The charged lysines are indicated by’*’. 
 
All defensin molecules contain six conserved cysteine residues which form three 
disulphide bridges (Ganz, 2003).  NMR analysis indicates that in Gallus gallus 
OvoDA1 these bridges are formed in a C1-C5, C2-C4 and C3-C6 arrangement 
(Herve et al., 2014) which is the same structure that is observed in all other classical 
vertebrate defensin molecules (Selsted and Ouellette, 2005).  A recent paper by 
Schroeder et al (2011) revealed that the reduction of human β-defensin 1 bonds 
unmasked potent antibacterial action and it would therefore seem sensible to 
determine the contribution of such bridges to Gallus gallus OvoDA1 activity.  In 
order to better understand how disulphide bonds affect activity it would be 
interesting to remove each of the cysteine pairs, this could be done by substituting 
cysteine with alanine which has similar properties and testing the peptide’s activity 
in vitro.  Moreover whilst discovering novel ovodefensin homologs it was possible to 
show that a previously studied turtle peptide belonged to this family.  This peptide 
belongs to the OvoDB subfamily and the previous study suggested that it has 
cysteine bonding that may not be classical (C1-C6, C2-C5, C3-C4) (Chattopadhyay 
et al., 2006).  It is unknown how this affects activity or if other OvoDB members also 
possess this arrangement.  It would therefore be interesting to determine the structure 
* 1  * 2     3  *              4 *   56        *  *
LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASWKWK
C1-C2 region C4-C5 region
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and arrangement of disulphide bonds of other OvoDB members such as Gallus 
gallus OvoDB1 and ultimately the disulphide arrangement of all the sub-families.   
The differences in spacing are ultimately due to differing numbers of amino acids 
between the cysteine residues.  The C1-C2 region varies among ovodefensin 
molecules and the wider family of classical avian β-defensins.  Within this region 
there is a highly conserved glycine residue, in Gallus gallus OvoDA1 the glycine is 
one residue from C1 whereas it is 3 residues from C1 in Gallus gallus OvoDB1 
which shows diminished activity.  It would therefore be interesting to synthesise 
peptides based on Gallus gallus OvoDA1 in which the spacer between C1 and the 
conserved glycine is reduced in length sequentially from three to zero and assess how 
this affects activity and conformation.  The C1-C2 region of Gallus gallus OvoDA1 
also contains a highly charged and hydrophilic lysine residue (K8) that protrudes 
from a region of otherwise intermediate hydrophobicity (Herve et al., 2014).  As 
charge is a varying factor in ovodefensins it would be interesting to study the effect 
of replacing the lysine residue with an uncharged hydrophobic alanine residue. 
The C4-C5 region in Gallus gallus OvoDA1 is preceded by two residues (HG) which 
are absent in classical β-defensins.  This addition results in two short parallel β-
sheets in place of the classical alpha helical N-terminus traditionally seen in β-
defensisns (Herve et al., 2014).  It would therefore be of interest to synthesise a 
Gallus gallus OvoDA1 molecule lacking these residues and determine if this affects 
conformation, disulphide bonding and activity.  The spacing within the C4-C5 region 
also varies from 3 to 4 residues among the ovodefensin sub-families and 5-6 residues 
in classical β-defensins.  Changing the spacing of this region in Gallus gallus 
OvoDA1 from 3 to 6 residues by the sequential addition of alanine would provide 
insight into the role of the structural features which distinguish the ovodefensin 
family from classical β-defensins. 
Finally charge varies from +4 to +10 within the currently identified ovodefensin 
peptides yet there was no clear relationship between charge and activity in the 
antibacterial studies outlined in chapter 5.  As ovodefensin activity in vitro is thought 
to rely on electrostatic interactions with the bacterial membrane (Gong et al., 2010) it 
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would be interesting to see the effect of altering the charge of Gallus gallus OvoDA1 
without changing its structure.  This could be achieved by replacing the lysines at 
positions 18 and 39 (Figure 1) with alanine molecules resulting in a change of charge 
from +6 to +3. 
Ultimately a greater understanding of the relationship between structure and function 
could lead to the production of a pipeline of antimicrobial peptides with improved 
activity. These could form the basis of a new group of “antibiotics” or to be more 
precise “antimicrobials” which is so desperately needed in this current era of 
antibiotic resistance both in the agricultural industry and also the human health and 
veterinary sectors. 
7.1.1.3. Peptide feed additives 
The data presented in Chapter 6 showed an impressive improvement in mean body 
weight gain when broilers were fed ovodefensin peptide in the feed.  This result was 
supported by an improvement in FCR.  Ovodefensin fed broilers also had an altered 
gut microflora; in particular there was a highly significant reduction in Clostridium 
perfringens in the ileum.  C. perfringens is the causative agent of necrotic enteritis 
and of major importance to the poultry industry (McDevitt et al., 2006, Dahiya et al., 
2006).  Particularly since the withdrawal of antibiotics in 1999 a reduction of this 
organism is likely to be well received.  Also of note was a reduction in the 
opportunistic pathogen E. coli in the caeca and a reduction in caecal Bifidobacteria.  
Although Bifidobacteria is generally considered part of a healthy gut microbiota it 
primarily metabolises simple sugars and is therefore more prevalent earlier in the 
digestive tract (Rinttila and Apajalahti, 2013).  Large numbers of Bifidobacteria and 
Lactobacillus in the caeca are indicative of poor nutrient absorption in the small 
intestine therefore a reduction is indicative of improved absorption which may have 
contributed to the increased body weight.  Another important observation from the 
peptide feed trial was an increase in caecal Clostridial clusters, particularly cluster 
IV.  These Clostridial clusters are considered to be beneficial for animals (Rinttila 
and Apajalahti, 2013) as they produce butyric acid as an end product of metabolism 
Chapter 7  Final discussion 
 
~ 200 ~ 
 
(Pryde et al., 2002).  Butyric acid is generally considered to be synonymous with 
good gut health and has been implicated in improved motility and gut barrier 
integrity (Pryde et al., 2002).  There is also some suggestion that butyrate stimulates 
the expression of endogenous defensin activity (Sunkara et al., 2011); the SCFA 
analysis supported an increase in butyric acid in the caeca.  The SCFA analysis also 
revealed an increase in acetic acid in the caeca; this may be an indication of an 
increase in heterofermentative Lactobacillus in the intestine.  Homofermentative 
fermentation results in >85% lactic acid production whereas heterofermentative 
metabolism results in the production of both lactic acid and acetic acid in equimolar 
concentrations (Ganzle and Follador, 2012).  Although both types of Lactobacillus 
are indicative of good gut health there is some evidence that heterofermentative 
metabolism is correlated with improved performance (Lidbeck et al., 1992). 
The effect of ovodefensins in the ex vivo gut model and in the in vivo feed trial was 
substantial, particularly when looking at growth and shifts in the microbiome.  
However the in vitro experiments, which measure the ability of the peptide to kill 
bacteria directly through membrane disruption was not predictive of such large 
effects.  It therefore seems unlikely that this mode of action was solely responsible 
for the impressive effects observed in these experiments and in fact there is some 
debate as to whether host defence peptides are directly antimicrobial in vivo at lower 
concentrations (Bowdish et al., 2006).  However, it is now widely accepted that 
defensins have a wide range of immune-modulatory activities and have been 
implicated in processes such as re-epithelisation and proliferation, chemokine 
production and chemotaxis and interactions with effector cells of the innate immune 
response (Bowdish et al., 2006).  There are some animal infection models which 
demonstrate a reduction in bacterial counts when host defence peptide expression is 
either introduced or increased.  For example when mice were challenged with 
Pseudomonas aeruginosa infection after lung transfer of LL-37/hCAP-18 there was 
an observed reduction in bacterial counts and inflammatory cytokine, TNF- 
production (Bals et al., 1999).  However an improved phenotype is not always 
associated with reduced bacterial counts.  For example in another P. aeruginosa 
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mouse lung study the instillation of either hBD2 or a LL-37 derivative did not lead to 
reduced bacterial counts despite a reduction in lung damage and pro-inflammatory 
cytokine production (Sawa et al., 1998).  The in vivo experiments from this trial 
show a change in the microflora, but unfortunately there was insufficient time to 
study changes in the host immune response which may have been responsible for the 
bacterial shift.  Although, as bacteria can also directly affect the immune system it 
may be difficult to determine what was cause and effect.  However, whatever the 
case, it is apparent that it is advantageous for pathogenic bacteria to subvert the 
expression of host defence peptides and decreased expression is often correlated with 
disease occurrence and severity (Bowdish et al., 2006).  For example both LL-37 and 
hBD2 expression are depressed in patients with atopic dermatitis (Ong et al., 2002) 
and LL-37 has been shown to be decreased in Shigella infection (Islam et al., 2001).  
Therefore if the increase in butyrate observed in this study does lead to an increase in 
endogenous defensin expression as predicted (Sunkara et al., 2011) then this may be 
advantageous to the host in controlling bacterial pathogens. 
Similarities between host defence peptides and chemokines have been documented, 
indeed antimicrobial activity has been observed in many chemokines and certain 
HDPs have chemotactic activity (Bowdish et al., 2006).  In fact it has previously 
been proposed that certain HDPs may have evolved from the duplication of 
chemokines, however this connection is considered controversial (Yang et al., 2002, 
Duerr and Peschel, 2002).  Chemotactic activity in HDPs has been shown to be 
diverse and varies between peptides.  For example both HNP1 and HNP2 can induce 
chemotaxis of monocytes; however HNP1 is a more potent chemoattractant than 
HNP2 and conversely HNP3 does not demonstrate any significant chemotaxis at all 
(Territo et al., 1989).  Both β-defensin hBD1 and hBD2 are chemoattractants for 
memory T-cells and immature dendritic cells (Yang et al., 1999), and LL-37 has 
been demonstrated to be chemotactic for many cell types across multiple species 
including rat mast cells (Niyonsaba et al., 2002) and human neutrophils and 
monocytes (De et al., 2000).  This diversity demonstrates the complexity of HDP 
chemotaxis and therefore different peptides are likely to be mediated through a 
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number of receptors and pathways.  Indeed if chemotaxis plays a role in ovodefensin 
activity in the peptide trials this will make understanding the mechanisms behind this 
difficult.  However, samples of the intestine which have been fixed for histology may 
reveal the increased presence of particular cell types such as heterophils and 
macrophages and give a starting point for investigation. 
There is a large body of literature demonstrating the interaction of HDPs with 
effector cells of the innate immune response such as natural killer and mast cells.  
Monocytes and macrophages when stimulated with LPS or pro-inflammatory 
mediators induce the production of HDPs by epithelial cells and keratinocytes (Liu et 
al., 2003); but in turn monocytes and macrophages are also responsive to HDPs 
(Bowdish et al., 2006).  Host defence cells have also been observed to interact with 
epithelial cells, for example in the induction of proliferation (Nishimura et al., 2004).  
The target of in-feed ovodefensin peptides is the small intestine where there is an 
abundance of epithelial cells and effector molecules.  To date there has been no work 
conducted as to the immune-modulatory abilities of ovodefensins and further 
investigation of gene expression and enumeration of innate immune cells may give 
an indication of mechanisms at work in the intestine.  Indeed, although the work 
carried out in this thesis did not look at ovodefensin activity in the natural setting, 
understanding the immune-modulatory capabilities in these trials may be informative 
of their natural role in the oviduct and the egg.  
Overall the results from the feed trial are extremely positive and suggest that 
ovodefensin feed additives may provide an interesting alternative to antibiotic 
growth promoters.  However in order for peptide feed additives to be considered a 
viable AGP replacement they would need to be accepted by regulatory bodies and 
the poultry industry.  Current EU directives impose a complete ban on the use of 
antibiotics as a prophylactic feed additive, therefore ovodefensin feed additives 
would have to be accepted as a separate class.  The European Commission (EC) 
regulation No 429/2008 states that ‘antibiotic’ means antimicrobials produced by, or 
derived from, a micro-organism, which destroys or inhibits the growth of other 
micro-organisms.  Whereas the alternative characterization ‘antimicrobials’ means 
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substances produced either synthetically or naturally, used to kill or inhibit the 
growth of micro-organisms, including bacteria, viruses or fungi, or of parasites, in 
particular protozoa.  As these peptides are natural peptides produced in fungi they 
clearly fall into the antimicrobials category and would therefore likely be accepted 
by the regulatory bodies.  The fact that these peptides are naturally occurring in eggs, 
routinely consumed by humans and not genetically modified in any way means that 
they are also likely to be widely accepted by both the poultry industry and consumers 
alike. 
Despite the fact that in-feed addition of ovodefensin peptide produced significant 
benefits to poultry performance it is important that their use is properly controlled as 
part of a good management strategy.  No sole intervention can successfully control 
disease whilst enabling the high performance and fast growth of broilers as well as 
maintaining high welfare standards.  Any AGP-like treatment should be considered 
as part of a wider programme ensuring good husbandry, diet, housing and welfare. 
7.1.2. Directions for future research 
Initial experiments outlined in this thesis demonstrate the potential of antimicrobial 
peptides to modulate the gut microbiome and improve broiler performance when 
administered in the feed. This discovery has enormous potential for 
commercialisation, but before this could be achieved further work would need to be 
carried out to determine whether these observations are reliably reproducible.  In 
addition to this it would be desirable to work out the best dosing and duration 
strategies for optimal performance at the lowest possible cost to ensure the product is 
economically viable in an industry where profit margins are extremely tight.  In the 
final part of this chapter areas of research will be discussed that may be important for 
progressing antimicrobial peptide feed additives both in terms of creating a viable 
pipeline of products and also in understanding the mechanisms behind their activity.  
Firstly, a full biological replicate of the data presented in Chapter 6 should be 
conducted to confirm the growth promoting activities of the ovodefensin family.  In 
this repeat experiment it would be interesting to include the supernatant control as in 
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the ex vivo gut model to determine if the beneficial effects observed are due to the 
peptide or background fungal components which are not removed during the 
purification stage.  In the initial experiment the birds were culled at 21 days and as 
broilers are commercially reared to between 35 and 42 days the beneficial effects 
should be observed for the duration of this period.  However, for an antimicrobial 
peptide feed additive to be commercially viable it is essential that it is cost effective 
therefore feeding the peptide for the duration of the rearing period may prove too 
expensive.  The first few days of life are considered critical for establishing a 
beneficial microbiota (Rinttila and Apajalahti, 2013) and therefore it may be possible 
to feed the peptide in the early stages of growth and still see benefits long after 
withdrawal.  Broilers are normally fed a starter diet for approximately the first 11 
days before the feed is changed to a grower diet; only including peptide in the starter 
diet would allow transient feeding without any additional labour.  Human diet has 
been shown to affect the gut microbiota but when the diet is altered the response in 
microbial composition to this change can be delayed (Maslowski and Mackay, 2011).  
If the same is true in chickens the fact that they are only reared for an additional 4 
weeks after the proposed withdrawal period would hopefully mean that the 
microbiota would not have time to revert back to ‘untreated’.  Indeed it may be that 
the beneficial microbiota developed in this early stage is able to out-compete 
opportunistic pathogens, which is the premise behind currently used competitive 
exclusion products (Lee et al., 2010).  
In the experiments carried out in this thesis an interesting observation was made with 
Taeniopygia guttata OvoDB1.  It appeared that the lowest dose of this peptide 
produced effects as beneficial as the highest dose and in fact much greater than the 
middle dose.  This observation may purely be down to chance or it may be that the 
middle dose did not perform as expected.  However if the biological replicate were to 
reproduce this effect then the possibility of feeding peptides at lower doses should be 
investigated.  In fact it is recommended that in the biological replicate a lower dose 
of Taeniopygia guttata OvoDB1 is included.  Being able to reduce the dose of a 
peptide has clear financial gain. 
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In section 7.1.1.2 the creation of variants of known ovodefensin peptides was 
proposed in order to produce an ‘optimal ovodefensin’.  If any of these variants 
showed greater performance in the in vitro tests or ex vivo gut model it would be 
interesting to determine whether improved performance in these tests resulted in 
improved performance in vivo.  It would also be of interest to see whether 
combinations of peptides such as Gallus gallus OvoDA1 and TENP which are 
proposed to function through very different mechanisms would produce a synergistic 
effect when fed together perhaps reducing the overall quantity of peptide required 
and thus in turn reducing the cost. 
Finally as the overall purpose of this experiment was to produce an alternative to 
traditionally used antibiotic growth promoters then ideally these peptide products 
should be compared to AGPs in the same experiment to compare their efficacy.  
When the ideal dose and feeding strategy has been identified it would be interesting 
to compare its performance against a known AGP such as bacitracin.   
Within this thesis it was demonstrated that the in-feed inclusion of ovodefensin 
peptides could modulate the gut microbiota and improve FCR and growth 
performance.  However the mechanisms behind this observation remain to be 
elucidated.  It is widely documented and accepted that as well as the ability to 
directly kill bacteria through the formation of pores in the cell membrane, defensins 
are able to modulate the immune system and as such this would make an interesting 
area to study. 
One approach to understanding the underlying mechanisms of improved growth 
would be to analyse intestinal gene expression in the birds with the greatest 
performance and compare it with the controls.  For a limited subset of birds RNA-
Seq analyses of ileal and caecal tissues should be conducted to observe global 
changes in the transcriptome.  By analysing expression globally it may be possible to 
detect changes not only in the immune response but also in other parameters that 
could affect the growth of the birds such as expression of molecules involved in 
digestion and nutrient uptake e.g. insulin and glucagon.  RNA-Seq is an expensive 
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tool and as such it would only be reasonable to look at a small subset of birds, 
however as currently very little is known about how growth promotion on the gut 
works it would not be feasible to take a more targeted approach.  However the 
information gathered could then be used to target particular genes or specific 
pathways of interest in a larger subset of birds using less expensive methods such as 
quantitative PCR.  One family of genes that would be of particular interest are the 
classical β-defensin genes expressed in the intestine.  This study observed an increase 
in the butyrate producing clostridial clusters and ultimately an increase in butyrate 
concentration in the animals treated with Ovodefensin peptides.  Butyrate is often 
associated with good gut function and health, but more recently it has been suggested 
that butyrate increases the endogenous expression of some defensin genes (Sunkara 
et al., 2011).  If this were the case in this study it would be a clear example of an 
indirect mechanism of immune modulation by antimicrobial peptide feed additives.  
Additionally, analysing gene expression in other regions of the gastrointestinal tract, 
particularly earlier steps in the digestive pathway, may prove insightful as the 
peptides may be affecting a very early stage of digestion which could be missed in 
the ileal and caecal samples. 
In addition to evaluation of gene expression it would be interesting to determine if 
in-feed inclusion of ovodefensin peptides impact on gut morphology.  It has been 
documented that traditional antibiotic growth promoters alter villi density, area and 
crypt death and can also alter the thickness of the mucularis mucosa in poultry 
(Miles et al., 2006).  Other factors such as epithelial cell density may also change 
which in turn may affect gut function and the resistance of the bird to pathogens.  
Fixed samples from the ileum and caeca of birds with a significant increase in weight 
gain could be stained with haemotoxylin and eosin for comparison of gross histology 
and immune cell numbers with the control birds.  The authors of a recent study fed 
small cationic peptides to birds and observed an effect on heterophil and monocyte 
function (Kogut et al., 2012).  It would be interesting to see if ovodefensin peptides 
were also able to stimulate phagocytosis and oxidative burst in the host cells as these 
functions contribute to the innate defence of the bird.  In addition to this the birds in 
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the field experiment described in Chapter 6 were vaccinated with a commercial 
Mareks vaccine at one day of age.  It would be possible, using serology techniques, 
to measure vaccine titres in the birds as another potential indicator of differences in 
immune function in the ovodefensin treated birds.  
Whatever the mechanisms behind the growth promoting effects of ovodefensin 
peptides they clearly offer an exciting avenue of exploration in finding an alternative 
to antibiotic growth promoters in the poultry industry.  Research into optimising this 
effect and understanding the mechanisms behind it are therefore of great interest to 
the poultry industry and also for those wishing to understand the biology behind 
HDP activity.  
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Appendix 1 
Reagents and solutions 
Phosphate buffered saline (pH adjusted) 
200 mM Na2HPO4, 200 mM NaH2PO4, 100 mM NaCl 
 
pH was adjusted by the addition of NaH2PO4 to Na2HPO4 until pH 6.4, 7.4 or 8.4 was 
obtained. 
Phosphate buffered saline (Salt adjusted) 
200 mM Na2HPO4, 200 mM NaH2PO4, * NaCl; pH 7.4 
 
*NaCl was added at a final concentration of 50, 100 or 150 mM. 
Ileal buffer 
0.02 M K2HPO4, 0.02 M NH4H2PO4, 0.0006 M MgSO4.  pH 6.5. 
Caecal buffer 
0.02 M K2HPO4, 0.02 M NH4H2PO4, 0.0006 M MgSO4.  pH 6.5. 
To 1 litre of caeca buffer add 0.3125 g L-cysteine and 0.3125 g Na2S·9H2O  
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Appendix 2 
Peptide information provided to Roal to aid in recombinant peptide production. 







Amino acid sequence 
LVLKYCPKIGYCSNTCSKTQIWATSHGCKMYCCLPASWKWK.  
PEPSTATS using Emboss 
Molecular weight = 4731.68     Residues = 41     
Average Residue Weight  = 115.407  Charge   = 6.5    
Isoelectric Point = 9.1165 
Probability of expression in inclusion bodies = 0.858 
Residue  Number  Mole%  DayhoffStat 
A = Ala  2  4.878    0.567    
B = Asx  0  0.000    0.000    
C = Cys  6  14.634   5.046    
D = Asp  0  0.000    0.000    
E = Glu  0  0.000    0.000    
F = Phe  0  0.000    0.000    
G = Gly  2  4.878    0.581    
H = His  1  2.439    1.220    
I = Ile  2  4.878    1.084    
J = ---  0  0.000    0.000    
K = Lys  6  14.634   2.217    
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L = Leu  3  7.317    0.989    
M = Met  1  2.439    1.435    
N = Asn  1  2.439    0.567    
O = ---  0  0.000    0.000    
P = Pro  2  4.878    0.938    
Q = Gln  1  2.439    0.625    
R = Arg  0  0.000    0.000    
S = Ser  4  9.756    1.394    
T = Thr  3  7.317    1.200    
U = ---  0  0.000    0.000    
V = Val  1  2.439    0.370    
W = Trp  3  7.317    5.629    
X = Xaa  0  0.000    0.000    
Y = Tyr  3  7.317    2.152    
Z = Glx  0  0.000    0.000    
Property  Residues   Number  Mole% 
Tiny  (A+C+G+S+T)  17  41.463 
Small  (A+B+C+D+G+N+P+S+T+V) 21  51.220 
Aliphatic  (A+I+L+V)   8  19.512 
Aromatic  (F+H+W+Y)  7  17.073 
Non-polar  (A+C+F+G+I+L+M+P+V+W+Y) 25  60.976 
Polar  (D+E+H+K+N+Q+R+S+T+Z) 16  39.024 
Charged  (B+D+E+H+K+R+Z)  7  17.073 
Basic  (H+K+R)   7  17.073 
Acidic  (B+D+E+Z)   0   0.000  
 
Other 
Antimicrobial activity demonstrated against E.coli; 50% inhibition at 0.25 µM and 
95% inhibition at 1 µM 
Cysteine bonds = 1-5, 2-4, 3-6. 
Proposed mode of action = pore formation due to electrostatic interaction. 
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Amino acid sequence 
QPKRSCRGHCSRTCGKGEREEHTEDCGGMHCCLTHRKRK.   
PEPSTATS using Emboss  
Molecular weight = 4499.12     Residues = 39     
Average Residue Weight  = 115.362  Charge   = 7.0    
Isoelectric Point = 8.9019 
Probability of expression in inclusion bodies = 0.811 
Residue  Number  Mole%  DayhoffStat 
A = Ala  0  0.000    0.000    
B = Asx  0  0.000    0.000    
C = Cys  6  15.385   5.305    
D = Asp  1  2.564    0.466    
E = Glu  4  10.256   1.709    
F = Phe  0  0.000    0.000    
G = Gly  5  12.821   1.526    
H = His  4  10.256   5.128    
I = Ile  0  0.000    0.000    
J = ---  0  0.000    0.000    
K = Lys  4  10.256   1.554    
L = Leu  1  2.564    0.347    
M = Met  1  2.564    1.508    
N = Asn  0  0.000    0.000    
Appendix 2  Peptide information sheets 
~ 232 ~ 
 
O = ---  0  0.000    0.000    
P = Pro  1  2.564    0.493    
Q = Gln  1  2.564    0.657    
R = Arg  6  15.385   3.140    
S = Ser  2  5.128    0.733    
T = Thr  3  7.692    1.261    
U = ---  0  0.000    0.000    
V = Val  0  0.000    0.000    
W = Trp  0  0.000    0.000    
X = Xaa  0  0.000    0.000    
Y = Tyr  0  0.000    0.000    
Z = Glx  0  0.000    0.000    
Property  Residues   Number  Mole% 
Tiny  (A+C+G+S+T)  16  41.026 
Small  (A+B+C+D+G+N+P+S+T+V) 18  46.154 
Aliphatic  (A+I+L+V)   1   2.564 
Aromatic  (F+H+W+Y)  4  10.256 
Non-polar  (A+C+F+G+I+L+M+P+V+W+Y) 14  35.897 
Polar  (D+E+H+K+N+Q+R+S+T+Z) 25  64.103 
Charged  (B+D+E+H+K+R+Z)  19  48.718 
Basic  (H+K+R)   14  35.897 
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The ‘transiently expressed in neural precursors’ (TENP) gene product is a member of the bacterial/permeability-
increasing (BPI) family of antimicrobial proteins but was first identified as having a role in an early neurological
event occurring in post-mitotic cells. However, recent characterisation of the eggwhite proteomehas shown that
TENP is an important egg component constituting ~0.1–0.5% of the total protein and suggesting it is expressed in
the adult oviduct. In this studywe confirmed quantitatively that the expression of TENP is largely confined to the
tubular glands of themagnum of the oviduct, where egg white synthesis occurs, with around 10,000 timesmore
expression than in the embryo where TENPwas first identified. TENP expression is significantly increased with
the administration of oestrogen or progesterone (P b 0.001) and is reduced in regressed oviducts (P b 0.001)
demonstrating gonadal steroid control, typical of an oviduct and egg specific gene. A putative translational
start site for TENP has been characterised and the evidence indicates that it is expressed as one predominant
transcript. In comparison with the published sequence, insertion and deletion events have been identified
causing a partial frame-shift that results in an altered amino acid sequence to that previously documented.
TENP is conserved across divergent avian species being found in chicken, turkey, duck and zebra finch and its
expression profile confirmed in both chicken and duck. Similarity searches have shown homology with the
BPI-like family of innate immune genes, particularly with palate, lung and nasal epithelial clone (PLUNC)
members of this family. We therefore believe that at least in adults the role of TENP is as a major component
of egg, particularly the white and it is probable that it contributes to its antimicrobial function.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
The eggmust provide an embryowith the nutrients it needs to grow
aswell as protection from pathogens to ensure it survives to hatch. One
way in which this is achieved is utilising antimicrobial proteins and
peptides, molecules of the innate immune system (Wellman-Labadie
et al., 2007). The current requirement to find new strategies to combat
infection makes the study of new antimicrobial proteins extremely
valuable and also aids our understanding of how the avian eggmanages
to prevent contamination during incubation (Kovacs-Nolan et al.,
2005).
A large amount of work has been made on proteins in the egg,
indeed investigators have utilised the prodigious expression of egg
protein genes, especially ovalbumin, to advance the understanding of
gene expression (McKnight, 1978). However, that very feature has
masked the identity of many of the components of the egg. Recently
proteomic studies have started to uncover some of the secrets that the
large quantities of ovalbumin were hiding (Mann et al., 2008). The
TENP gene appears to be an example of one such protein. The TENP
(transiently expressed in neural precursors) gene was first identified
in the brain and retina of developing neural tissues of chickens using
reverse transcription polymerase chain reaction (RT-PCR), and was
proposed to function in an early neurological event occurring in post-
mitotic cells before they enter the stage of overt differentiation (Yan
and Wang, 1998). The 47 kDa protein has since been identified during
proteomic studies of chicken egg white, vitelline membrane, shell and
yolk (D'Ambrosio et al., 2008; Farinazzo et al., 2009; Guerin-Dubiard
et al., 2006; Mann, 2007, 2008; Mann and Mann, 2008; Mann et al.,
2006). TENP has also been identified in proteomic analysis of emu egg
white (Maehashi et al., 2010) showing its conservation across divergent
avian species.
Similarity searches have shown homology of TENP with the
bactericidal/permeability-increasing (BPI)-like family of innate immune
genes (Mulero et al., 2002), which are found in adjacent chromosomal
regions to TENP on chromosome 20 (Chiang et al., 2011). Computer
Gene 538 (2014) 99–108
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IHC, immunohistochemistry.
⁎ Corresponding author.
E-mail address: natasha.whenham@roslin.ed.ac.uk (N. Whenham).
0378-1119/$ – see front matter © 2014 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.gene.2013.12.065
Contents lists available at ScienceDirect
Gene
j ourna l homepage: www.e lsev ie r .com/ locate /gene
analysis of the primary sequence of TENP predicted three putative
transmembrane helices suggesting it may be a membrane protein
(Yan and Wang, 1998). This was supported by the immunodetection
of TENP in cellular membrane fractions after expression in chicken
embryonic fibroblast cells (Yan and Wang, 1998). However, it has
been suggested that TENP, as previously proposed for BPI (Beamer
et al., 1998),may bemembrane associated rather than an integralmem-
brane protein. It has been suggested that TENP is a divergent ortholog of
human LPLUNC2 (Chiang et al., 2011). The PLUNC (palate, lung andnasal
epithelial clone) protein family are structural homologues of BPI
proteins (Chiang et al., 2011) and are divided into two groups; short
(SPLUNC) and long (LPLUNC) proteins. SPLUNCs contain a region struc-
turally homologous to the BPI N-terminal domain whereas LPLUNCs
contain domains similar to both the BPI domains (Bingle and Craven,
2002). The N-terminal domain of BPI is responsible for lipopolysaccha-
ride (LPS) and bacterial binding as well as endotoxin neutralisation
and antibacterial cytotoxicity whereas the C-terminal domain is associ-
ated with opsonic effects thus enhancing phagocytosis (Schultz et al.,
2001). The TENP molecule detected in the embryo has two distinct re-
gions that are analogous to the BPI1 (N-terminal) and BPI2 (C-terminal)
domains of the BPI protein. There is currently little evidence from EST
data (Chicken (Gallus gallus) Genome Browser Gateway, 2013) to sup-
port a full length TENP transcript in adult birds which would allow
both the BPI-like domains present to be expressed in one molecule;
however the proteomic evidence supports both domains being present
in egg white (Karlheinz Mann, personal communication, November 11,
2010). It has been proposed that the function of TENP is associated with
the innate defence of eggs against pathogens (D'Ambrosio et al., 2008;
Guerin-Dubiard et al., 2006; Mann, 2007) however its proposed func-
tion is yet to be experimentally proven and is largely based on its rela-
tionship to the BPI-like family. A chicken member of the BPI/PLUNC
superfamily is found in the egg shell and has previously been shown
to possess modest antibacterial activity against a range of gram positive
and gramnegative bacteria (Gautron et al., 2011). It is also documented
that this protein is able to bind Escherichia coli LPS in vitro (Gautron
et al., 2011) and its expression in the infundibulum is up-regulated
after systemic administration of this molecule (Bedrani et al., 2013)
strongly supporting a role in egg antimicrobial defence. Althoughmam-
malian members of this family have been documented to interact with
LPS this has been demonstrated to be both pro and anti-inflammatory
and the family's role in host defence against bacteria is still to be fully
elucidated (Bingle and Craven, 2004). However, due to the large
number of known antimicrobial proteins, including Ovocalyxin 36,
already identified in the egg an antimicrobial rolewould seemplausible.
The overall aim of this study was to determine the expression of
TENP in different tissues and physiological states to support the hypoth-
esis that its role is as a specific egg protein in addition to its proposed
developmental role. This study has defined the transcriptional start
site and putative translational start site and also investigated the evolu-
tionary relationship of TENP in a number of bird species and demon-




The TENPprotein sequence (NCBI accession no. AF029841)wasused
to perform a BLAT search (Kent, 2002) of the May 2006 release of the
chicken EST database using the default parameters of the UCSC genome
browser (Chicken (Gallus gallus) Genome Browser Gateway, 2013) to
identify ESTs and sequences related to the locus. The Staden package
(Staden, 1996) was used to build a consensus sequence using the ESTs
available. This allowed a gap present in the genome build to be bridged
and allowed a comparison to be made between the genomic, EST and
published TENP mRNA sequences in order to address differences in se-
quence identity. Primer3 (2013) was used to design primers (Table 1)
for re-sequencing across the length of the consensus sequence including
a putative alternative transcriptional start site identified in the consen-
sus sequence. Signal P (Bendtsen et al., 2004) was used to assess the
likelihood of a signal peptide produced by each translational start site.
Exon contributions were estimated from genomic DNA using BDGP
NNSPLICE version 0.9 (Reese et al., 1997) (Table 2).
The duck genome database (Anas platyrhynchos — version 1)
(Ensembl Pre-releaseGenomeBrowser, 2013) and turkey genome data-
base (Meleagris gallopavo — assembly UMD2) (Ensembl Genome
Browser, 2013)were searched using TBLASTN for potential homologues
using the 629 amino acid mature TENP protein. Primers were designed
using Primer3 (2013) to amplify both the potential turkey and duck
TENP sequences from cDNA (Table 1).
2.2. Animals and tissue collection
2.2.1. Tissue panel
To determine TENP expression the following tissueswere taken from
sexually mature White Leghorn LSL hens (Gallus gallus) (Lohmann):
Oviduct (magnum, shell gland, isthmus, vagina), ovarian stroma, crop,
duodenal loop, gizzard, caeca, cloaca, lung, adrenals, cerebellum, retina,
spleen, liver, kidney, and heart (n = 4). After dissection tissue was
placed in RNA later (Ambion, Applied Biosystems, Warrington, UK)
and stored at 4 °C overnight before storage at−80 °C. Samplesweighed
no more than 100 mg.
Sexually mature Pekin ducks (Anas platyrhynchos) (Cherry Valley):
Oviduct (magnum, shell gland, isthmus, vagina), ovarian stroma, crop,
proventriculus, small intestine, duodenal loop, gizzard, large intestine,
caeca, cloaca, gall bladder, lung, trachea, pituitary, adrenals, cerebellum,
hypothalamus, tongue, spleen, breast muscle, liver, kidney and heart.
Samples were stored as above.
2.2.2. Embryonic tissue
Brain, retina and heart tissue were taken from embryonic day 10
(E10) (n = 6) and day 16 White Leghorn chickens (E16) (n = 6). E10
and E16 correspond with the Hamburger–Hamilton (HH) embryonic
Table 1
Names and sequences of primers used in the study.
Forward primer name Forward primer sequence Reverse primer name Reverse primer sequence
TENP Exon1F1 AGGATGGGAACAGCAAACAG TENP End1 ATCCTCCTTCTGCACCAAAA
TENP RTF CACTGCTGGAGGAGCTGTT TENP RTR ACAACGTTGACGTCGGTGTA
D.TENP F3 AGACCATACGCAGAGGTGGT D.TENP R3 AGGTTGCACAGGAGCAAGAC
D.TENP F8 AGGGAATCACCATGTCCTTG D.TENP R10 TGATCTTCTGTGCCATGGTG
T.TENP F1 GTCTCAAAGCCACATGCAGA T.TENP R1 GGTTTTCCACTGCTTTCACC
SP1 ATCTGGAGGACTTGCTTTCC
SP2 CCCATGTCTACGTGGAGGTC
100 N. Whenham et al. / Gene 538 (2014) 99–108
developmental stages HH36 and HH42 respectively. Samples were
stored as above.
2.2.3. Time of oviposition
Magnum tissue was obtained from sexually mature White Leghorn
hens with an ovum at various positions in the oviduct, see Gong et al.
(2010) for details. Briefly, magnum tissue was processed either when
the egg was in the magnum (n = 5), in the shell gland where the
stage of calcification was determined by electron microscopy and
recorded as early (n = 8), mid (n = 9) and late (n = 10) calcification
or during a pause day (n = 11) when there was no evidence of ovula-
tion. Tissues for immunolocalisation studies (magnum, isthmus, shell
gland and caecum) were harvested from 5 of these laying hens post
mortem and fixed in 10% buffered-neutral formalin (BNF) for 24 h
prior to being processed to paraffin wax using a 16 hour processing
cycle in a Thermo Shandon Excelsior tissue processor.
2.2.4. Effect of oviduct development
In domestic chickens, the onset of incubation behaviour is
characterised by the regression of the oviduct due to the withdrawal
of gonadotrophic support (Dunn et al., 1996). This natural phenomenon
was exploited to determine if TENP expression differed between in lay
hens (n = 11) and those where the oviduct had regressed (n = 11).
Magnum and shell gland tissue was collected from hens of a Silkie ×
White Leghorn cross, after dissection tissue was frozen in liquid N2
and stored at−80 °C. Samples weighed no more than 100 mg.
2.2.5. Northern analysis
To determine definitively the expression of TENP isoforms a
northern analysis was carried out using magnum from in-lay layer
(n = 3) and broiler (n = 3) lines. Broiler liver was included as a
negative control. After dissection, tissue was placed in RNA later
(Ambion, Applied Biosystems, Warrington, UK) at 4 °C overnight
then stored at −80 °C.
2.2.6. Induction of TENP with steroid hormones
The induction of TENP with steroid hormones was adapted from a
method described previously by Kunnas et al. (1992). Three week old
ISA brown chicks (n = 60) were given an intramuscular injection of
0.5 mg diethylstilbestrol (DES) in 0.5 ml propylene glycol daily for
seven days (primary stimulation) and then split into two groups.
Following the primary DES treatment there was a period of withdrawal
from DES for 12 days in group one (non-primed) birds (n = 30)
followed by a single injection of progesterone (20 mg/kg) (n = 10),
oestradiol (10 mg/kg) (n = 10) or vehicle (propylene glycol; 1 ml/kg)
(n = 10). In the second group (primed) the birds (n = 30) were re-
stimulated daily for two days with DES after a withdrawal period of
10 days followed by a single injection of progesterone (n = 10),
oestradiol (n = 10) or vehicle (n = 10) as already detailed for the
non-primed birds. All chicks were killed 12–16 h after the single injec-
tion; magnum tissue was removed and immediately frozen in liquid ni-
trogen then stored at −80 °C.
All animals were killed in accordancewith schedule 1 of the animals
(scientific procedures) act 1986, UK under project licence PPL 60/3964.
2.3. RNA preparation
Soft tissues (magnum, shell gland, isthmus, lung, cerebellum, spleen,
liver, kidney and embryonic) were homogenised in Lysing matrix D
tubes (Qbiogene-Alexis Ltd. Nottingham, UK) containing Ultraspec II
total RNA isolation reagent (AMS Biotechnology, Oxon, UK) using a
FastPrep FP120 homogeniser (Qbiogene-Alexis Ltd. Nottingham, UK).
All other tissues were homogenised in Ultraspec II total RNA isolation
reagent (AMS Biotechnology, Oxon, UK) using an Ultraturrax
homogeniser (IKA®-Werke GmbH & Co. KG, Germany). Samples were
then processed as per the Ultraspec II protocol.
2.4. Transcript determination
2.4.1. PCR and sequencing
1 μg samples of chicken, duck and turkey magnum RNA were re-
verse transcribed using a high capacity cDNA reverse transcription kit
(Applied Biosystems, UK) according to the manufacturer's protocol.
Primers TenpExon1F1 and TenpEnd1 (chicken), D.TenpF3, D.TENP R3,
D.TENP F8 andD.TENP R10 (duck) and T.TENPF1 and T.TENPR1 (turkey)
(Table 1) were designed to ensure complete coverage of the TENP
sequence (see bioinformatics previous analysis). PCR amplification
was performed using the following conditions: an initial denaturation
at 95 °C for 4 min, followed by 40 cycles of 30 s at 95 °C, 30 s at 58 °C
and 30 s at 72 °C, followed by an extension of 7 min at 72 °C. All prod-
ucts were separated by 2% agarose-gel electrophoresis and visualised
using SYBR Safe DNA gel stain (Invitrogen, UK).
The amplified PCR fragments were sequenced with the forward and
reverse primers. Sequences were assembled by Staden (1996) to
produce consensus sequences.
A phylogramwas constructed using Mega5 to infer the evolutionary
history of the TENP homologues. Included in this analysis was human
LPLUNC2 (NCBI reference sequence no. NM_025227) and chicken
Ovocalyxin 36 a BPI like gene (NCBI reference sequence no. NM_
001030861) as outliers.
2.4.2. Northern analysis
MagnumRNA (2 μg) and liver RNA (12 μg)were run on a 2% agarose
gel under denaturing conditions (Pelle and Murphy, 1993), SYBR safe
DNA gel stain (Invitrogen, UK) was used for visualisation. The RNA
was then transferred to an Amersham Hybond N+ nylon membrane
(GE Healthcare Life Sciences, Buckinghamshire, UK) after washing the
gel in dH20 for 30 s; 50 mM NaOH, 10 mM NaCl for 45 min; 0.1 M
Tris HCl pH7.5 for 45 min; 20× SSC for 60 min and UV-crosslinked
(Stratagene Stratalinker) at 120,000 μJ/cm2. A Riboprobe in-vitro
Transcription Systems kit (Promega, Southampton, UK) was used to
produce a single stranded RNAprobe via the T3RNApolymerase system
and incorporated 32P labelled UTP. Template DNA consisted of a HindIII
linearised pBluescript plasmid (p347_TENP) containing the cloned BPI2
(EMBL HG007958 position 1196–1569) domain present in both poten-
tial TENP transcripts. Hybridisation of 32P probe was detected using the
Typhoon FLA7000 (GE Healthcare Life Sciences, Buckinghamshire, UK).
2.4.3. 5′ RACE
5′ RACE (Roche Diagnostics 2nd Generation, Mannheim, Germany)
was carried out to determine the transcriptional start site of TENP.
Table 2
Exon contributions. Exons are shown as nucleotide
contributions in relation to the TENP sequence produced in
this study (EMBL HG007958).
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Briefly, synthesis of first strand cDNA was carried out on magnum RNA
using primer SP1 and themRNA template degraded. cDNAwas purified
using a High Pure PCR Product Purification kit (Roche Diagnostics,
Mannheim, Germany) and polyA tailed at the 3′ end. The tailed cDNA
was amplified by PCR using the Oligo (dt)-anchor primer provided
and a further nested primer SP2. The product from this PCR was run
using 3% agarose-gel electrophoresis and visualised using SYBR Safe
DNA gel stain (Invitrogen, UK). PCR product was excised from the gel
and cleaned from the agarose using a QIAEX II Gel Extraction Kit
(Qiagen, UK) and sequenced using primer SP2.
2.5. Reverse transcription quantitative polymerase chain reaction
(RT-QPCR)
A first strand cDNA synthesis kit (GE Healthcare Life Sciences,
Buckinghamshire, UK) was used for reverse transcription of a 1 μg sam-
ple of total RNA as per the manufacturer's instructions. Reverse tran-
scribed samples were diluted by a factor of 10 with H2O prior to use.
Primer3 (2013) was used to design primers TENP RTF and TENP RTR
for amplification of chicken TENP; D.TENP F8 and D.TENP R10 for duck
TENP. RT-QPCR was carried out with 10 μl of the diluted cDNA and a
primer concentration of 20 mM according to Agilent Brilliant II SYBR®
Green QPCR master mix (Stratagene, UK) instructions. The following
conditions were used for RT-QPCR; 95 °C for 2 min, then 40 cycles of
95 °C for 15 s, 60 °C for 30 s using an MX3000 (Stratagene, UK). Reac-
tions containing no template were run as a control. Standard PCR con-
ditions were used to obtain products for the construction of a
standard curve in order to determine the absolute concentration of
TENP. PCR products were purified using a QIAEX II Gel Extraction
Kit (Qiagen, UK) and quantified using a Nanodrop™ spectrophotom-
eter (Thermo Scientific, UK). Standards were diluted to produce a
top standard that was detectable at around 8 cycles during RT-
QPCR amplification with six ten-fold serial dilutions forming the
standard curve. Products were run on an agarose gel to confirm
only products of the correct length with no primer-dimer were am-
plified as well as ensuring that there was only a single peak dissoci-
ation curve. Correct amplification was also confirmed through
sequencing of the PCR product. Lamin B-receptor (LBR) expression
was measured in the same way to normalise concentrations as
used previously (McDerment et al., 2012). One way or two way
ANOVA and least significant difference to test between the means
were used as appropriate for statistical analysis of log transformed
data. (Genstat 13th edition, VSN International Ltd, Oxon, UK).
2.6. Production and titres of polyclonal anti-TENP antibodies
Production of antibodieswas carried out byDundee Cell Products Ltd,
Dundee. Briefly, two rabbits (R106 and R107) were immunised four
times at three week intervals by intramuscular injection of synthesised
TENP epitopes (AWMDDVLREGVHLPHLSH and DAELSLAASNVGLVRAA)
emulsified in Freund's adjuvant. Serum was collected after each
immunisation. Antiserum was purified via a two-step affinity purifica-
tion using cognate peptides coupled to beads.
Tomeasure the titres of anti-TENP in the R106 and R107 antisera, the
synthesised epitopes were diluted with 50 mM Na2CO3 (pH9.6) to a
final concentration of 1 ng/μl (0.5 ng/μl of each epitope) and 50 μl of
the solution was added to each well of a 96 well plate. The plate was
covered and stored overnight at 4 °C. This was aspirated and the wells
incubated for 2 h at room temperature with 200 μl tris-buffered saline
(pH7.5), 0.5% tween 20 (TBST), 1% bovine serum albumin (BSA) to
block unsaturated binding sites. Pre-immune (null) sera and antisera
were serially diluted 1/1000 to 1/32,000 with TBST, 1% BSA, pH7.5. To
each well, 10 μl of diluted null sera or antisera were added and the
plate incubated for 2 h at room temperature. The plate was washed 5
times with TBST. Horse radish peroxidase (HRP) conjugated Anti-
rabbit IgG (SAPU, Edinburgh, Scotland) diluted 1/2000 with TBST, 1%
BSA, pH7.5 100 μl was applied to each well and the plate incubated at
room temperature for 2 h. After five washings with TBST, peroxidase
activity was detected by adding 100 μl detection solution (100 mM
citric acid, 200 mM Na2HPO4, O-Phenylenediamine (OPD), H2O2). The
reaction was stopped with 50 μl 2 M H2SO4 and absorbance (490 nm)
measured spectrophotometrically.
2.7. Immunohistochemistry (IHC)
Wax embedded tissues were sectioned at 3 μm using a
Thermoshandon Finesse microtome, lifted onto vecta slides and incu-
bated at 60 °C for 1 h before they were de-waxed and taken down to
water. Each section was then treated with Proteinase K for 20 min at
room temperature (antigen retrieval) before loading onto a Dako
Autostainer (Dako, Cambridgeshire, UK). A standard IHC protocol was
then used; optimal staining was achieved at a 1:3000 dilution of the
polyclonal anti-TENP antiserum (107_AWM_1.1) for 30 min. The
sections were viewed using a Leica DM 4000 B microscope and images
captured using a Leica DC480 camera with Qwin programme for PC
(Leica, London, UK).
2.8. Sequencing and database submission
All sequencingwas carried out byGATCbiotech (Konstanz, Germany)
and consensus sequences were submitted to EMBL, chicken TENP (EMBL
accession no. HG007958), turkey TENP (EMBL accession no. HG425203)
and duck TENP (EMBL accession no. HG425202).
3. Results
3.1. Bioinformatic analysis and transcript confirmation
A BLAT search of the May 2006 chicken genome (Chicken (Gallus
gallus) Genome Browser Gateway, 2013) using the published TENP pro-
tein sequence (NCBI reference sequence. NM_205026) returned a result
indicating a 98.2% identity. However there was a gap in the genomic
data between 10248912 and 10249705 bp on chromosome 20.
Searching the EST and cDNA database produced the following sequence
accession numbers; GenBank accession no. DT657251, BM439389,
DT655485, DT655483, DT654774, DT657764, BU357647, BX265690,
BX265691, BU210629, BU266397 and AF029841. All sequences were
derived from hen reproductive tract except AF029841 which was from
the original TENP publication (Yan andWang, 1998) that used embryos.
These were aligned using Staden (1996) and the consensus sequence
produced was used to close the gap in the genomic sequence. The EST
and genomic data either side of the gap were identical; the published
sequence for TENP was 99.1% identical to the sequence generated by
the Staden alignment. When the TENP PCR products generated in this
study were sequenced, they were identical to the available genomic
and EST sequences. However they differed from the current RefSeq
(NM_205026) by an insertion of G between positions 190 and 191
(NM_205026.1:c.190_191insG) and a deletion of G at position 251
(NM_205026.1:c.251delG) resulting in a partial frame shift, altering
part of the protein sequence (Fig. 1). Analysis of the sequence from
this study (EMBL HG007958) identified a potential alternative transla-
tional start site (Fig. 1). The published translational start site (Yan and
Wang, 1998) at genome position Chr20:10,647,277 (reverse strand) of
the November 2011 build with the signal peptide prediction
MGALLALLDPVQPTRA gives a signal peptide probability of 0.661 and a
max cleavage site probability of 0.651 whilst the new putative transla-
tional start site at position Chr20:10,647,544 (reverse strand) in the
November 2011 build identified in this study results in a signal peptide
prediction of MGTANRKGSAVPLLCTMGALLALLDPVQP that gives a
stronger prediction for the signal peptide probability (0.996) and a
maximum cleavage site probability of 0.534. 5′ RACE using magnum
RNA supported the presence of the transcript postulated in this paper,
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which in turn supported the new translational start site (Fig. 1). No
evidencewas found for a sequencewhichwould support the previously
published translational start site, however this may be expressed below
the detection level of the methods used (Fig. 1). The same method was
used to detect the transcriptional start site used in embryonic brain
tissue (not shown) however no transcript was detected.
It was noted that the EST data, although supporting the presence of
each BPI-like domain in the reproductive tract, offered little evidence for
their expression in one full length TENP transcript, rather supporting
that the protein may be expressed as two separate molecules each
encoding for one of the BPI domains (Fig. 2). PCR using magnum
cDNA with primers TENP Exon1F1 and TENPEnd1 designed to amplify
Fig. 1.Northern analysis and 5′ RACE. A) Northern analysis of p347_TENP. Lanes A–C contain 2 μg broilermagnumRNA, lanes D–F contain 2 μg layer magnum RNA, 12 μg liver RNA (G) is
used as a negative control. B) 5′RACEusing primer SP2 resulting in one band. C) cDNAsequencingof the 5′RACE product fromB confirmed thepresence of an alternative translational start
site (underlined), the published start site is highlighted ( ). D) The first 180aa of the new putative protein (HG007958) translated from the alternative start site in C is shown in a clustal
alignment with the published TENP sequence (AF029841), the location of the frameshift is highlighted ( ). The proposed new protein has 455 amino acids.
Fig. 2. Schematic representation of chicken ESTs using the EST data displayed by the UCSC Genome Browser website. ESTs were all isolated from the reproductive tract of adult hens and
provided no evidence for a transcript where both BPI-like domains are expressed in one molecule.
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the whole of the TENP protein coding region from chr20:10642981 to
10647548 resulted in two strong bands. Sequencing of these PCR prod-
ucts confirmed that one of the transcripts encoded for a full length tran-
script including the new predicted translational start site, the second
smaller transcript would, if translated, encode only the BPI2 region of
the TENP protein (Fig. 2). In order to confirm the expression of these
TENP transcripts in magnum tissue northern analysis using an RNA
probe corresponding to the BPI2 domain, present in both forms detect-
ed by PCR, was carried out. The results proved the presence of only the
full length transcript in both layer and broiler type birds (Fig. 1) but
showed no indication of a smaller transcript despite the PCR evidence.
In general the intensity of the signal from the layer line was lower and
more variable than that of the broiler (Fig. 1). It was predicted that
chicken TENP has 16 exons (Table 2).
Potential TENP homologues were identified in both duck and turkey
genomes and their expression was confirmed using PCR and sequenc-
ing. The phylogenetic analysis (Fig. 4) suggests that TENP molecules
from avian species aremore similar to each other than eitherOvocalyxin
36 or LPLUNC2.
3.2. Tissue expression
TENP expressionwas detected in embryonic brain and retinal tissues
(Fig. 5) and decreased as development progressed from E10 to E16. In
contrast measurement of TENP expression in adults indicated that ex-
pression was restricted to the oviduct of adult hens and almost exclu-
sively the magnum with no detectable expression in either the brain
or retina suggesting TENP plays a different role in the adult bird
(Fig. 6). Expression was also restricted to the magnum of the oviduct
in the duck tissues sampled (Fig. 6). TENP expression was measured in
the magnum of the oviduct when the egg was either in the magnum,
the shell gland or during a pause day. Eggs in the shell gland were clas-
sified as either early, mid or late depending on the level of calcification
as determined by electron microscopy. The position of the egg in the
oviduct or the occurrence of a pause day, when the hen did not ovulate
and so no egg was present, did not significantly alter the level of TENP
expression in the magnum (data not shown)(ANOVA, P = 0.083).
However if the data was categorised into when an egg was in the
magnum or had just recently left it (early) versus the later stages of cal-
cification (mid/late) then the difference is verging on significance
(ANOVA, P = 0.051). The level of TENP expression in both themagnum
and the shell gland was higher (P b 0.001) in birds in-lay than in adult
hens whose oviduct had regressed due to incubation behaviour
(Fig. 7) which suggests that the level of TENP expression is affected by
the reduction in gonadotrophics which in turn causes reduction in
Fig. 3. TENP PCR — Amplification of TENP from magnum cDNA using primers TENP
Exon1F1 and TENP End 1 in the first and last exon of TENP. Lane 1, 100 bp molecular
weight marker; lanes 2 and 3 TENP. Results indicate two TENP transcripts with sizes
corresponding to a transcript encoding the full TENP protein and also that of just one
BPI domain.
Fig. 4. Evolutionary relationships of avian TENP homologues, LPLUNC2 and Ovocalyxin 36. A phylogram indicating the evolutionary history of TENP was inferred using the Neighbour-
Joining method (Saitou and Nei, 1987) from an alignment of the mature proteins. Included for comparison were human LPLUNC2 and chicken Ovocalyxin 36. The percentage of replicate
trees inwhich the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches (Felsenstein, 1985). The branch lengths are proportional to the
evolutionary distances which were computed using the Poisson correction method (Zuckerkandl and Pauling, 1965). The units are the number of amino acid substitutions per site. All
positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA5 (Tamura et al., 2011). The common name of the species is included with
the protein names.
Fig. 5. Expression of TENP mRNA in embryonic days 10 (■) and 16 ( ) chicken brain,
retina and heart tissues measured by RT-QPCR (n = 6). TENP expression was corrected
for LBR expression to normalise for any differences between tissues. ANOVA indicated
that embryonic stage was significant at P b 0.001 and tissue was significant at P b 0.001.
TENP expression clearly diminished with development. Heart was included as a negative
control, as expected no expression was detected. Significance between embryonic stage
within tissue is indicated P b 0.001(***) and P b 0.01 (**).
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steroid secretion from the ovary. Oestrogen is well characterised as a
key regulator in the development and function of the oviduct and is
therefore unsurprisingly linked to regulation of the expression of
many egg specific genes. When oestrogen and progesterone were
administered to juvenile hens, TENP expression (Fig. 8) was higher in
birds treated with the two steroids (P b 0.001) and where priming
with an oestrogenic compound had been performed overall expression
increased (P b 0.001).
3.3. Immunohistochemistry
The anti-TENP antiserum (107_AWM_1.1) produced positive
staining in the tubular gland cells of the magnum (Fig. 9A). The ciliated
and non-ciliated cells lining the magnum region of the oviduct did not
react to the primary antibody. No stainingwas observed in the isthmus,
shell gland or caecum (Fig. 9C–E).
4. Discussion
The conservation of TENP among avian species and the results
outlined in this study strongly suggest a major egg specific role for
TENP protein in the adult hen. However, local tissue activity cannot be
ruled out and TENP may provide antimicrobial protection in both the
egg and the oviduct. The fact that this protein also plays a transient
role in the developmental stages of the chicken embryo suggests a
dual purpose for TENP. This makes understanding how expression of
TENP is controlled and of course its purpose extremely valuable in
providing an insight into the biology of not only the egg but the chick
as well.
The EST data aligned to the May 2006 chicken genome assembly
confirmed the expression of both of the TENP BPI domains in the hen
reproductive tract but offered little evidence for their expression in
one full length TENP transcript, as originally identified in neural precur-
sors (Chicken (Gallus gallus) Genome Browser Gateway, 2013), rather
supporting that the protein may be expressed as two separate
Fig. 6. Expression of TENPmRNA in a range of adult chicken (n = 4) andduck (n = 3) tis-
sues measured by RT-QPCR. TENP expression was corrected for chicken LBR and duck LBR
expression to normalise for any differences between tissues. Expression is restricted to the
oviduct in both species with the greatest level of expression seen in the magnum.
Fig. 7. Expression of TENPmRNA in A)magnum and B) shell gland tissue of laying (L) and out of lay (NL) birdsmeasured by RT-QPCR (n = 11,mean ± sem). Non-laying henswere those
where the oviduct had regresseddue to thewithdrawal of gonatrophic supportwith the onset of incubation behaviour. TENP expressionwas correctedusing LBR expression.Note the large
difference in the Y-axis scale between A and B. Significance between laying state is indicated at P b 0.001, ***.
Fig. 8. Expression of TENPmRNA in the magnum of juvenile chicks treated with steroids
measured by RT-QPCR (n = 10, mean ± SEM). TENP expression was corrected using
LBRexpression. Female chicks at 3 weeksof agewere either primedwith diethylstilbestrol
(■) or vehicle ( ) then subsequently treated with either progesterone, oestradiol
(oestrogen) or vehicle (control). ANOVA indicated primed or not primed was significant
at P b 0.001; steroid treatment was significant at P b 0.001. Significance between primed
state within treatment is indicated, P b 0.001(***) and significance between treatments
regardless of primed state between the brackets, P b 0.001(***).
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molecules each encoding for one of the BPI domains (Fig. 3). Sequencing
of PCR products usingmagnum cDNAwith primers designed to amplify
the whole of the TENP protein coding region produced a full length
transcript including the new predicted translational start site and a
second smaller transcript which if translated would encode only for
the BPI2 region of the TENP protein (Fig. 2). Although in theory intensi-
ties of DNA bands on a gel amplified from targetswith the sameprimers
should be indicative of the relative abundance of each transcript in the
starting sample if amplification efficiency is equal (Cottrez et al.,
1994), factors such as amplicon size or sequence can lead to a bias in
amplification with smaller amplicons being amplified more efficiently
(Cha and Thilly, 1993) or possibly differences in reverse transcription
efficiency. Indeed Northern analysis indicated that the full length
transcript (Fig. 1) was the dominant form of TENP and the lack of signal
for the smaller transcript suggested that it may be below the threshold
of detection for this method contrary to the PCR results. Although these
results indicate that a transcript encoding both BPI-like domains is the
dominant form in the oviduct the presence of a smaller transcript
cannot be ruled out completely. It may be that this gene encodes for
alternate forms of TENPwhere only one of the BPI domains is expressed,
as seen with SPLUNCs (Bingle and Craven, 2002).
The PCR products from this study (TENP Exon1F1-Tenp End1) were
identical to the available genomic and EST sequences yet contained an
indel when compared to the previously published TENP sequence
resulting in a frameshift (Fig. 1). We would therefore propose that the
previously published protein sequence for TENP is either incorrect or
specific to the strain used in that study. Potential TENP homologues
were identified in both the duck and turkey genomes and sequencing
of PCR products confirmed the presence of TENPmRNA in the magnum
of both species. A potential TENP homolog is predicted in the zebra finch
(NCBI Reference Sequence: XP_002192628.1) and TENP has also been
identified in proteomic analysis of emu egg white (Maehashi et al.,
2010). These results coupled with a high level of sequence similarity
suggest that TENP is highly conserved across avian species. From the
phylogenetic analysis (Fig. 4) the TENP molecules are more similar to
each other than either Ovocalyxin 36 or LPLUNC2. The analysis infers
that TENP is a divergent ortholog of LPLUNC2, and that Ovocalyxin 36
may have evolved from an ancestral LPLUNC2-related gene as previous-
ly suggested (Chiang et al., 2011), perhaps from a duplication event
occurring before mammals and birds diverged.
Since this analysis was carried out, deposits in theGenBank database
made by Kinoshita K., et al. became visible (accession no. BAM13270.1,
BAM13271.1, BAM13272.1, BAM13273.1, BAM13274.1 and BAM13275.
1). The text proposed that TENP is identical to the chicken egg white
protein ovoglobulinG2 and is expressed as a full length protein in the
adult reproductive tract which would concur with the results seen in
this study, however as far as we are aware, no paper has been published
related to this observation. We believe that these submissions refer to a
globulin fraction separated by Longsworth et al. (1940). In the paper
Longsworth et al. identified three globulins G1, G2 and G3 using electro-
phoresis to separate egg white and examining the electrophoretic pat-
terns of ovalbumin and the globulin fractions.
Analysis of TENP sequence from the genome discovered a potential
alternative translational start sitewhichwas confirmed as the dominant
site used for transcription in magnum tissue. Because the expression of
TENP is low in the embryowewere unable to confirm the transcription-
al start site. The proof from the magnum that the predominant transla-
tional start site is at position 32 (Fig. 1C) combined with the Signal P
predictions probability score of 0.996 for the new signal peptide proba-
bility and the signal peptide cleavage point suggests that at least in the
adult the sequence proposed in our paper is correct. There is no exper-
imental evidence to support the translational start site, however, if we
were to assume a typical Kozac initiation of translation (Kozak, 1999)
then the evidence for the transcription start site from the 5′ RACE
makes the proposed translational start site the most likely. However it
must be noted that in the absence of functional evidence the transla-
tional start site cannot be confirmed as upstreamATGs occur frequently
in vertebrate mRNA (Rogozin et al., 2001) and we cannot rule out the
possibility of multiple sites of translation (Kochetov et al., 2005).
Measurement of TENP expression in embryonic brain and retinal
tissues concur with the developmental down-regulation seen by Yan
and Wang (1998)); expression seen at E10 is dramatically decreased
by E16 and no expression is detected in adult brain or retinal tissues
(Fig. 5). In contrast, expression of TENP in the adult hen is restricted to
the oviduct (Fig. 6) suggesting that at this stage TENP plays a different
role. Expression is almost exclusively in the magnum with expression
here around 400× more than in the shell gland and almost 10,000×
greater than in embryonic retina tissue. The magnum is responsible
for the production of egg white and the high level of expression here
would suggest that TENP is primarily a component of egg white.
Fig. 9. The tubular gland cells of the magnum region (A) of the oviduct stained positive and the surface epithelium (ciliated and non-ciliated cells) did not stain with anti-TENP antisera
(107_AWM_1.1). The corresponding negative controls for A are shown in image B. The isthmus (C), shell gland (D) and caecum (E) were not reactive to the primary antibody.
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However this study did detect some expression in other regions of the
oviduct which would concur with the proteomic evidence for TENP in
the other egg compartments e.g. the shell. Immunohistochemistry
confirmed the presence of TENP as a protein in the tubular gland cells
of themagnum region of the oviduct (Fig. 9); this would support the se-
cretion of TENP. Interestingly TENP was not detected in the epithelial
cells which may indicate that TENP is less involved in local protection
of the oviduct. In duck tissues TENP expression is also restricted to the
magnum of the oviduct (Fig. 6). TENP expression in the caecum had
previously been reported by Chiang et al. (2011) however when using
our quantitative approach no significant expression was measured in
this tissue compared to other tissues (Fig. 6) which was further
confirmed through IHC (Fig. 9).
Expression in the magnum of the oviduct did not differ significantly
in relation to the position of the egg in the oviduct at the time of
sampling or if it was a pause day when no egg was present, although
there was a tendency for the level to be lower when the egg was in
the magnum or had recently left it (P = 0.051) (data not shown).
This pattern of expression is typical of egg proteins and has been
described previously for others including gallin (Gong et al., 2010) and
ovalbumin (Muramatsu et al., 1994). In the magnum and shell gland
there is significantly more TENP expression when the hen is in-lay
compared to when the oviduct is regressed (Fig. 7) suggesting that the
expression of TENP is specifically up-regulated during egg production
when steroids are elevated and is likely to be under the control of
gonadal steroids. This was confirmed by the measurement of TENP
expression after the administration of oestrogen and progesterone to
juvenile hens, with the increase in expression greatest with the dose
of oestrogen compared to that of progesterone. Most importantly the
response was strongest when the animals had previously been primed
with an oestrogenic compound and showing that oestrogen andproges-
terone act synergistically as one would expect of an oviduct gene
controlled directly or indirectly by gonadal steroids. Analysis for tran-
scriptional factor binding sites 20 kb upstream of the gene using
MATCH (2013) did not identify any oestrogen or progesterone recep-
tors so the effect may be secondary to stimulation of transcription
factors by these steroids.
These results strongly suggest that in the adult hen TENP's role is as a
major component of the egg. Although local tissue activity, for example
antimicrobial protection of the oviduct cannot be ruled out and it may
serve both these roles. It is also notable that proteomic analysis has
recently identified TENP as a possible requisite host protein in infectious
bronchitis virus (IBV) life cycles (Kong et al., 2010). The relationship of
TENP to the PLUNC/BPI family of proteins suggests a role for TENP in the
innate defence of eggs against pathogens and the presence of LPS bind-
ingdomainswouldmake an antimicrobial role seempossible as demon-
strated with Ovocalyxin-36 (Gautron et al., 2011). If this is the case it is
interesting to note that TENP is present in all components of the egg and
is a significant eggwhite component representing ~0.1–0.5% of the total
protein, similar to the levels of ovoinhibitor, a multitype serine protein-
ase inhibitor which is present at 0.1–1.5% (Guerin-Dubiard et al., 2006).
The large number of known antimicrobial proteins already identified in
the eggwouldmake this seem plausible although experimental proof of
the activity of TENP does not yet exist.
5. Conclusion
TENP, a PLUNC homolog andmember of the BPI family of LPS binding
proteins is expressed in the retina and brain of chicken embryos.
Expression diminishes over time in the embryo but in any case it is
10,000 times less than in adult oviduct. In the adult hen and duck
TENP expression is restricted to the oviduct, almost exclusively the
magnum. The expression of TENP is up-regulated in laying hens versus
those with a regressed oviduct suggesting it to be under the control of
gonadal steroids; this is further supported by the increased expression
of TENP after administration of oestrogen and progesterone in juveniles.
In adult birds TENP shows the classic signature of an egg specific gene.
This, coupled with its relationship to the BPI/PLUNC family, suggests a
role in protecting the egg from microbial attack.
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